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1 Abstract	  
This thesis investigates the function of Roquin-1 (Rc3h1) and its paralog Roquin-2 (Rc3h2) in the 
immune system. Roquin-1 is an essential factor in the prevention of autoimmune diseases by 
controlling T cell co-stimulation. This was first observed in mice harboring a single point 
mutation (san mutation) in Roquin-1, which developed a lupus-like disease with increased levels 
of the inducible co-stimulator Icos on all T cells. Roquin-1 represses Icos mRNA levels by 
interacting with factors of the mRNA decay machinery to induce mRNA degradation.  
The first part of this thesis significantly contributes to the discovery of this mechanism by 
demonstrating direct Roquin-1 protein interaction with human ICOS mRNA. Furthermore, in 
vitro shift assays reveal a newly defined cis-element in the 3’untranslated region (UTR) of ICOS 
mRNA, which is required for preferential Roquin-1-binding. This cis-element comprises a two-
finger-like secondary RNA structure that might be crucial for Roquin-1 protein recognition. The 
paralog of Roquin-1, Roquin-2, with so far unknown function, is equally able to bind to the cis-
element in the ICOS 3’UTR, indicating some degree of redundancy. 
The second part of the presented work focuses on potential redundancy of Roquin-1 and Roquin-2 
in mice to solve a current paradox: The san mutation in Roquin-1 leads to severe autoimmune 
disease, but the complete absence of the protein does not. Investigating the complete deletion of 
the paralog Roquin-2 reveals postnatal death, but no unique role can be found for Roquin-2 upon 
conditional deletion in T cells. However, combined ablation of Roquin-1/2 in T cells reproduces 
most of the phenotypes observed in san/san mice. This implies that Roquin-2 can compensate for 
loss of Roquin-1-function, but is inhibited by the Roquin-1san protein. We suggest the disrupted 
splenic architecture in Rc3h1/2-deficient mice as one reason, why these mice do not develop anti-
nuclear antibodies, a hallmark of lupus-disease. Mechanistic analyses reveal that both Roquin-1 
and Roquin-2 proteins can independently repress Icos mRNA and further identify Ox40 mRNA as 
a novel molecular target of both proteins. In addition, combined acute ablation of Roquin-1/2 
proteins augments Ox40 co-stimulation through the alternative NF-κB pathway and increases Irf4 
transcription factor levels. This results in enhanced follicular T helper (Tfh) cell and Th17 
differentiation, implying that Roquin-1/2 proteins control these differentiation programs. 
Adoptive transfer experiments further corroborate this finding. Finally, the contribution of Icos or 
IFN-γ to the observed phenotypes in Rc3h1/2-deficient mice is investigated in triple knockout 
situations, revealing a potential overlap of Icos and Ox40 functions in Tfh cell differentiation. 
In summary, this thesis demonstrates the redundant functions of Roquin-1 and Roquin-2, which 
provide a crucial safeguard mechanism in the prevention of autoimmunity. 
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2 Zusammenfassung	  
Diese Dissertation untersucht die Funktion von Roquin-1 (Rc3h1) und seinem Paralog Roquin-2 
(Rc3h2) im Immunsystem. Durch die Kontrolle von T-Zell Co-Stimulierung verhindert Roquin-1 
die Entstehung von Autoimmunerkrankungen. Diese wichtige Funktion wurde in der san/san 
Maus entdeckt, die eine Punktmutation in Roquin-1 aufweist. Das dadurch entstehende Lupus-
ähnliche Krankheitsbild ist unter anderem durch die Überexpression von dem induzierbaren Co-
Stimulator Icos auf T-Zellen gekennzeichnet. Roquin reprimiert Icos mRNA durch Interaktion mit 
Proteinen, die den Abbau von mRNA einleiten.  
Der erste Teil dieser Dissertation trägt wesentlich zu der Entschlüsselung dieses Mechanismus 
bei, indem sie aufzeigt, dass Roquin-1 direkt mit der humanen ICOS mRNA interagiert. Hierbei 
bindet Roquin-1 bevorzugt an ein neu entdecktes cis-Element in dem 3’untranslatierten Bereich 
(UTR) der ICOS mRNA. Dieses cis-Element weist eine zwei-Finger artige Sekundärstruktur der 
RNA auf, die eine wichtige Rolle bei der Erkennung durch Roquin-1 Proteine spielen könnte. Das 
Paralog von Roquin-1, Roquin-2, dessen Funktion bis jetzt nicht bekannt ist, bindet genauso gut 
an das cis-Element im ICOS 3’UTR, wodurch eine gewisse Redundanz angedeutet wird.  
Im zweiten Teil dieser Arbeit sollen daher redundante Funktionen von Roquin-1 und Roquin-2 
untersucht werden um eine wichtige Frage zu klären: Warum führt die san Mutation, nicht jedoch 
das völlige Fehlen von Roquin-1, zu einer schweren Autoimmunerkrankung? Fehlt das Paralog 
Roquin-2 in der Maus, stirbt diese. Das Fehlen von Roquin-2 nur in T-Zellen legt keine 
einzigartige Funktion von Roquin-2 offen. Das Fehlen beider Proteine in T-Zellen, ruft jedoch die 
meisten san/san Phänotypen hervor. Dies bedeutet, dass Roquin-2 den Funktionsverlust von 
Roquin-1 ausgleichen kann, nicht jedoch wenn das mutierte Roquin-1san Protein Roquin-2 daran 
hindert. Die zerstörte Milz-Struktur in Rc3h1/2-defizienten Mäusen ist eine mögliche Ursache, 
weshalb im Gegensatz zur san/san Maus keine anti-nuklearen Antikörper entstehen. Funktionell 
zeigt diese Arbeit, dass Roquin-1 und Roquin-2 unabhängig voneinander Icos reprimieren können 
und Ox40 mRNA eine weitere Ziel-RNA beider Paraloge ist. Der Verlust von Roquin-1/2 steigert 
Ox40 Co-Stimulation durch den alternativen NF-κB Signalweg und erhöht die Expression des 
Transkriptionsfaktors Irf4. Dadurch erhöht sich die Differenzierung in follikuläre Helfer-T-Zellen 
(Tfh) und Th17 Zellen, die offenbar von Roquin-1/2 Proteinen kontrolliert wird. Dies wird auch 
durch Transfer-Experimente bestätigt. Zuletzt wird der Effekt von Icos oder IFN-γ auf den 
Funktionsverlust von Roquin-1/2 Proteinen in Dreifach-Knock-out Studien untersucht. Dabei 
zeigt sich eine mögliche Redundanz von Icos und Ox40 in der Tfh Differenzierung. 
Diese Arbeit zeigt somit die Redundanz von Roquin-1 und Roquin-2 Proteinen auf, welche einen 
wichtigen Schutzmechanismus zur Vermeidung von Autoimmunität darstellt. 
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4 Abbreviations	  and	  nomenclature	  
 
Human RCK, EDC4, ICOS, OX40 and CTLA4 are written in capitals. 
Mouse Rck, Edc4, Icos, Ox40 and Ctla4 are written in lowercase. 
 
-/-    knockout 
%    percent 
°C    degree Celsius 
+/+    wild-type 
α   alpha 
A    adenine 
A549   human lung adenocarcinoma epithelial cell 
AGO   argonaute protein 
Ala   alanine 
ANAs   anti-nuclear antibodies 
APC   antigen-presenting cell 
APS    ammonium persulphate 
ARE   AU-rich element 
Arg   arginine 
Asn   asparagine 
ATP   adenosine triphosphate  
AUF   ARE RNA-binding protein 
β   beta 
BAFF   B cell-activating factor 
BATF   basic leucine zipper transcription factor 
BCR   B cell receptor 
Bim   Bcl2-like 11 (BCL2L11) 
Blimp1  B lymphocyte-induced maturation protein 1    
bp    base pairs 
BSA    bovine serum albumin 
C   cytosine 
Ca2+   calcium 
CAR   coxsackie adenovirus receptor 
CCR7   CC-motif chemokine receptor 7 
CD   cluster of differentiation 
cDNA   complementary DNA   
CDS    coding sequence 
cIAP   cellular inhibitor of apoptosis protein 
CTLA4  cytotoxic T-lymphocyte antigen 4 
CXCR   CXC-motif chemokine receptor  
δ   delta 
DAG   diacylglycerol 
DAPI    4,6-diamidino-2-phenylindol-dihydrochloride 
DCP   decapping protein 
dG   Gibbs free energy 
DDX6   DEAD box helicase 6 (Rck) 
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DLBCL  diffuse large B cell lymphoma 
DMSO  dimethyl sulfoxide 
DN   double negative 
DNA    deoxyribonucleic acid 
dNTP    deoxynucleotide triphosphate 
DP   double positive 
dpc    days post coitum 
ds    double-stranded 
DTT    dithiothreitol 
ε   epsilon 
E. coli    Escherichia coli 
EAE   experimental autoimmune encephalomyelitis 
EDC   enhancer of decapping 
EDTA   ethylenediaminetetraacetic acid 
eGFP    enhanced green fluorescent protein 
eIF   eukaryotic translation initiation factor  
EMSA   electrophoretic mobility shift assay 
EPRS   glutamyl-prolyl tRNA synthetase 
EtOH   ethanol 
FACS    fluorescence-activated cell sorting 
FCS    fetal calf serum 
FITC   Fluorescein isothiocyanate 
FL   full-length 
fl/fl   floxed allels 
Foxp3   forkhead box P3 
γ   gamma 
G   glycine 
g   relative centrifugal force 
g    gramm 
GAIT   IFN-γ-activated inhibitor of translation 
GAPDH  glyceraldehyde 3 phosphate dehydrogenase 
Gata3   GATA binding protein 3 
GC   germinal center 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
GRB   growth factor receptor-bound protein 
GSK   glycogen synthase kinase 
h   hour 
HBS   Hank’s Balanced Salt solution 
HEDLS  human enhancer of decapping large subunit 
HEK   human embryonic kidney cells 
HIV   human immunodeficiency virus 
HLA   human leucocyte antigen   
HNRNPQ1  heteronuclear ribonucleoprotein Q1 
HRP   horseradish peroxidase 
i.v.   intravenously 
ICOS   inducible T cell co-stimulator (CD278) 
ICOSL  ICOS ligand 
IFN   interferon 
Ig    immunoglobulin 
IKK   IκB kinase 
IL   interleukin 
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IP3   inositol-1,4,5-trisphosphate 
IPTG    Isopropyl b-D-1-thiogalactopyranoside  
IRES    internal ribosome entry site 
Irf4   interferon regulatory factor 4 
ITAM   immunoreceptor tyrosine-based activation motif 
IκB   inhibitor of κB 
κ   kappa 
kb    kilo base pairs 
kDa    kilo Dalton 
LAT   linker for activation of T cells 
LB   lysogeny broth (Luria-Bertani) medium 
LCK   lymphocyte-specific protein tyrosine kinase 
LMW   low molecular weight standard 
LPS   lipopolysaccharide 
LR   lambda recombination 
Lsm   Like Sm proteins 
LTαβ   lymphotoxin alpha, beta   
Lys    lysine 
µ   micro 
M   molar 
MEF   mouse embryonic fibroblast 
Met   methionine 
Mg2+   magnesium 
MHC   major histocompatibility complex 
min   minute 
miR   microRNA 
miRNA  microRNA 
ml   milliliter 
mM    millimolar 
Mnab   membrane-associated nucleic acid binding protein (Roquin-2) 
MOI    multiplicity of infection 
mRNA   messenger RNA 
mRNP   messenger ribonucleoprotein 
NEMO  NF-κB essential modulator 
Neo   neomycin 
NFAT   nuclear factor of activated T cell 
NIK   NF-κB inducing kinase 
NK cell  natural killer cell 
NKT cell  natural killer T cell 
NLS   nuclear localization signal 
nm   nanometer 
NMIA   N-methylisatoic anhydride 
NMR   nuclear magnetic resonance 
nts    nucleotides 
OVA   ovalbumin 
P body   processing body 
PABP   poly(A)-binding protein 
PAGE    polyacrylamide gel electrophoresis 
PAMP   pathogen-associated molecular pattern 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
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PD-1   programmed cell death protein 1 
PDK   phosphoinositide-dependent kinase 
pH    potentia hydrogenii 
PI3K   phosphatidylinositol 3-kinase 
PIP2   phosphoinositol-4,5-bisphosphate 
PIP3   phosphoinositol-3,4,5-triphosphate 
PKB / AKT  protein kinase B 
PLC   phospholipase C 
PTEN   phosphatase and tensin homologue deleted on chromosome 10 
PTK   protein tyrosine kinase 
PVDF   polyvinylidene fluoride 
qPCR   quantitative PCR 
R   arginine 
RA   retinoic acid 
RAG    recombinase activating gene 
RANKL  receptor activator of NF-κB ligand 
Rc3h1   ring finger and CCCH-type zinc finger domains 1 (Roquin-1) 
Rc3h2   ring finger and CCCH-type zinc finger domains 2 (Roquin-2) 
Rck   DEAD box helicase 6 (DDX6) 
RIP1   receptor interacting protein 1 
RISC   RNA-induced silencing complex 
RNA   ribonucleic acid 
RNase   ribonuclease 
RORγt   RAR-related orphan receptor gamma T 
RPL13A  ribosomal protein L13A 
RRM   RNA recognition motif 
RT    room temperature 
s   second 
san   sanroque allele (Roquin-1 mutation M199R) 
SD   standard deviation 
SDS    sodium dodecyl sulfate 
SH   SRC homology 
SHAPE  selective 2’-hydroxyl acylation analyzed by primer extension 
SLE   systemic lupus erythematosus 
SLP   SRC homology 2 (SH2)-domain-containing leukocyte protein 
SP   single positive 
SRBC   sheep red blood cells 
SRC   sarcoma 
Stat   signal transducer and activator of transcription 
T   thymidine 
T-bet   T-cell-specific T-box transcription factor 
TAK1   Transforming growth factor beta activated kinase-1 
TCR   T cell receptor 
TEC   tyrosine-protein kinase 
TEMED  N,N,N’,N’-tetramethylethylendiamine 
Tfh   follicular helper T cells 
TGF   transforming growth factor 
Th cell   T helper cell 
TIA   T cell internal antigen 
TKO   triple knockout 
TNF   tumor necrosis factor 
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TNFR   tumor necrosis factor receptor 
TNFRSF  tumor necrosis factor receptor superfamily 
TRADD  TNFR1-associated DEATH domain protein 
TRAF   TNF receptor associated factor 
Treg cell  regulatory T cell 
tRNA    transfer RNA 
TTP   tristetraprolin 
TUTase 4  terminal uridylyltransferase 4 (ZCCHC11) 
Tyr   tyrosine 
U   units 
U   uracil 
UTR   untranslated region 
UV   ultraviolet 
V   volt 
v/v    volume per volume 
vs.   versus 
w/v   weight per volume 
WT    wild-type 
Xaa   unspecific amino acid 
XRN   exoribonuclease 
ζ   zeta 
ZAP   zeta-chain-associated protein 
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5 Introduction	  
5.1 Boon	  and	  Bane	  of	  the	  immune	  system	  
The immune system protects an organism from invading pathogens. One of the most ancient 
means of defense is the innate immune system, which ensures rapid, unspecific responses to 
pathogens without establishing long-lasting immunity. The innate immune system is found in 
all animals and plants 1 and is seen as an evolutionary early immune response based on the 
recognition of specific pathogen-associated molecular patterns (PAMPs) such as bacterial 
LPS (lipopolysaccharide), double-stranded RNA viruses or glycolipids 1,2. Detection of such 
structures by the innate immune system can activate the complement system or attract anti-
microbial peptides, which attack the invaders. However, the fast co-evolution of pathogenic 
microorganisms necessitated the development of a second defense mechanism capable of fast 
adaptation and memory. This was established in jawed vertebrates, when a transposon 
carrying the precursors for the recombinase activating genes RAG-1 and RAG-2 created a new 
line of defense, called the adaptive immune system 2. RAG-1 and RAG-2 proteins are 
essential for V-D-J gene rearrangement of T and B cell receptors (TCR and BCR, 
respectively) 3,4. V-D-J rearrangement is a mechanism to create an enormous repertoire of 
heavy and light chains of the TCR or BCR 5. During an immune response there is additional 
diversification of the variable (V) region of these receptors by somatic hypermutation, which 
introduces mutations into the V region to increase the receptor affinity. Together with further 
mechanisms, the human immune system comprises at least an estimated 108 lymphocyte 
receptors with unique specificity to detect invading pathogens 1. However, the enormous 
diversity of the adaptive immune system is seen as double-edged sword as in this random 
process of modifying the receptor repertoire, each newly generated receptor could potentially 
react against the body’s own cells (self-reactivity). Therefore, a number of tolerance 
mechanisms co-evolved to protect the body against self-reactive cells.  
 
5.1.1 Generation	  and	  selection	  of	  T	  lymphocytes	  
The T and B lymphocytes are the centerpiece of the adaptive immune system. The bone 
marrow is the place of origin of both B and T cells. While B cells further mature in the bone 
marrow, T cell precursors migrate to the thymus for maturation and selection. The thymus 
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therefore has a pivotal role in shaping the peripheral T cell repertoire with unique T cell 
receptors recognizing foreign antigens 6.  
During T cell development, two T cell lineages with different TCRs (α:β or γ:δ) are formed, 
and α:β T cells differentiate further into CD4+ or CD8+ T cells. Progenitor T cells start to 
rearrange their T cell receptor genes upon entering the thymus. If gene rearrangement creates 
a functional β-chain first, γ and δ gene rearrangement is stopped and vice versa 1,7. The 
predominant T cell lineage in the thymus exhibits α:β TCRs. Development of α:β T cells 
starts with a CD4/CD8 double-negative (DN) state, which can be divided into the four 
precursor stages DN1, DN2, DN3 and DN4. Rearrangement of the β-chain starts at the DN2 
stage and stalls in the DN3 stage, where the first pre-T cell receptor is expressed. In the DN4 
stage, CD3, an essential component of the mature TCR complex, is expressed. Subsequently, 
the surface molecules CD4 and CD8 are expressed in a double-positive (DP) stage, which is 
accompanied by α-chain rearrangement and a process called positive selection 1,7. In this 
process, α-chain gene rearrangement is continued until the TCR recognizes a self-
peptide:self-MHC complex (major histocompatibility complex). Self-MHC restriction is a 
crucial step in the process of positive selection. It is ensured by a germline-encoded 
specificity of both chains of the TCR to the MHC and the requirement for CD4 and CD8 co-
receptor binding 1,8. T cells recognizing MHC class I molecules become cytotoxic CD8+ T 
cells, while cells recognizing MHC class II complexes become CD4+ T cells. The latter 
develop either into helper T cells or thymic regulatory T (Treg) cells. To limit maturation of 
potential self-recognizing T lymphocytes, cells will undergo apoptosis if they bind too 
strongly to their MHC. An intermediate-affinity to self-peptide:self-MHC complexes selects 
for thymic Treg cells 9. During the process of positive selection only 10–30% of all 
thymocytes are selected. These cells further undergo negative selection during the double-
positive and single-positive stage. Negative selection ensures that T cells recognizing self-
peptides presented by stromal cells in the cortex as well as in the medulla of the thymus die 
by apoptosis. Only 2% of all thymocytes survive these selection processes and migrate into 
the periphery 1. 
 
5.1.2 T	  cell	  co-­‐stimulation	  and	  signaling	  
The strict selection processes to eliminate potentially self-reactive T cells during T cell 
development are not the only safety mechanisms in the adaptive immune system. Further 
receptor editing or deprivation of nutrients and growth factors can eliminate self-reactive T 
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cells 6. Another fundamental control mechanism is the need of co-stimulation for T cell 
activation in the periphery, known as the “two-signal hypothesis” 10. T cells encountering an 
antigen without receiving a second signal via a co-stimulatory receptor will become anergic 
(Figure 1).  
 
 
Figure 1: Two signals are required for effective T cell activation. (A) Antigen-presenting cells (APC) 
activated by contact with pathogens present foreign peptides bound to their MHC. Furthermore they up-
regulate the expression of co-stimulatory ligands such as B7. T cells are activated by B7–CD28 co-
stimulation in combination with recognition of peptide-MHC complexes. (B) APCs presenting self-
peptides on their MHC do not provide co-stimulatory signals. Without a second signal, the interaction is 
not sufficient to fully activate the T cell, which becomes anergic. (Modified from 11.) 	  
Anergy is a state of T cell unresponsiveness and ensures that self-reactive T cells cannot be 
activated but still survive. The avoidance of anergy is achieved by at least two mechanisms 12. 
Signaling via the essential co-stimulatory receptor CD28 can inhibit the production of anergic 
factors 13. However, the co-stimulus alone is not sufficient to avoid an anergic state. In 
addition, the stimulated cell has to progress through the cell cycle to develop its effector 
functions 14. 
Upon encounter of a pathogenic microorganism, antigen-presenting cells (APCs) will take up 
the invading microorganism or antigens derived from them and present the antigen peptides 
on their MHC. Furthermore, they will up-regulate the ligands B7 and ICOSL (inducible co-
stimulator ligand) for T cell co-stimulation 11,15. CD28 is crucial for early signaling events 
after antigen-encounter 16-18. It binds to the B7 ligands B7.1 (CD80) and B7.2 (CD86) on 
APCs. In the process of antigen recognition, an immunological synapse forms, to bring co-
receptors and their ligands in close proximity 19. Upon activation of the T cell by TCR and 
receptor stimuli, a complex cascade of TCR signaling events switches on effector functions in 
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the T cells. The ζ-chain dimer in the TCR complex contains immunoreceptor tyrosine-based 
activation motifs (ITAMs) in its cytoplasmic tail, which are phosphorylated upon activation 
and lead to the recruitment of the protein tyrosine kinase (PTK) ZAP70 (ζ-chain-associated 
protein of 70 kDa). ZAP70 is activated by the co-receptor-associated Src kinase LCK and in 
turn activates LAT (linker for activation of T cells) and SLP76 (SRC homology 2 (SH2)-
domain-containing leukocyte protein of 76 kDa). These proteins act as scaffold and recruit 
PLCγ (phospholipase Cγ1), which is subsequently phosphorylated by kinases of the TEC 
family. Active PLCγ catalyzes the cleavage of phosphoinositol-4,5-bisphosphate (PIP2) to 
inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). While DAG stays associated 
with the membrane, IP3 causes the depletion of Ca2+ stores in the endoplasmic reticulum. This 
store-depletion induces an opening of store-operated calcium channels in the membrane that 
then allows extracellular Ca2+ to enter the cytoplasm. This influx of Ca2+ eventually activates 
NFATs (nuclear factors of activated T cells), which are essential for the induction of genes 
involved in establishing effector functions 1,20. 
One of the most important co-stimulatory receptors in early T cell activation is CD28. It 
induces the expression of the growth-factor IL-2 and anti-apoptotic factors, thereby 
preventing anergy and apoptosis 20. Furthermore, CD28 ligation reduces the number of TCRs 
sufficient for activation by lowering the activation threshold for signaling 21. The essential 
role of CD28 in co-stimulation is demonstrated in mice deficient for CD28. These mice 
exhibit reduced levels of immunoglobulins and are impaired in class switching 22. Likewise, 
mice deficient for B7 receptors fail to elicit immunoglobulin class switching and germinal 
center formation after immunization 23. However, these studies also point out the existence of 
alternative co-stimulatory mechanisms 22.  
CD28 belongs to the immunoglobulin superfamily with a variable immunoglobulin-like 
domain for ligand recognition. The inducible co-stimulator ICOS and Cytotoxic T-
Lymphocyte Antigen 4 (CTLA4) are two additional co-stimulators, which are structurally 
related to CD28 24,25. They all share the common intracellular signaling motif Tyr-Xaa-Xaa-
Met. This motif functions as a binding site for the SH2 domains of p85, an adaptor protein for 
the catalytic subunit of phosphatidylinositol 3-kinase (PI3K). PI3K signaling is one of the 
central pathways for T cell activation and the production of an active immune response. 
CD28, ICOS and CTLA4 have developed diversified functions, despite their structural 
relationship. The cytosolic portion of CD28 binds to GRB2 (growth factor receptor-bound 
protein 2) via an asparagine (Asn) residue at the +2 position (Tyr-Xaa-Asn-Met), which is not 
present in the cytosolic tails of ICOS or CTLA4 25. On the extracellular level, both CD28 and 
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CTLA4 bind to the B7.1 and B7.2 receptors on APCs. CTLA4 has a higher binding affinity to 
these receptors, as it interacts as a dimer with two different B7 dimers, while CD28 can only 
bind one dimer 25. CTLA4 is an essential negative regulator of the immune response. It is 
induced on T cells after activation and captures its ligands on APCs by a mechanism called 
trans-endocytosis. The ligands are internalized into the CTLA4-expressing cells and 
subsequently degraded. This leads to a stop of T cell proliferation, as CD28 is no longer able 
to signal 26. Mice deficient for Ctla4 die soon after birth, because of overshooting T cell 
proliferation, which finally causes organ destruction by lymphocyte infiltration 27. This 
highlights the importance of negative co-stimulation and regulation in immune responses. 
ICOS is another activator of the immune system. It is induced after T cell activation and is 
dependent on CD28 co-stimulation 17,28. Its ligand (ICOSL) is constitutively expressed on B 
cells and macrophages and can be induced on non-lymphoid tissues by inflammatory 
stimuli 15. Unlike CD28, ICOS cannot induce IL-2 expression, but is responsible for 
stimulating the production of a number of other cytokines such as IFN-γ, TNFα, IL-4, IL-5 
and IL-10 17,28,29. ICOS influences both IL-4 and IL-21 expression by regulating the 
transcription factor c-Maf 30-32. Furthermore, ICOS is essential for class switching and affinity 
maturation of immunoglobulins. Mice deficient for Icos exhibit diminished T cell effector 
functions and impaired germinal center formation, which cannot be formed in a secondary 
immune reaction 33-35. Additionally, the development of follicular T helper (Tfh) cells is 
severely impaired in the absence of ICOS co-stimulation 36,37. Both deficiency and 
overexpression of ICOS are linked to autoimmune diseases. Icos-deficient mice are more 
susceptible to experimental autoimmune encephalomyelitis (EAE) than wild-type mice 38. 
Conversely, increased ICOS levels are linked to systemic lupus erythematosus (SLE), as an 
overactive immune system fails to suppress self-reactive T cell responses 39. 
Other co-stimulators such as tumor necrosis factor (TNF) receptor family members 4-1BB 
(tumor necrosis factor receptor superfamily 9 or TNFRSF9) or OX40 (tumor necrosis factor 
receptor superfamily 4 or TNFRSF4) also play key roles in T cell survival and cell division. 
OX40 and 4-1BB are important for memory formation and maintenance 40-43. Transgenic 
expression of OX40L on T cells leads to autoimmune-like diseases with massive 
accumulation of effector memory CD4+ T cells 44. A single dose of an antibody, which 
stimulates OX40 signaling was able to break established tolerance in CD4+ T cells and 
restored T cell effector function 45. This further underlines the potential damage of excessive 
or defective co-stimulation. Therefore, therapeutic targeting of co-stimulatory receptors might 
be beneficial in a number of human autoimmune diseases. 
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5.1.3 Common	  co-­‐receptor	  signaling	  pathways	  
There are numerous signaling pathways that determine lymphocyte development and 
differentiation, thereby responding to a complex network of intracellular and intercellular 
signals. This section focuses on the fundamental mechanisms of NF-κB and PI3K signaling 
(Figure 2), both involved in the regulation of cell growth, proliferation, survival and 
differentiation 46,47. 
The co-receptors CD28, ICOS and CTLA4 can all signal via PI3K recruitment 25. Receptors 
binding to PI3K stimulate the generation of phosphatidylinositol-3,4,5-triphosphate (PIP3), 
leading to the subsequent activation of PDK1 (phosphoinositide-dependent kinase 1) and 
PKB (protein kinase B, also known as AKT) 46. PKB phosphorylates GSK3 (glycogen 
synthase kinase 3) and loss of inhibition by GSK3 as well as dephosphorylation of NFAT by 
Ca2+ signaling events allow the translocation of NFAT into the nucleus and the induction of 
transcription 25. PTEN (phosphatase and tensin homolog deleted on chromosome 10) is 
opposing PI3K signaling by controlling basal PIP3 levels 48. In the absence of PTEN, TCR 
engagement without co-stimulation is sufficient for proliferation and induction of IL-2, 
leading to lymphomas and autoimmunity 49-51. Buckler et al. therefore suggest that CD28 co-
stimulation is required to overcome negative regulation by PTEN, which sets a threshold for 
full TCR activation 49 (Figure 2, left). 
CD28 family members can also induce the NF-κB (nuclear factor-κB) pathway 52-54. NF-κB 
signaling is also responsible for the production of IL-2 and anti-apoptotic factors as well as 
for the induction of other transcription factors such as Irf4 55. Rel/NF-κB family members 
include RelA, c-Rel, RelB, NF-κB1 (p50 and its precursor form p105) and NF-κB2 (p52 and 
its precursor p100). They share a common Rel homology domain (RHD) in their amino-
terminal region, which is essential for their dimerization and binding to DNA 56. RelA, RelB 
and c-Rel further contain a carboxy-terminal TAD domain (transcription activation domain). 
Without activation, these NF-κB factors are retained in the cytoplasm by IκBs (inhibitors of 
NF-κB), comprising several members such as IκBα, IκBβ or IκBε. These inhibitors bind to 
NF-κB dimers by multiple ankyrin repeats and mask their nuclear localization signal 
(NLS) 57,58. Both the canonical and alternative NF-κB pathway can be activated by a number 
of stimuli such as cytokines or the receptors of the TNF family OX40 and CD40L. There are, 
however, also specific sets of receptors activating only one of these pathways 59. For example 
RANKL (receptor activator of NF-κB ligand) and LTαβ predominantly activate the 
alternative pathway 47, while LPS, IL-1β and TNFα activate the canonical pathway. Upon 
TNFα signaling via the receptor TNFR1, the adapter protein TRADD (TNFR1-associated 
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DEATH domain protein) recruits the ubiquitin ligases TRAF2 and TRAF5 (TNF receptor 
associated factor) as well as the protein kinase RIP1 (receptor interacting protein 1). 
However, RIP1 probably functions more as another adapter protein for the recruitment of the 
trimeric IKK (IκB kinase) complex. TRAF2 ubiquitinates RIP1 and further recruits IKKα, 
IKKβ and IKKγ (also named NEMO for NF-κB essential modulator). The binding of the IKK 
complex to ubiquitinated RIP1 stabilizes the interaction with the TRAF receptor complex. 
Furthermore, RIP1 ubiquitination as well as conformational changes in the IKK complex 
structure lead to the recruitment of TAK1 (transforming growth factor β activated kinase-1) to 
TRAF2. TAK1 phosphorylates IKKβ and the subsequent phosphorylation of IκBα leads to 
ubiquitination and proteasomal degradation of the inhibitor 60. This liberates the NF-κB 
heterodimer p50 and RelA (also named p65), which translocates into the nucleus for 
activation of transcription (Figure 2, middle). 
Activation of the alternative NF-κB pathway establishes the formation of an ubiquitin ligase 
complex consisting of TRAF2, TRAF3, cIAP1 and cIAP2 (cIAP1/2, cellular inhibitor of 
apoptosis protein). The formation of this complex leads to self-ubiquitination of TRAF2 and 
TRAF2-dependent polyubiquitination of cIAP1/2. Modified cIAP1/2 ubiquitinates TRAF3, 
which leads to the proteasomal degradation of the latter. Low levels of TRAF3 stabilize  
NF-κB inducing kinase (NIK) as it cannot be recruited to the TRAF2/cIAP1/2 complex 
anymore, which would ensure constant degradation of NIK in the absence of activation. 
However, stabilization of NIK, accompanied by trans-autophosphorylation, results in the 
phosphorylation and activation of the IKKα dimers. IKKα phosphorylates p100, which is 
partially degraded to p52, and releases the p52/RelB complex to translocate into the nucleus 
for inducing gene transcription 47,56,61 (Figure 2, right). 
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Figure 2: PI3K and NF-κB signaling. Activation of the PI3K pathway leads to a phosphorylation cascade 
and the initiation of transcription upon nuclear translocation of NFAT. Signaling via the canonical and 
alternative NF-κB pathway leads to the release of transcriptional activators from their inhibition and 
their translocation into the nucleus. A detailed description of these pathways is given in section 5.1.3. 
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Research in the field of NF-κB signaling is progressing fast, as defects in the signaling 
pathway are responsible for lymphoid malignancies. This adds numerous branches as well as 
negative and positive regulators to these pathways and elucidates cross-connections to other 
signaling pathways such as the PI3K pathway. The phosphorylation cascade of PI3K, PDK 
and PKB, for example, leads to the phosphorylation of IKKs and the subsequent degradation 
of IκBs, thereby activating the canonical or alternative NF-κB pathway 25. This was 
demonstrated by disrupting CD28 receptor binding, which diminished the activation of 
IKK 62, while CD28 signaling normally enhances the activity of IKK 63,64. 	  
5.1.4 Differentiation	  of	  T	  helper	  cells	  
By regulating cytokine transcription, the NF-κB pathways not only influence cell survival and 
proliferation, but also play an essential role in effector T cell differentiation 65. CD4+ T cells 
can differentiate into several distinct T helper (Th) cell subsets, depending on the 
environmental stimulus and type of infection. The cytokine profile of helper T cells together 
with specific “key” transcription factors are used to distinguish the different T helper cell 
subsets. It is generally understood that Th1 cells are characterized by the transcription factor 
T-bet, Th2 by Gata3, Th17 by RORγt and Treg cells by Foxp3. However, recent research has 
discovered remarkable plasticity among T helper cells 66-68. Furthermore, new subsets were 
discovered, such as follicular T helper (Tfh) cells, which were not readily acknowledged by 
the community. While Tfh cells were accepted as a new T helper cell subset with the 
discovery of the transcription factor Bcl6 as essential transcription factor for their 
development 69-71, other subsets such as Th9 or Th22 cells are still not fully appreciated 66,68,72 
(Figure 3). 
The first subsets described were Th1 and Th2 cells 73. Intracellular pathogens trigger the 
differentiation of Th1 cells producing IFN-γ. The release of IL-12 by innate immune cells and 
IFN-γ by NK and T cells induces the differentiation program of Th1 via the transcription 
factors T-bet, Stat1 and Stat4 66,74,75. Th2 cells secrete the cytokines IL-4, IL-5 and IL-13 and 
are effective against helminthes and extracellular pathogens. Their differentiation program is 
initiated by IL-4 and the transcription factor Stat6, both activating Gata3 expression 66,76-79. 
However, even these seemingly stable Th1 and Th2 cell subsets can be converted upon 
certain stimuli. Th2 cells can be reprogrammed to T-bet/IFN-γ expressing cells in viral 
infections 80,81 and Th1 cells can convert into Th2 cells under certain circumstances 81. 
Redirecting a transcriptional T cell profile might be beneficial for the host, as it provides 
certain flexibility to react appropriately to specific pathogens by simply shifting resources 66. 
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Figure 3: T cell differentiation and plasticity. The differentiation program of T cell subsets is governed by 
cytokines and transcription factors. However, recent studies reveal unexpected flexibility and plasticity of 
these differentiation programs. Seemingly stable T helper cell subsets were shown to completely switch 
their cytokine and gene expression profile or to express more than one key transcription factor. This 
flexibility might ensure a fast and specific response against invading pathogens. (Adapted from 66,67.) 	  
Th17 cells are another subset important in the control of extracellular bacteria or fungi, 
especially at mucosal surfaces. The Th17 differentiation program is initiated by the cytokines 
TGF-β, IL-6, IL-21 and IL-23. The cytokine signaling activates the Th17 transcription factor 
RORγt via phosphorylation of the transcription factor Stat3 82. After an initial phase of 
effector cell expansion, regulatory T cells are induced to limit the immune response and to 
maintain immune homeostasis. Scurfy mice lacking thymus-derived (CD4+ CD25+) and  
TGF-β-induced Treg cells develop a severe autoimmune disease by producing excessive 
amounts of Th1 and Th2 cytokines 83-85. 
Although originated by a reciprocal differentiation program 86,87, both peripheral Treg cells 
and Th17 cells depend on TGF-β. Th17 cells loose IL-17A and IL-17F expression in culture 
without addition of TGF-β or IL-6 and can convert into Th1 or Th2 cells in the presence of 
IL-12 or IL-4, respectively. Furthermore, mice, deficient for TGF-β, lack Treg cells as well as 
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Th17 cells and develop an autoimmune disease characterized by uncontrolled Th1 cell 
differentiation. TGF-β causes the up-regulation of both Foxp3 and RORγt, leading to the 
assumption that there might be a transient cell population, which can give rise to both Treg 
cells and Th17 cells 88. Low TGF-β amounts together with pro-inflammatory cytokines up-
regulate RORγt favoring Th17 differentiation and Foxp3 can no longer inhibit RORγt. High 
amounts of TGF-β, IL-2 and retinoic acid (RA) enhance Treg and inhibit Th17 
differentiation 87. However, these subsets are not terminally differentiated. In the gut, Treg 
cells can be converted into Th17 cells. This switch might be beneficial in response to specific 
pathogens such as fungi, which are known to induce this conversion 66,89. Another 
transcription factor crucial for Th17 differentiation is Irf4 90, which is also a direct target of 
Foxp3 91. Irf4 might also be involved in reprogramming Treg cells towards the Tfh cell 
phenotype 66. Interestingly, a subgroup of Treg cells was discovered, expressing the Tfh 
transcription factor Bcl6. These regulatory Tfh cells constrain B cells in the germinal center, 
suggesting that Treg cells adapt to the transcriptional profile of their target cells 92,93. 
In the germinal center reaction, T cells are required for humoral immune responses in which 
they give help to B cells. This function is provided by specialized Tfh cells that express the 
chemokine receptor CXCR5, the co-stimulatory molecules PD-1 and ICOS, the transcription 
factor Bcl6 and the cytokine IL-21 94. Tfh cell differentiation has been proposed to occur in a 
step-wise manner 94. A strong TCR signal already drives T cells towards Tfh cell 
differentiation 95. This priming by dendritic cells then triggers up-regulation of ICOS on the T 
cell, which is required for the subsequent expression of Bcl6. Induction of CXCR5 by Bcl6 96 
and down-regulation of the chemokine receptor CCR7 allows T cell migration towards the T-
B cell boundary of follicles in the secondary lymphoid organs 97-99. There, the contact with B 
cells and sufficient co-stimulation through several receptor-ligand pairs is required for the 
maintenance of Tfh cells 94. The initial up-regulation and sustained expression of Bcl6 100 is 
crucial for Tfh cell differentiation, but additional transcription factors such as c-Maf and Batf 
cooperate in the program 30,101-103. Furthermore, mice deficient for Irf4 cannot develop 
follicular helper T cells 104,105 and Irf4 cooperates with Stat3 to regulate gene expression 
downstream of IL-21 stimulation 104. In contrast, Blimp1 which is induced through IL-2 and 
Stat5 signaling, counteracts the commitment to this subset 69,70,106.  
The transcription factors involved in Tfh cell differentiation also play a role in other subsets 
suggesting functional plasticity 30,31,90,107,108. Furthermore, it was recently shown that cells in 
Th1 in vitro differentiation conditions pass through a stage shared with Tfh cells, which was 
marked by simultaneous expression of Bcl6, T-bet, IL-21 and IFN-γ. Subsequent input from 
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cytokines such as IL-12 and balanced regulation of epigenetics and gene expression then 
either enforces Th1 or Tfh commitment 108. Moreover, plasticity of the differentiation 
program was also demonstrated in an IL-21 reporter mouse model in vivo 109.  
 
5.1.5 Autoimmunity	  caused	  by	  inappropriate	  or	  defective	  co-­‐stimulation	  and	  T	  cell	  
differentiation	  
The cellular transition point to the Tfh cell subset has to be tightly controlled, since auto-
reactive Tfh cells play a role in the development of autoimmune diseases 110,111. In humans, a 
circulating Tfh-like population was found in 20–30% of patients with systemic lupus 
erythematosus. Patients with Sjogren’s syndrome also displayed an increased population of 
circulating Tfh-like cells 112. Tfh cells regulate the development of antigen-specific B cells 
and trigger germinal center formation. It is therefore not surprising that failed negative 
selection of somatically mutated germinal center B cells can also lead to lupus-like 
autoimmunity 113,114. In systemic autoimmune diseases such as SLE, auto-reactive antibodies 
are often directed against nuclear antigens such as dsDNA 114,115. Such auto-antigens are 
abundantly expressed on apoptotic cells present in the germinal center 116. 
Systemic autoimmune diseases such as SLE are normally caused by the concurrence of 
several cellular abnormalities 117. However, a single point mutation in the gene Rc3h1 (named 
Rc3h1san, expressing the protein Roquin-1san) caused a lupus-like autoimmune phenotype in 
mice, involving enhanced numbers of Tfh cells and spontaneous germinal center formation. 
These findings imply an important role for Roquin-1 in Tfh cell differentiation or 
homeostasis. The san/san mice developed anti-nuclear and anti-DNA antibodies and showed 
elevated levels of Icos on all T cells 39. This suggested that increased Icos co-stimulation 
could lead to the autoimmunity observed in the san/san mouse. In fact, a number of studies 
showed that experimentally induced constitutive co-stimulation, which is normally restricted 
in a spatial or temporal manner, can trigger autoimmunity. One example is Ox40 on T cells. 
Mice with ectopic co-expression of the Ox40 ligand on T cells develop autoimmune and auto-
inflammatory phenotypes and have anti-DNA antibodies in the serum 44. In line with this 
notion is that CD28 deficiency, which normally prevents germinal center reactions, was 
functionally reconstituted in the context of the san/san genotype 118. Conversely, 
heterozygosity of Icos partially rescued san/san-associated phenotypes 119. However, 
increased Icos levels on all T cells were also observed in mice that lack Roquin-1 in T cells or 
in the hematopoietic system, but failed to elicit elevated follicular helper T cell numbers or 
anti-nuclear antibody responses 120. These findings question the previous concept in which 
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impaired post-transcriptional regulation of Icos mRNA by the Roquin-1san protein leads to 
increased differentiation or expansion of auto-reactive Tfh cells, which then cause 
autoimmunity.  
 
5.2 Post-­‐transcriptional	  gene	  regulation	  
Transcriptional regulons control the first steps in gene expression and have been intensively 
studied over the past decades. This transcriptional regulation is rather a slow process, in 
which a gene is switched on, transcribed and translated or switched off and repressed. In the 
latter case, transcripts can persist long after transcription has been terminated, constituting a 
potential drawback if rapid responses are required 121. Post-transcriptional gene regulation on 
the other hand ensures rapid changes in target gene expression in the course of changing 
environmental stimuli and is well established in the control of several cellular transition 
points in immune cells 122,123. Such post-transcriptional mechanisms influence the stability 
and translation of mRNA and even include modifications at the protein level. 
In immune responses for example, rapid induction of pro-inflammatory molecules is crucial 
to combat invading pathogens. However, of similar importance is the intensive control and 
timed shut down of pro-inflammatory molecules during the resolution phase of the 
inflammatory response to avoid excessive tissue damage 124. For the coordination of such pro-
inflammatory molecules in immune responses, post-transcriptional control mechanisms have 
evolved to play a dominant role 123.  
Consequently, failed post-transcriptional control is associated with a number of human 
diseases such as cancer or Alzheimer’s disease 125. In many human tumors, the mRNAs of 
growth factors are stabilized, including GM-CSF (granulocyte-macrophage colony-
stimulating factor), IL-1 and IL-6 126. Another example is the proto-oncogene c-myc, which is 
frequently mutated in cancer 127,128. Hollis et al. discovered that a chromosomal translocation 
event in c-myc, causing the deletion of a 61 nucleotide AT-rich sequence in the 3’untranslated 
region (3’UTR), stabilized c-myc mRNA and led to T cell leukemia 127. 
 
5.2.1 Trans-­‐acting	  factors	  and	  cis-­‐elements	  regulate	  mRNA	  stability	  
The structure and sequence of an mRNA crucially determines the way it is regulated. A 5’ 7-
methyl-guanosine (7meG) cap and 3’ poly(A) tail stabilize the mRNA, which further consists 
of a 5’UTR, a coding sequence (CDS) and a 3’UTR. Most trans-acting factors target the 
3’UTR for mRNA regulation by binding to specific cis-elements 121 and the number of such 
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cis-elements in the 3’UTR greatly influences the stability of mRNA transcripts 123. Therefore, 
activated T cells express mRNAs with shortened 3’UTRs to avoid destabilization by such cis-
elements 129. 
In eukaryotic cells, the first step of mRNA degradation is the shortening of the poly(A) tail. 
However, as long as the poly(A)-binding protein (PABP) is associated with the mRNA, it is 
protected against degradation 130,131. PABP binds to eIF4G1 (eukaryotic initiation factor 4G1), 
which is associated with the cap-binding factor eIF4E leading to the circularization of the 
mRNA and stimulation of translation 121 (Figure 4). 
 
 
Figure 4: Regulation of mRNA stability. The first step in mRNA degradation is the shortening of the 
poly(A) tail by the deadenylase complexes PAN2–PAN3 and (CNOT6)-CAF1-NOT1. Subsequent 
replacement of the poly(A)-binding protein (PABP) and binding of the LSM1–7-PAT1 complex recruits 
and stimulates the decapping complex DCP1A–DCP2, which associates with EDC4, RCK/p54 and EDC3. 
The DCP1A–DCP2 complex subsequently removes the 5’cap structure of the mRNA and the mRNA is 
further degraded by the exoribonuclease XRN1. (Modified from 121.) 
 
Degradation of mRNA is accomplished by the sequential action of two deadenylase 
complexes. Initially, the PAN2–PAN3 complex shortens the poly(A) tail to a size of 50–110 
nucleotides, depending on the organism and the respective mRNA. These nucleotides are then 
further trimmed by the (CNOT6)-CAF1-NOT1 complex (CCR4-NOT transcription complex 
subunit 6 (CNOT6)-CAF1-NOT1 complex) with its catalytically active CCR4 and CAF1 
(=POP2) subunits. The conversion of polyadenylation into oligoadenylation displaces PABP 
from the mRNA and enables the binding of the LSM1–7-PAT1 complex 121,132,133. The 
binding of this complex stimulates the decapping activity of DCP2 and enables the decapping 
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complex DCP1A–DCP2 to remove the 5’cap structure. Assembly and activity of the DCP1A–
DCP2 complex is also enhanced by EDC4 (enhancer of decapping 4, also named HEDLS), 
which interacts with the complex together with EDC3 and RCK/p54 134. The helicase 
RCK/p54 (also named DDX6) is essential for ATP-dependent unwinding of RNA structures 
or for displacing other factors bound at the mRNA 135. The 5’-3’ exoribonuclease XRN1 then 
degrades the mRNA (Figure 4). However, also 3’-5’ exoribonucleases are involved in further 
mRNA degradation.  
Trans-acting factors bind to certain cis-elements in their target mRNAs. Some of these cis-
elements are well characterized, such as AU-rich elements (AREs). These AREs are 
characterized by clusters of AUUUA pentamers or UUAUUUAUU nonamers 136. Well-
known examples for ARE-binding proteins are HuR, AUF1 (ARE RNA-binding protein 1) 
and TTP (tristetraprolin), the latter one contains a tandem RNA-binding zinc finger domain. 
TTP destabilizes important inflammatory molecules such as TNFα, IL-2, IL-6, IL-10, IFN-γ 
or GM-CSF. Mice deficient for TTP suffer from arthritis, dermatitis and cachexia, a syndrome 
caused by the overexpression of pro-inflammatory cytokines including TNFα 137. TTP 
negatively regulates TNFα by binding to its ARE and directly interacting with components of 
the mRNA decay machinery, including the decapping complex DCP1A–DCP2, the 
deadenylase CNOT6, the exoribonuclease XRN1, the exosome complex endonuclease PM-
SCL75 and AGO2 121. Most trans-acting factors destabilize mRNA either by inducing mRNA 
decay by decapping or by interfering with translation initiation. However, HuR acts both as 
stabilizer and destabilizer. Three classic RNA recognition motifs (RRMs) allow binding of 
HuR to AREs in transcripts encoding IL-4, TNFα or IFN-γ, thereby stabilizing their 
expression 121,138. In contrast, HuR represses c-Myc expression in cooperation with AGO2 and 
let-7 microRNA (miRNA) 139. The terminal uridylyltransferase 4 (TUTase 4 or ZCCHC11) is 
another stabilizing factor, however, interfering with the miRNA-pathway. ZCCHC11 inhibits 
the miR-26 family of miRNAs by adding uridine residues to their 3’end. This leads to the de-
repression of the IL-6 transcript 140.  
MicroRNAs are another class of trans-acting factors. These small (ca. 22 nucleotides) non-
coding single-stranded RNAs are generated from precursors, which are processed in the 
nucleus by the RNaseIII Drosha and the RNA-binding protein DGCR8, before they are 
exported into the cytoplasm. There, the RNaseIII Dicer performs the essential processing of 
the pre-miRNA into a mature miRNA duplex. One strand of this mature miRNA is loaded 
onto the AGO-containing RNA-induced silencing complex (RISC). The RISC-loaded miRNA 
then binds to partially complementary sequences mostly in the 3’UTR of target mRNAs and 
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represses their expression 122. MicroRNAs regulate essential processes such as development, 
cell differentiation and immune cell homeostasis. Although most miRNAs are responsible for 
fine-tuning of gene expression, functional analyses revealed several single miRNAs with 
crucial roles in controlling cellular transition points 122. The germinal center response, for 
example, is controlled by miR-155. Mice deficient for miR-155 develop less germinal center 
B cells in Peyer’s patches and mesenteric lymph nodes. MiR-155 seems to be required for the 
efficient selection of cells producing high affinity antibodies 141. Conversely, miR-155 is 
highly expressed in a wide range of B cell-derived lymphomas, including Burkitt’s lymphoma 
or the aggressive diffuse large B cell lymphoma (DLBCL) 142. Overexpression of the miRNA 
cluster miR-17–92 in mice also promoted lymphomagenesis and autoimmune disease, 
probably by suppressing the tumor suppressor PTEN and the pro-apoptotic protein Bim 143. 
It is important to note that trans-acting proteins can bind to specific sequences as well as to 
structural elements. Watts et al., who have deciphered the entire structure of the HIV genome 
by SHAPE-analysis, pointed out that secondary RNA structures contain numerous 
unrecognized regulatory elements, playing essential roles in the genetic landscape 144. An 
example for structure-specific binding is the GAIT element, a 29-nucleotide hairpin structure 
in the 3’UTR of inflammatory modulators. Inhibition of target transcripts can be induced by 
IFN-γ, which initiates the formation of the GAIT (IFN-γ activated inhibitor of translation) 
complex and the binding to the GAIT element. This complex consists of the four proteins 
glutamyl-prolyl tRNA synthetase EPRS, heteronuclear ribonucleoprotein Q1 (HNRNPQ1), 
glyceraldehyde 3 phosphate dehydrogenase (GAPDH) and the ribosomal protein L13A 
(RPL13A). The GAIT complex interferes with the initiation of translation: RPL13A binding 
to eIF4G1, a factor of the 48S pre-initiation complex, prevents the recruitment of eIF3, 
thereby inhibiting translation 121. 
 
5.2.2 P	  bodies	  and	  stress	  granules	  regulate	  mRNA	  processing	  
The rate of translation or degradation of mRNAs is determined by a dynamic balance between 
polysomes (cluster of translating ribosomes bound to RNA) and processing (P) bodies. P 
bodies are membrane-less foci in the cytoplasm of cells, where mRNAs are stored for 
reversible repression or degradation 145. Most of the factors described above (section 5.2.1) 
localize to these P bodies. However, no components of translation initiation such as PABP or 
ribosomal proteins are present in P bodies, indicating that P bodies are primarily places of 
mRNA decay and storage. Consequently, the decapping enzymes DCP1A–DCP2 localize to P 
bodies as well as decapping enhancers such as RCK/p54, EDC3 or EDC4. Furthermore, the 
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deadenylation complex (CNOT6)-CAF1-NOT1, LSM proteins and the 5’-3’ exoribonuclease 
XRN1 localize to P bodies. Importantly, also factors of the miRNA-pathway are found within 
P bodies 145. So far the exact mechanism of P body assembly has not been described, but is 
known to be dependent on the presence of RNA, since treatment of P bodies with RNase 
disrupts their structure. The contribution of other P body components is less clear, though. 
Knockdown of components of the miRNA biogenesis pathway as well as other P body-
residing proteins such as RCK/p54 or LSM4 reduces P body numbers to a great extent 145. 
However, P body formation is not per se dependent on those components, which rather might 
contribute to P body assembly by influencing the translationally inactive RNA pool. In 
addition, although RNA decay is generally associated with P bodies, the formation of the foci 
is not crucial for mRNA repression. Knockdown of RCK/p54, for example, disrupts P body 
formation, yet without affecting miRNA-mediated translational repression 146. Therefore, P 
bodies might constitute compartments for the assembly of decay enzymes to increase their 
efficiency in two ways. First, compartmentalization brings interaction partners in close 
proximity and second, the protein–RNA complexes are isolated from the translation 
machinery. 
In addition to P bodies, eukaryotic cells also contain other messenger ribonucleoprotein 
(mRNP) complexes such as stress granules. These granules accumulate adjacent to P bodies if 
cells undergo environmental stress conditions such as heat shock or oxidative stress. Stress 
causes the phosphorylation of eIF2α (eukaryotic translation initiation factor 2 alpha), which 
leads to a reduction of eIF2-GTP-tRNAMET, the ternary complex that normally loads 
methionine onto the 48S pre-initiation complex to initiate translation. The T cell internal 
antigen-1 causes the assembly of stress granules by dissolving such translationally inactive 
pre-initiation complexes 147. The lack of the decapping enzymes DCP1A–DCP2 and the 
presence of transcription initiation factors in stress granules indicate that these mRNP 
complexes function in the storage of stalled translation initiation complexes due to adverse 
environmental conditions. Interestingly, Roquin-1 was also proposed to localize to stress 
granules 39. Stress granules and P bodies also share components such as XRN1 and TTP, the 
latter one being responsible for mRNA exchange between P bodies and stress granules 148. 
However, there are still many open questions concerning the significance and assembly of P 
bodies and stress granules as well as the dynamics of mRNA exchange and degradation. 	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5.3 Objective	  of	  the	  research	  work	  
The protein Roquin-1 is one of the rare examples in which a single point mutation in a gene 
results in a complex autoimmune disease in mice 39. Elevated Icos levels were held 
responsible for the spontaneous formation of follicular helper T cells and germinal centers in 
mice with the M199R mutation in Roquin-1san. Although the same group could show that 
Roquin-1 limited the abundance of Icos mRNA 119, the exact mechanism how Icos was 
regulated remained unknown. 
Before the start of this research project, extensive structure-function analyses were performed 
to investigate the role of each protein domain in Roquin-1. Furthermore, the molecular 
mechanism by which Roquin-1 represses Icos was investigated with respect to dependency on 
or cooperation with the miRNA pathway. These studies revealed that Roquin-1 functions 
independently of the miRNA pathway to repress Icos 149,150. Amino-terminal sequences, 
especially the newly defined ROQ domain, are involved in mRNA interaction, whereas the 
carboxy-terminal parts are required for target repression and localization of Roquin-1. 
In cooperation with this study 149, one part of this thesis work was the investigation of direct 
protein–RNA interactions in vitro as a crucial first step for Icos repression. Furthermore, the 
in vitro binding studies aimed at discovering the cis-element for Roquin-1 binding. 
Contrary to earlier publications, which report localization of Roquin-1 to stress granules 39, 
Roquin-1 localizes in P bodies in various cell lines. Only after induction of cell stress by 
arsenite treatment Roquin-1 translocates into stress granules 149,150. The present work 
corroborated these results by investigating localization of Roquin-1 in primary CD4+ T cells. 
These combined results allowed the elaboration of a molecular mechanism of Icos repression: 
Roquin-1 post-transcriptionally regulates Icos by directly binding to the Icos mRNA and by 
interacting with Rck and Edc4 149, two factors of the decapping pathway (section 5.2), to 
induce Icos mRNA decay. 
The second part of this thesis addresses the functions of Roquin-1 and its paralog Roquin-2 in 
vivo. Roquin-2, also named Mnab, was first described in 2000 as a nucleic acid binding 
protein with unknown function 151. Interestingly, it exhibits remarkable similarities with 
Roquin-1. Roquin-1 and Roquin-2 share the same domain organization with high homology 
of the RING finger, the ROQ domain and the zinc finger in their amino-terminal parts. To 
investigate Roquin-2 functions in vivo, a conditionally targeted Roquin-2 knockout mouse 
was obtained to analyze Roquin-2 deficiency in different cell types. 	    
Introduction  39 
At the same time, Rc3h1-deficient mice were generated and analyzed by a collaborating 
research group 120. As described above, the M199R mutation in Roquin-1san caused a lupus-
like autoimmune disease with T cell-intrinsic phenotypes 39. The complete loss of the  
Roquin-1 protein was therefore assumed to cause an even more severe phenotype. Indeed, 
systemic deletion of Roquin-1 resulted in perinatal death. However, loss of Roquin-1 in  
T cells, B cells or the hematopoietic system led to elevated Icos levels, but failed to induce 
anti-nuclear antibody responses 120.  
We therefore speculated that Roquin-2 could compensate for the complete loss of Roquin-1, 
thereby preventing the development of an autoimmune disease. An essential part of this 
research project therefore aimed at investigating the potential redundancy of Roquin-1 and 
Roquin-2 by analyzing mice deficient for both Rc3h1/Rc3h2 in T cells. 
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6 Material	  
6.1 Mice	  
Mice with Rc3h2tm1a(KOMP)Wtsi alleles were obtained from the International Knockout Mouse 
Consortium. For removing of the Frt-flanked NeoR cassettes hACTB::FLPe.9205 mice were 
obtained from Jackson and CD4-Cre mice 152 were used for loxP site recombination. To 
obtain mice, which can be adenovirally transduced, standard targeting procedures were used 
to generate transgenic CAG-CARstop-fl mice (Heger and Schmidt-Supprian, unpublished). 
Specifically, the targeting vector pROSA26-1 was modified to contain the CAG promoter, a 
loxP-flanked neomycin resistance gene/STOP cassette, the truncated human coxsackie 
adenovirus receptor (CAR), which is inactive in its intracellular signaling domain (CARΔ1) 
and the bovine growth hormone polyadenylation site. All mice were on a C57BL/6 genetic 
background or for Rc3h2 also on a mixed C57BL/6-NMRI background. C57BL/6, DOCAR 
and DO11.10 mice were obtained from Taconic Farms. DOCAR (Tg(DO11.10)10Dlo 
Tg(CARΔ-1)1Jdgr) and DO11.10 mice bear a transgenic DO11.10 T cell receptor specific for 
a chicken ovalbumin (OVA) peptide. T cells from these mice are predominantly naive, if not 
experimentally activated by OVA-loaded APC or polyclonal stimulation. DOCAR mice 
additionally bear the truncated CARΔ1 receptor. All animals were housed in a special 
pathogen-free barrier facility in accordance with the Helmholtz Zentrum München 
institutional, state and federal guidelines. 
 
6.2 Cell	  lines	  and	  cell	  culture	  
Human embryonic kidney cells (HEK293T) as well as human lung adenocarcinoma epithelial 
cells (A549) were purchased from ATCC. The HEK293A cell line was obtained from 
Invitrogen. Mouse embryonic fibroblasts (MEFs) were obtained from breedings of Rc3h2+/neo 
x Rc3h2+/neo and Rc3h1fl/fl; Rc3h2fl/fl x Rc3h1+/fl; Rc3h2+/fl mice, respectively and prepared as 
described in section 7.4 to produce MEFs deficient for Roquin-2 or both Roquin-1 and 
Roquin-2 proteins. Media used for cultivating cell lines (DMEM, supplemented with 10% 
FCS, 1% PenStrep and 1% HEPES) and primary T cells (RPMI, supplemented with 10% FCS 
and 1% of NEAA, β-mercaptoethanol-L-glutamine, vitamins, HEPES, PenStrep and sodium 
pyruvate) are described below (Table 1). 
 
42 
Table 1: Cell culture components 
Name Company 
β-Mercaptoethanol Sigma-Aldrich 
Dulbecco's Modified Eagle Medium (DMEM) Gibco, Invitrogen 
Fetal calf serum (FCS) PAN BIOTECH GmbH 
RPMI 1640, without L-glutamine BioWhittaker, Lonza 
100x NEAA BioWhittaker, Cambrex 
GIBCO™ L-Glutamine-200 mM (100x), flüssig Gibco, Invitrogen 
GIBCO™ MEM Vitamin Solution (100x), flüssig Gibco, Invitrogen 
HEPES (1M) Gibco, Invitrogen 
PenStrep (10,000 U/ml) Gibco, Invitrogen 
Sodium pyruvate (100 mM) BioWhittaker 
 
6.3 Antibodies	  and	  cytokines	  
For intracellular staining and Western blotting of Roquin-1/2, we generated monoclonal 
antibodies against an amino-terminal fragment of Roquin-1 (aa 1–441) via immunization of 
rats. All antibodies described below were against mouse antigens unless otherwise stated. 
 
Table 2: Antibodies and cytokines for stimulation and differentiation of primary mouse T cells 
Antibody / cytokine Company 
Anti-CD3 (145-2C11) In-house production 
Anti-CD28 (37N) In-house production 
Anti-hamster IgG (goat) MP biochemicals 
Anti-IFN-γ (XMG1.2) In-house production 
Anti-IL-2 Miltenyi Biotec. 
Anti-IL-4 (IIB11) In-house production 
Anti-IL-12 (C17.8) In-house production 
Anti-Ox40 antibody (Ox86) In-house production 
Anti-rat IgG eBioscience 
IL-4 supernatant In-house production 
Recombinant human IL-2 (ProleukinS) Novartis 
Recombinant human TGF-b1 R&D Systems 
Recombinant mouse IL-6 PeproTech 
Recombinant mouse IL-12  BD Biosciences 
 
Table 3: Antibodies for histology 
Antibody Company 
Anti-B220 (RA3-6B2) BD Biosciences 
Anti-CD4 (H129.19) BD Biosciences 
Anti-CD8a (53-6.7)  BD Biosciences 
Anti-ER-TR7 Novus Biologicals, ImmunoResearch 
Anti-FDC-M1 (4C11) BD Biosciences 
Anti-F4/80 (BM8) BMA Biomedicals AG 
Anti-IgD (11-26c.2a) BD Biosciences 
Anti-MOMA-1 (MOMA-1)  BMA Biomedicals AG 
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Table 4: Antibodies for Western blot analyses 
Antibody Company 
Anti-Edc4 (RCD8) Bethyl 
Anti-GAPDH (6C5)  Calbiochem 
Anti-histone H3 (C-term) Millipore 
Anti-IκBα (44D4) Cell Signaling 
Anti-Ikkβ (2C8) Cell Signaling 
Anti-Irf4 (P173) Cell Signaling 
Anti-NF-κB p65 Cell Signaling 
Anti-NF-κB2 p100/p52  Cell Signaling 
Anti-P-IκBα (Ser32/36; 5A5) Cell Signaling 
Anti-P-NF-κB p65 (Ser276) Cell Signaling 
Anti-Roquin-1/2 (3F12) In-house production 
Anti-RelB Cell Signaling 
Anti-tubulin (B-5-1-2) Santa Cruz 
 
Table 5: Antibodies for flowcytometric analyses 
Antibody Company 
Anti-B220 (RA3-6B2) eBioscience 
Anti-Bcl6 (K112-91) BD Biosciences 
Anti-CAR (E1-1)  eBioscience 
Anti-CD3 (145-2C11) eBioscience 
Anti-CD4 (GK1.5) eBioscience 
Anti-CD8 (53-6.7) eBioscience 
Anti-CD11c (N418) eBioscience 
Anti-CD21/35 (7G6) eBioscience 
Anti-CD23 (B3B4) eBioscience 
Anti-CD44 (IM7) eBioscience 
Anti-CD62L (MEL-14) eBioscience 
Anti-CD90.1 (Thy1.1, clone OX-7) eBioscience 
Anti-CD95 (Jo2) eBioscience 
Anti-CD134 (Ox40, clone OX-86) eBioscience 
Anti-CD278 (Icos, clone C398.4A) eBioscience 
Anti-CD279 (PD-1, clone J43) eBioscience 
Anti-CXCR5 (2G8) eBioscience 
Anti-F4/80 (BM8) eBioscience 
Anti-Foxp3 (FJK-16s) eBioscience 
Anti-GL-7 (GL7) eBioscience 
Anti-Gr-1 (RB6-8C5) eBioscience 
Anti-human IgG, Fcg-specific  Jackson ImmunoResearch 
Anti-IFN-γ (XMG1.2) eBioscience 
Anti-MHCII (I-A/I-E; M5/114.15.2),  eBioscience 
Anti-mIL-21R subunit FC chimera  R&D Systems 
Anti-NK1.1 (PK136) eBioscience 
Anti-rat IgG (biotinylated) Jackson ImmunoResearch 
Anti-Roquin-1/2 (3F12) In-house production 
Anti-Siglec-F (E50-2440) eBioscience 
Anti-TCRβ (H57-597) eBioscience 
PBS57-loaded CD1d Tetramer  National Institutes of Health 
Streptavidin  eBioscience 
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Table 6: Antibodies for confocal microscopy 
Antibody Company 
Anti-Rck (A300-461A)  Bethyl 
Anti-FMRP Gift from U. Fischer 
Anti-rabbit Cy5 Jackson Laboratories 
Anti-mouse Cy3 Jackson Laboratories 
 
6.4 Vectors	  and	  oligonucleotides	  
Most expression constructs were generated by TOPO® cloning. By cloning the sequence of 
interest into an entry vector (pCR8-GW, pENTR11, pCR2.1), the Gateway® system 
(Invitrogen) can be used to further insert the sequence into any destination vector by lambda 
recombination using LR clonase II (section 7.1.5). Point mutations were introduced into the 
insert of interest using site-directed mutagenesis (section 7.1.6).  
 
6.4.1 Entry	  vector	  constructs	  
Entry vectors were generated for mouse Roquin-1 (AY948287) and human ICOS 
(NM_012092). Mouse Ox40 (NM_011659) and mouse Ctla4 (NM_009843.3) were amplified 
from cDNA and cloned into the entry vector pCR8-GW. 
 
Table 7: Entry-plasmids for LR recombination into expression vectors. 
Entry plasmid Insert Purpose 
pCR8-GW hICOS full-length EMSA experiments and viral expression 
pCR8-GW hICOS CDS (nts 1–600) EMSA experiments 
pCR8-GW hICOS nts 1–700 EMSA experiments 
pCR8-GW hICOS nts 1–800 EMSA experiments 
pCR8-GW hICOS nts 1–900 EMSA experiments 
pCR8-GW hICOS nts 1–1000 EMSA experiments 
pCR8-GW hICOS nts 1–1210 EMSA experiments 
pCR8-GW hICOS nts 1–1810 EMSA experiments 
pCR8-GW hICOS nts 1–2210 EMSA experiments 
pCR8-GW hICOS nts 600–700 SHAPE analysis 
pCR8-GW hICOS nts 700–800 SHAPE analysis 
pCR8-GW hICOS nts 800–900 SHAPE analysis 
pCR8-GW mCtla4 full-length EMSA experiments 
pCR8-GW mOx40 full-length EMSA experiments and viral expression 
pCR8-GW mRoquin-1 CDS Viral expression 
pCR8-GW mRoquin-1 (aa 1–509) Inactive mutant for viral expression 
pCR8-GW Cre w/o poly(A) Viral expression 
pCR8-GW mMnab aa 1–1125 Viral expression 
pCR8-GW mMnab aa 1–1187 Viral expression 
pENTR11 Roquin eGFP Viral expression 
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6.4.2 Viral	  expression	  constructs	  
Retrovirus was expressed from pMSCV-IRES-Thy1.1, pLNCX2 or pDest12.2 vectors. The 
expression constructs had been equipped with a gateway cassette to allow for lambda 
recombination (LR) using the gateway system. Sequences of Roquin-1–eGFP and Cre 
recombinase were inserted using the LR clonase II Kit (Invitrogen) (7.1.5). 
LR was also used to insert the following sequences into the adenoviral vector pCAGAdDu: 
Roquin-1 (aa 1–509 and WT), Roquin-2 (aa 1–1125 and aa 1–1187). The vector contained a 
bovine growth hormone poly(A)-signal in the context of the CAG (chicken actin promoter 
and CMV enhancer) promoter. 
 
6.4.3 Additional	  constructs	  
Mouse Roquin-1 was cloned NcoI – XhoI into the bacterial expression vector pETM-11. The 
mouse Roquin-2 construct mMNAB pcDNA3 (IRCLp5011C0928D) was purchased from 
Source BioScience ImaGenes and the amino-terminal part (aa 1–438) cloned PciI – SalI into 
the pCR2.1 vector. By using the compatible restriction sites NcoI/PciI – XhoI/SalI, Roquin-2 
(aa 1–438) was exchanged with Roquin-1 (aa 1–441) in the pETM-11 vector (Table 8). 
 
Table 8: Plasmids for protein expression 
Entry plasmid Insert Purpose 
pETM-11 Roquin-1 full-length EMSA experiments 
pETM-11 Roquin-1 aa 1–414 EMSA experiments 
pETM-11 Roquin-1 aa 1–441 EMSA experiments 
pETM-11 Roquin-2 aa 1–438 EMSA experiments 
 
For immortalization of MEF cells a large T-plasmid was used, kindly provided by W. 
Hammerschmidt (Helmholtz Zentrum München, Germany). Ecotropic or amphotropic 
packaging vectors were used for retrovirus production.  
For adenoviral knockdown approaches, constructs were obtained from the Sirion GmbH. The 
vectors expressed hairpins from a U6 promoter and independently co-expressed GFP  
(Table 9). 	  
Table 9: Sequences for adenoviral knockdown approaches 
Target Sequence 
Sh-Rc3h1    CGCACAGTTACAGAGCTCATT 
Sh-Rc3h2 GCCAAGAGTAACTCATTACTT 
Sh-U6-Stop cassette  TTTTTGGCCTTTTTTAGCTG 	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6.4.4 Oligonucleotides	  synthesized	  by	  the	  company	  METABION	  
 
Table 10: Oligonucleotide sequences for DNA constructs 
Name Sequence (5’-3’) Application 
mMNAB SalI forw GTCGACCATGCCTGTGCAGGCAGCTC Clone mRoquin-2 
mMNAB NotI rev GCGGCCGCTCAGCTGTTAACCATCTTCCCA
TTTG 
Clone mRoquin-2 
mMNAB PciI1-438for CCCACATGTTACCTGTGCAGGCAGCTCAAT
GG 
Clone mRoquin-2 N-term 
mMNAB SalI1-438 rev GTCGACCTATTCCTGAGAATGGGCAAATGT
ACAATTTG 
Clone mRoquin-2 N-term 
hICOS BamHI for GAGAATCCGGACCATGAAGTCAGGCCTCT
GGTATTTC 
Clone hICOS  
hICOS CDS XhoI rev GAGACTCGAGGGTTATAGGGTCACATCTGT
GAG 
Clone hICOS CDS 
hICOS1-700 XhoI rev GAGACTCGAGTAAGTCAGACTCTCCGTGGT
CC 
Clone deletion construct 
hICOS1-800 XhoI rev GAGACTCGAGAGAGGACTCGGCAGTACCA
AG 
Clone deletion construct 
hICOS1-900 XhoI rev GAGACTCGAGGCACTGCTAGGAGCAGATG
TG 
Clone deletion construct 
hICOS1-1210 XhoI rev CTCGAGTGAGGGCACAAGAAAGCA Clone deletion construct 
hICOS1-1810 XhoI rev CTCGAGATACCTAGTGGCCTCTGGCTC Clone deletion construct 
hICOS1-2210 XhoI rev GAGACTCGAGGGTTAAGATAATATAAGTAT
GC 
Clone deletion construct 
hICOS full-length XhoI rev GAGCTCGAGGGTTACTACTGTTAAAATCTC
TTTG 
Clone hICOS full-length 
2deltaZincQCfor GCCTCCACAGCATAGCAAATAGAAAACATA
CATGTGTCG 
Quick change for 
Roquin-1ΔZn 
2deltaZincQCrev CTCGACACATGTATGTTTTCTATTTGCTATG
CTGTGGAG 
Quick change for 
Roquin-1ΔZn 
hICOS PCR 600 for TAATACGACTCACTATAGGTATGGAACTCT
GGCACCCAGGCATG 
T7 promoter for in vitro 
transcription 
SHAPE-ICOS 700 rev TGTAAAACGACGGCCAGTGTATGTAGTTAA
GTCAGACTCTCCGTGG 
M13 Primer sequence for 
probe annealing 
hICOS PCR 700 for TAATACGACTCACTATAGGACTACATACATC
TTCTGCTGGTGTTTTGTTC 
T7 promoter for in vitro 
transcription 
SHAPE-ICOS 800 rev TGTAAAACGACGGCCAGTGTTTGTTTTGAG
AGGACTCGGCAGTAC 
M13 Primer sequence for 
probe annealing 
hICOS PCR 800 for TAATACGACTCACTATAGGCAAAACAAACA
CCCTCTTGCAACCAGC 
T7 promoter for in vitro 
transcription 
SHAPE-ICOS 900 rev TGTAAAACGACGGCCAGTCTGGCTGATGCA
CTGCTAGGAGC 
M13 Primer sequence for 
probe annealing 
Mouse Ox40 for GAGGTCGACCATGTATGTGTGGGTTCAGC Clone mouse Ox40 
Mouse Ox40 FL rev CTCGCGGCCGCTAGCATGTTTATTAGGAG Clone mouse Ox40 
Mouse Ctla4 for GAGGTCGACCATGGCTTGTCTTGGACTC Clone mouse Ctla4 
Mouse Ctla4 FL rev CTCGCGGCCGCAACAATCACAAGAAACTT Clone mouse Ctla4 
Zinc419Argfornew GCAAATACAAAACATACATGCGTCGAGATA
TGAAAGGG 
Quick change to mutate 
Zn finger of Roquin-1 
Zinc416Argnewrev CCCTTTGCTTCATATCTCGACGCATGTATGT
TTTGTATTTGC 
Quick change to mutate 
Zn finger of Roquin-1 
M13 for TGTAAAACGACGGCCAG Sequence SHAPE assay 
M13 rev CAGGAAACAGCTATGAC Sequence SHAPE assay 
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Table 11: Oligonucleotides for genotyping 
Name Sequence (5’-3’) Application 
FlxFwN TACAAGGTAGAGACGTTTGGGAAG Rc3h1 detection 
RoqflxRv AAAGCCCTCAAGATTCTTTGGGCA Rc3h1 detection 
RoqloxFw GTAAATGAGATTCAGTGTGTCCAG Rc3h1 detection 
Rc3h2 5'arm CTGCCTAATCTCTGCTAGATG Rc3h2 detection 
Rc3h2 3'arm CTCAATGACAGGCAGTGATTC Rc3h2 detection 
LAR3 CAACGGGTTCTTCTGTTAGTCC Rc3h2 detection 
ICOS1228for GGTGTCCATCAAGAATCCAATG Icos detection 
ICOS1228rev CCTTCTTAACTACTATTGGTACCTTG Icos detection 
Neo-for GATTGAACAAGATGGATTGC Icos detection 
Neo-rev CAGAAGAACTCGTCAAGAAG Icos detection 
IFNg MUT for CCTTCTATCGCCTTCTTGACG IFN-γ detection 
IFNg WT for AGAAGTAAGTGGAAGGGCCCAGAAG IFN-γ detection 
IFNg rev AGGGAAACTGGGAGAGGAGAAATAT IFN-γ detection 
Car for CAGGAGCGAGAGCCGCCTAC Car detection 
Car rev CAGCCACTCGATGTCCAGCGGTC Car detection 
CD4Cre for ACGACCAAGTGACAGCAATG CD4-Cre detection 
CD4Cre rev CTCGACCAGTTTAGTTACCC CD4-Cre detection 
VavCre 1 GACAGGCAGGCCTTCTCTGAA Vav-Cre detection 
VavCre 2 CTTCTCCACACCAGCTGTGGA Vav-Cre detection 
 
Table 12: Oligonucleotides and probes (Universal probe library of Applied Biosystems) for qPCR 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) Probe  
Irf4 AGCACCTTATGGCTCTCTGC TGACTGGTCAGGGGCATAAT #3 
RelB GCCTTGGGTTCCAGTGAC TGTATTCGTCGATGATTTCCAA #103 
Chuk (Ikkα) GCACAGTAACCCCTCCAGTATC CATTTGTGCTAACGTCTCTCCA #46 
Ikbkb (Ikkβ) CCGGAAAGTGTCAGCTGTATC CCTCAGCTGGAAGAAGGAGA #92 
Ikbkg (Ikkγ) GGTACTCCTGAGACCCTCCA CTGATTGCTCTGCCGGATA #27 
Map3K14 (NIK) TCCACAGAATGAAGGACAAGC TACCCGAAACACCTCGAGTC #47 
Birc2 (Ciap1) GAAGAAAATGCTGACCCTACAGA CATGACGACATCTTCCGAAC #80 
Birc3 (Ciap2) CGATGCAGAAGACGAGATGA TTTGTTCTTCCGGATTAGTGC #68 
Traf2 GCTCCTTCTGCCTGACCA AGACACAGGCAGCACAGTTC #73 
Traf3 GTTCAGACTCTTCTAAGGAGTGAGG TCCAGGGAGTTGCTCCAC #62 
Tradd TGAATTACATCTTAGCCCAGAAGC CACACGTCAGTTTGCAGAGC #78 
Icos  CGGCAGTCAACACAAACAA TCAGGGGAACTAGTCCATGC #6 
Tnfrsf4 (Ox40) GCTTGGAGTTGACTGTGTTCC GGGTCTGCTTTCCAGATAAGG #79 
Ywhaz CGCTAATAATGCAGTTACTGAGAGA TGGAAGGCCGGTTAATTTT #2 
 
6.5 Chemicals,	  enzymes	  and	  kits	  	  
Table 13: Chemicals and reagents 
Compound Company 
Ampicillin  Roche 
Biozym DNA Agarose Biozym Scientific GmbH 
Brefeldin A Sigma-Aldrich 
BSA (Albumin Fraktion V) Roth 
Chloroform min. 99% Sigma-Aldrich 
Deoxynucleotide (dNTP) set Fermentas 
DEPC Roth 
Dimethyl Sulphoxide (DMSO)  Sigma-Aldrich 
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DNA Ladder 1 kb Plus  Invitrogen 
DNA Ladder 2-Log (0.1–10.0 kb) New England BioLabs 
Dynabeads MyOne Tosylactivated  Invitrogen 
ECL plus Western blotting reagent GE healthcare 
Ethidium bromide 1% (w/v) Serva 
Formaldehyde solution 36.5–38% Sigma Life Science 
FuGENE reagent Roche 
Ionomycin, Free Acid, Streptomyces conglobactus Calbiochem 
IPTG VWR International GmbH 
JetPI Polyplus 
Kanamycin sulfate Roth 
Milk powder Roth 
Paraformaldehyde Sigma-Aldrich 
Phorbol-12-myristate-13-acetate (PMA) Calbiochem 
RiboRuler™ High Range RNA Ladder Fermentas 
Saponin VWR International GmbH 
Tri®Reagent (Trizol) Invitrogen 
Trypsin 0.05% / EDTA 0.02% in PBS  Pan biotech GmbH 
Trypton Merck 
Tween 20 Applichem 
β-Mercaptoethanol 99% Sigma-Aldrich 
 
Table 14: Enzymes 
Enzymes Company 
Gateway LR Clonase II Enzyme Mix Invitrogen 
Proteinase K Invitrogen 
Restriction enzymes New England BioLabs 
T4 DNA Ligase (10,000 U/ml) New England BioLabs 
Taq Polymerase (5,000 U/ml) New England BioLabs 
Taq Polymerase (5,000 U/ml) Invitrogen 
Vent Polymerase (2,000 U/ml) New England BioLabs 
 
Table 15: Kits 
Kit Company 
Annexin V-Cy5 Apoptosis Detection Kit BioVision 
CD4+ CD62L+ T cell Isolation Kit II, mouse  Miltenyi Biotec 
CD4+ T cell Isolation Kit (mouse) Miltenyi Biotec. 
DETACHaBEAD® Mouse CD4 Invitrogen 
Dynabeads®Mouse CD4 (L3T34) Kit  Invitrogen 
mMESSAGE mMACHINE(R) Kit Ambion 
Nucleobond®Xtra Maxi Kit Macherey-Nagel GmbH & Co. KG 
pCR™8/GW/TOPO® TA Cloning® Kit Invitrogen 
PureYield™ Plasmid Miniprep System Promega 
QIA®quick gel extraction Kit Qiagen 
RNeasy® Mini Kit Qiagen 
TaqManMicroRNA Assay Applied Biosystems 
TOPO® TA Cloning® Kit Invitrogen 
Universal Probe Library  Roche 
XL QuickChange Stratagene 	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6.6 Buffer	  and	  solutions	  	  
Table 16: Buffers and solutions 
Standard solution Composition 
APS  10% APS w/v in ddH20 
Buffer A for nuclear fractionation 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM 
EDTA, 1 mM dithiothreitol, protease inhibitor 
mix without EDTA (Roche) in ddH20 
Coomassie staining solution 50% methanol, 40% H2O, 10% glacial acid, 
0.25 g/l brilliant-blue R-250 
Destaining solution 50% methanol, 40% H2O, 10% glacial acid 
DNA dye (6x) 0.25 % bromophenol blue, 0.25 % xylene 
xyanol, 30% glycerol 
Meister lysis buffer 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.25% 
(v/v) Nonidet-P40, 1.5 mM MgCl2, 1 mM DTT, 
protease inhibitor mix without EDTA (Roche) in 
ddH20 
PBS 137 mM NaCl, 10 mM phosphate, 2.7 mM KCl 
RIPA buffer 20 mM Tris-HCl (pH 7.5), 250 mM NaCl, 10 mM 
MgCl2, 1% NP-40, 0.1% SDS, 0.5% Na-
desoxycholate, 1 mM DTT, protease inhibitor 
mix without EDTA (Roche) in ddH20 
SDS (10%) 10% SDS (w/v) dissolved in ddH20 
SDS sample buffer (4x) 200 mM Tris/HCl (pH 6.8), 8% w/v SDS, 4% 
glycerol, 0.1% w/v bromophenol blue, 10% v/v 
β-mercaptoethanol in ddH20 
SDS-PAGE running buffer (5x) 25 mM Tris-Base, 200 mM Glycine, 10% (w/v) 
SDS in ddH2O 
TAC lysis buffer 13 mM Tris, 140 mM NH4Cl (pH 7.2) in ddH20 
TBE (5x) 45 mM Tris-HCl, 1 mM EDTA (pH 8.0) in ddH20 
TBS (1x) 20 mM Tris-Base, 137 mM NaCl, 3.8 ml 1M 
HCl, dissolved in ddH20 
TBS-T (1x) 20 mM Tris-Base, 137 mM NaCl, 3.8 ml 1M 
HCl, 0.1% (v/v) Tween 20, dissolved in ddH20 
TE (10x) 100 mM Tris/HCl (pH 8.0), 10 mM EDTA (pH 
8.0) in ddH20 
Western blot buffer 25 mM Tris-Base, 192 mM glycin, 20% v/v 
methanol (pH 8.4) in ddH20 	  
6.7 Instruments	  	  
Table 17: Instruments and devices 
Instrument Official name and company 
Accuracy weighing machine KERN ABJ-220-4M (Kern und Söhne GmbH) 
KERN EW 220-3NM (Kern und Söhne GmbH) 
Agarose gel chambers Peqlab Biotechnologie GmbH 
Bacterial incubator Brutschrank BINDER BF 53 (Binder 
Labortechnik) 
Innova 4400 incubator shaker (New Brunswick 
Scientific GmbH) 
BD FACS AriaIII Cell Sorter BD Biosciences 
BD FACS Calibur Flow Cytometer BD Biosciences 
BD LSRFortessa Cell Analyzer BD Biosciences 
BD LSRII Flow Cytometer BD Biosciences 
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Blotting chamber BioRad 
Centrifuges and rotors Beckman Coulter Avanti-J-26XP (Beckman 
Coulter); JA-10 Rotor, Fixed Angle (Beckman 
Coulter) 
Allegra®X-12R Centrifuge (Beckman Coulter); 
Rotor SX 4750 (Beckman Coulter) 
Eppendorf Centrifuge 5810R (Eppendorf); 
Rotor A-4-62 and F-34-6-38 
Multifuge Heraeus (Thermo Scientific); Rotor 
SN179 
CO2 incubator Forma Direct Heat CO2 Incubator HEPA Class 
100 (Thermo Electron Corporation) 
Coasting mixer Tube Roller-Mixers, SRT1 (Stuart) 
(ScienceLab) 
Confocal microscopy Type: 301-185.104-000 Order-No: 500277 
(Leica) 
Energy supplier Stromgeber EC105 (Thermo Electron 
Corporation) 
BioRad energy supplier (BioRad) 
Fluorescence microscope Axiovert 200M (Zeiss) 
Olympus DP72  
Hamamatsu NanoZoomer 2.0-HT 
Gel documentation (Peqlab Biotechnologie GmbH) 
Ice machine Scotsman AF 200 (Scotsman Icesystem) 
Magnet stirrer RCT basic safety control (IKA) 
Microscope Axiovert 40C (Zeiss) 
Microwave Bosch 
pH meter pH-Meter inoLab® pH 720 (Wissenschaftlich 
Technische Werkstätten) 
Protein gel chamber BioRad 
Spectrophotometer Eppendorf BioPhotometers (Eppendorf) 
Thermo Scientific NanoDropTM 1000 
Spectrophotometer (Thermo Fisher Scientific 
Inc.) 
Sterile-working bench  BDK, Luft und Reinraumtechnik 
Table centrifuge Centrifuge 5415D (Eppendorf) 
Centrifuge 5417R (Eppendorf) 
Thermo cycler DNA Engine 48/48 Dual Alpha Unit With Two 
Heated Lids (BioRad) 
Light Cycler 480II (Roche) 
Thermo mixer Thermomixer compact (Eppendorf) 
Thermomixer comfort (Eppendorf) 
UV-lamp Transilluminator model. TS-40 (Ultra-Violet 
Products Ltd.) 
Vortexer Vortex Genius 3 (IKA) 
Water bath WB7 (Memmert) 	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7 Methods	  
7.1 Molecular	  standard	  procedures	  
7.1.1 Bacterial	  culture	  
Chemically competent E. coli DH5alpha bacteria (Invitrogen) were used for plasmid DNA 
amplification. For the expression of recombinant protein, E. coli Rosetta(DE3)pLysS bacteria 
(Novagen) were used. The bacteria were transformed by incubation of 50 µl E. coli culture 
with plasmid DNA for 20 min on ice, followed by 30 s heat shock at 42°C. After brief 
equilibration on ice, 250 µl LB medium was added and cells were gently shaken (500 rpm) 
for 1 h at 37°C. The suspension was spread onto LB-agar containing the respective antibiotics 
and incubated at 37°C over night. For storage, a single colony was picked and used for 
inoculation of a fresh overnight culture. A mix of bacteria suspension and glycerol (1:1) was 
stored at –80°C. 
LB media and LB agar were prepared with “ready to mix” powder (SERVA), supplemented 
with ampicillin (100 µg/ml), spectinomycin (50 µg/ml), kanamycin (30 µg/ml) or 
chloramphenicol (170 µg/ml) for the selection of bacterial resistance.  
 
7.1.2 PCR	  for	  cloning	  and	  genotyping	  
For the generation of DNA constructs, PCR was performed according to standard protocols. 
The Taq polymerase (Invitrogen or New England BioLabs) was used for the amplification 
and generation of A-overhangs important for TA cloning. For more efficient proofreading, the 
Vent polymerase (New England BioLabs) was added to the Taq polymerase at a ratio of 1/10. 
Primers were designed with an annealing temperature of 53–62°C. A standard PCR reaction 
to amplify a DNA of interest contained: 10–150 ng DNA template, 0.25 µl of 100 pmol/µl 
forward primer, 0.25 µl of 100 pmol/µl reverse primer, 0.5 µl dNTP-mix (25 mM each), 
2.5 µl 10xPCR Rxn Buffer, 1 µl 50 mM MgCl2, 0.7 µl Taq DNA polymerase and 0.3 µl Vent 
polymerase. The mixture was filled up with H2O to a volume of 25 µl. Cycling reactions 
were: 94°C for 2 min; 28 cycles of 94°C for 45 s, 58°C for 30 s, 72°C for 60 s (1 min per kb 
of DNA); 72° for 10 min and hold at 4°C.  
For genotyping, the tip of the mouse tail was lysed overnight at 55°C in 200 µl genotyping 
buffer (100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 0.2 mg/ml 
proteinase K). After inactivation of the Proteinase K at 95°C for 15 min, 300 µl of water were 
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added and 0.4 µl were used as template for the PCR (see above). Primers for genotyping are 
listed in Table 11. For analysis or purification a minimum of 15 µl of the PCR product were 
loaded onto an agarose gel. 
 
7.1.3 Preparation	  and	  purification	  of	  DNA	  
DNA was purified with the PureYield™ Plasmid Miniprep System (Promega). For larger 
amounts of DNA, the Nucleobond®Xtra Maxi Kit (Macherey-Nagel GmbH & Co. KG) was 
used, both according to the manufacturer’s protocol. 
 
7.1.4 DNA	  extraction	  from	  agarose	  gels	  
DNA was loaded on 1% agarose gels containing 3.5 µl ethidium bromide per 75 ml gel. The 
desired PCR product was excised under 254 nm UV light and purified using the QIAquick 
PCR Purification Kit according to the manufacturer’s protocol (Qiagen). 
 
7.1.5 TOPO®	  cloning	  and	  site-­‐specific	  recombination	  
PCR products can be cloned in a very efficient and rapid way using TOPO® cloning. The 
linearized entry vector is supplied with overhanging 3’deoxythymidine (T) residues and the 
topoisomerase I covalently bound to the vector. Furthermore, the Taq polymerase has a 
terminal transferase activity that adds a single deoxyadenosine (A) to the 3’ends of PCR 
products. This allows efficient ligation of the PCR product into the vector.  
Gateway® cloning allows the transfer of DNA sequences from an entry vector to a destination 
vector via lambda recombination (LR) based on specific recombination sites (Attl1 and 2, 
AttR1 and 2, respectively). A switch in antibiotic resistance between entry and destination 
vectors and the expression of a bacterial death gene (Toxin ccdB) ensure that only destination 
vectors are selected, which have recombined. TOPO® and Gateway® Cloning (Gateway LR 
Clonase II Enzyme Mix) reactions were carried out according to the manufacturer’s protocol. 
For LR reactions of plasmids with more than 20 kb, the reaction was performed at 16°C 
overnight. 
 
7.1.6 Site-­‐directed	  mutagenesis	  with	  QuikChange®	  II	  XL	  
The QuickChange® II XL Kit (Stratagene) is designed to insert point mutations, deletions or 
insertions of single nucleotides into DNA constructs. Primers were chosen to match a melting 
Methods  53 
temperature above 75°C and a GC content of at least 40% (Table 10). The PCR was slightly 
altered to increase the number of colonies (Table 18), followed by a DpnI digested for 1 h to 
degrade the methylated and hemi-methylated parental template. Then, 4 µl of the PCR 
product were transformed into DH5alpha bacteria. One of the resulting plasmids was 
sequenced to check for the desired mutation. 
 
Table 18: PCR conditions for site-directed mutagenesis 
Cycles Temperature Time 
1 95°C 1.2 min 
18 
 
95°C 1 min 
60°C 1 min 
68°C 1.1 min 
1 68°C 7 min 
 
7.1.7 Ligation	  of	  DNA	  fragments	  
For ligation of the digested pETM-11 vector with the mRoquin-2 (amino-terminus) insert, the 
fragments were incubated at 16°C overnight with 1 µl T4 DNA ligase (New England 
BioLabs) and 1 µl ligase buffer (10x), adjusted to a total volume of 10 µl.  
 
7.1.8 Extraction	  of	  RNA	  
RNA for array approaches was extracted by using the mirVana™ miRNA Isolation Kit 
(Ambion). Up to 107 cells were lysed for 10 min on ice in 600 µl Lysis/Binding buffer with 
60 µl Homogenate Additive. After adding 600 µl Acid-Phenol-Chloroform and vortexing for 
60 s, the samples were centrifuged for 5 min, at 10,000 g and RT. The upper phase was 
transferred to a new tube and mixed with 1.25 volumes of 100% EtOH, loaded onto the filter 
cartridge and centrifuged 15 s at 10,000 g. After washing with Wash1 (one time) and 
Wash2/3 (two times), the samples were eluted with 100 µl hot elution buffer (95°C) at 
maximum speed for 20–30 s. 
For quantitative real-time PCR, RNA was extracted from cells by using 1 ml of Trizol reagent 
(Invitrogen) according to the manufacturer’s protocol. Shortly, the cells in Trizol reagent were 
mixed with 200 µl chloroform and incubated at RT for 2 min. The organic and aqueous 
phases were separated by centrifugation at 12,000 g for 15 min at 4°C. The aqueous phase 
was transferred to a new tube and subjected to isopropanol precipitation for 10 min at RT. 
RNA precipitates were centrifuged at 12,000 g for 10 min at 4°C, washed with 75% ethanol, 
air-dried and resuspended in 20 µl RNase-free water (treated with 0.1% DEPC). 
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7.1.9 Reverse	  transcription	  of	  RNA	  
RNA was reverse transcribed using the QuantiTect Reverse Transcription Kit (Qiagen) 
according to the manufacturer’s instructions. Up to 1 µg purified RNA was incubated in 
gDNA Wipeout buffer at 42°C for 2 min. For the reverse transcription a mix prepared from 
QuantiTect Reverse Transcriptase, QuantiTect RT Buffer (5x) and 3 µg Random Primers 
(Invitrogen) was used. The reaction was performed at 42°C for 15 min and was then stopped 
by incubation at 95°C for 3 min. The resulting cDNA was diluted with H2O (ad 100 µl) and 
stored at –20°C. 
 
7.2 Cell	  culture	  
Mouse embryonic fibroblasts (MEFs), HEK293A/T and A549 cells were grown in DMEM 
with 10% (v/v) FCS, penicillin-streptomycin (1,000 U/ml) and HEPES (10 mM), pH 7.4 at 
37°C in a 5% CO2 humidified incubator. 
For storage, cells were frozen in a mixture of 90% FCS and 10% DMSO in NUNC-freezing 
tubes. The cells were first slowly cooled down to –80°C and then transferred into a liquid 
nitrogen container for long-time storage.  
 
7.3 Preparation	  and	  stimulation	  of	  primary	  T	  cells	  	  
Organs were pressed through rough nets and filtered (rough and fine nets obtained from BD 
Falcon) before analysis by FACS or isolation and differentiation of CD4+ T cells. For Th1 
differentiation, CD4+ T cells were isolated from spleens and lymph nodes using CD4 
dynabeads and detachabeads (Invitrogen) according to the manufacturer’s protocol. For 
differentiation into Th0, Th1, Th2, Th17 and Treg subsets, cells were enriched in CD4+ T 
cells using CD4 dynabeads and then sorted on a BD FACS AriaIII Cell Sorter to obtain naive 
CD4+ T cells (CD4+ CD25– CD62L+ CD44–). The cells were stimulated on pre-coated plates 
(goat anti-hamster IgG; MP biochemicals) with anti-CD3 (145-2C11; 0.1–0.25 µg/ml) and 
anti-CD28 (37N; 1–2.5 µg/ml) or with anti-CD3/anti-CD28 antibodies coupled to magnetic 
beads (Dynabeads M-450 Tosylactivated, Invitrogen) at a ratio of 1:1 (beads:cells). Skewing 
antibodies and cytokines for the respective differentiation conditions are listed in Table 19. 
Suppliers are given in Table 2. Two days after activation, CD4+ T cells skewed for Th0, Th1 
or Th2 subsets were cultured in the presence of recombinant hIL-2 (20 U/ml, ProleukinS, 
Novartis). An anti-Ox40 antibody (Ox86, 10 µg/ml) or isotype control antibody (rat IgG,  
10 µg/ml, eBioscience) was used for NF-κB activation.  
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Table 19: Antibodies and cytokines for T cell differentiation 
Differentiation condition Antibody / cytokine Concentration 
Th0 – – 
Th1 anti-IL-4 10 µg/ml 
 IL-12 10 ng/ml 
Th2 anti-IL-12 10 µg/ml 
 anti-IFN-γ 5 µg/ml 
 IL-4 hybridoma supernatant 1:10 (v/v) 
Th17 anti-IL-12 10 µg/ml 
 anti-IFN-γ 5 µg/ml 
 anti-IL-4 10 µg/ml 
 anti-mIL-2 2.5 µg/ml 
 IL-6 5 ng/ml 
 TGF-β 1 ng/ml 
Treg TGF-β 1 ng/ml 
 IL-2 100 U/ml 
 
7.4 Generation	  of	  mouse	  embryonic	  fibroblasts	  
Mouse embryonic fibroblasts (MEF) were generated by intercrossing Rc3h2+/neo mice or 
Rc3h1/2+/fl mice and removing the embryos at 13.5 dpc. The trunk of the embryos excluding 
the head and the liver was sliced into very small pieces, incubated with trypsin for 15 min at 
37°C and then cultivated in DMEM medium. Cells were directly taken for experiments or 
immortalized via ecotropic retroviral infection with an SV40 large T antigen plasmid 
followed by hygromycin selection at 100 µg/ml for two weeks. Rc3h1/2-/- cells were obtained 
by retroviral Cre transduction of Rc3h1/2fl/fl MEFs. 
 
7.5 Virus	  production	  and	  transduction	  
7.5.1 Adenovirus	  
Type 5 replication-deficient adenovirus was produced by transfection of linearized 
adenovirus-encoding plasmids into HEK293A (Invitrogen) with JetPI (Polyplus) transfectant 
according to the manufacturer’s instructions. Adenovirus-producing cells were harvested after 
ten days and, subjected to three freeze-thaw cycles to release virus particles. In order to obtain 
a higher virus titer, the resulting virus lysate was amplified by infection of 2*107 HEK293A 
cells. After 48 h, cells were harvested and resuspended in 800 µl medium before freeze-thaw 
cycles to generate the amplified virus lysate. 2*106 CD4+ CAR+ T cells were incubated for 2 h 
at 37°C with 100–300 µl virus lysate if the virus did not contain a marker for titration or with 
an MOI (multiplicity of infection) of 100–300.  
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7.5.2 Retrovirus	  
Retroviral supernatants were produced by calcium-phosphate transfection of HEK293T cells 
with the retroviral expression plasmid and an ecotropic packaging vector. After 48 h the 
supernatant was harvested, filtered (0.45 µm; Millipore) and concentrated (6,000 g; 4°C; o/n). 
Transfection of T cells with retrovirus is described below (section 7.6).  
 
7.6 In	  vitro	  deletion	  of	  loxP-­‐flanked	  Rc3h1/2	  alleles	  
CD4+ T cells were transduced 40 h after Th1 stimulation with concentrated MSCV-Cre-
Thy1.1 retrovirus by spin-infection (830 g; 1 h; 18°C) in the presence of 9 µg/ml polybrene 
(SIGMA). After 6–7 h incubation the virus supernatant was removed and cells were cultured 
with recombinant hIL-2 (20 U/ml, ProleukinS, Novartis). 3–4 days after retroviral 
transduction, cells were lysed to generate protein extracts for Western blot analysis or were 
used for adoptive transfer. In this process, CD4+ T cells (10–15*106 per mouse) were injected 
i.v. into Icos-/- animals. For analyzing cell proliferation, cells were labeled before transfer with 
the Cell Proliferation Dye eFlour450 (eBioscience) according to the manufacturer’s protocol. 
 
7.7 Confocal	  microscopy	  
CD4+ T cells were transfected with LNCX2-Roquin-1-eGFP constructs using FuGENE 
reagent (Roche) according to the manufacturer’s protocol. Cells were then seeded on 
Diagnostica glass cover slips and subjected to oxidative stress for 1 h at 37 °C with 0.5 mM 
sodium arsenite (Sigma). Diagnostica glass cover slips were coated first with 0.01% (w/v) 
poly-L-lysine and then with anti-CD3 (2.5 µg/ml) and anti-CD28 (5 µg/ml) before the 
addition of T cells in a volume of 50 µl. Cells were fixed with 4% (w/v) paraformaldehyde 
and were washed three times in 0.5% (v/v) Nonidet-P40, 0.01% (w/v) NaN3 and 10% (v/v) 
FCS in PBS. Antibodies to Rck or FMRP were used for staining in combination with the 
secondary antibodies anti-rabbit Cy5 and anti-mouse Cy3. Images were captured on a Leica 
DM IRBE microscope and were analyzed with LCS Lite software. 
 
7.8 Protein	  purification	  
Roquin-1 (aa 1–441) was expressed from the pETM-11 bacterial expression vector (modified; 
Novagen) in E. coli Rosetta (DE3) pLysS bacteria. After induction of the protein expression 
with 1 mM IPTG (VWR International) and disruption of the cells by sonification, the protein 
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was purified by histidine-tag chromatography (GE Healthcare) and desalted via PD10 gel 
filtration (GE Healthcare). Roquin-2 (aa 1–438) was expressed from the vector pETM-11 in 
E. coli Rosetta2 (DE3) and purified by affinity chromatography (HiTrap Chelating column) 
and size exclusion chromatography (16/60 HiLoad Superdex 200 column). The purification 
buffer was 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 0.01% (v/v) 1-thioglycerol. Protein was 
visualized on SDS-polyacrylamide gels by Coomassie staining and subsequent de-staining. 
 
7.9 In	  vitro	  RNA	  transcription	  
For in vitro transcription, constructs containing the CDS with or without parts of the 3’UTR 
were introduced into the destination vector pDest17 (Invitrogen) by LR. The vector was 
linearized by digestion with restriction enzymes. The mMessage mMachine T7 transcription 
kit was used according to the manufacturer’s instructions (Ambion) and RNA was purified 
with an RNeasy Kit (Qiagen). 
 
7.10 Electrophoretic	  mobility	  shift	  assay	  (EMSA)	  
Samples were separated by electrophoresis through native 0.75% agarose gels and were 
stained with ethidium bromide after the run. Recombinant protein (0.5–200 pmol) was 
incubated for 20 min on ice with in vitro transcribed mRNA (0.6 or 1 pmol) in a buffer of 
150 mM KCl, 50 mM Tris-HCl (pH 7.4), 1 mM MgCl2, 1 mM EDTA and 1 mM DTT, and 
was then adjusted to a concentration of 16% (v/v) glycerol. The buffer conditions were 
optimized at a later time point to: 150 mM NaCl, 20 mM HEPES (pH 7.4), 1 mM MgCl2 and 
1 mM DTT, adjusted to 16% (v/v) glycerol.  
 
7.11 SHAPE	  assay	  
The selective 2’-hydroxyl acylation analyzed by primer extension (SHAPE) assay was used to 
model the secondary structure of an mRNA 153. As readout radioactive sequencing was 
chosen. For that purpose M13-primer DNA and a LMW DNA-ladder (New England BioLabs) 
were tagged with γ32P ATP. For the assay 2 pmol of the RNA of interest was first denatured at 
95°C for 2 min and then refolded on ice for 2 min in 0.5xTE buffer (total volume 12 µl). 6 µl 
folding mix (333 mM HEPES (pH 8.0), 20 mM MgCl2, 333 mM NaCl) were added and the 
sample was incubated for 20 min at 37°C. The RNA was modified with either 1 µl of 
130 mM NMIA or DMSO as a control for 45 min at 37°C. The RNA was precipitated with 
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EtOH for 30 min at –80°C and dissolved in 0.5xTE buffer. For the primer extension reactions, 
0.5 µM of the radiolabeled M13-primers were added to the NMIA (N-methylisatoic 
anhydride) or control reaction, incubated for 5 min at 65°C, slowly cooled down to 35°C and 
put on ice. 6 µl of SHAPE enzyme mix (4 parts Superscript III FS buffer, 1 part 0.1 M DTT 
and 1 part 10 mM dNTP mix) were added for 1 min at 52°C, followed by 1 µl Superscript III 
RT for 10 min at 52°C. After adding 1 µl 4 M NaOH for 5 min at 95°C, the reaction was 
stopped with 29 µl acid stop mix and subjected to a polyacrylamide sequencing gel. To assign 
the bands in the NMRI and control reaction, sequencing lanes were generated by adding 
2.5 µl ddNTP mix to the NMRI and control reactions. One or two sequencing reactions (here 
ddA and ddT) are usually sufficient to infer the entire sequence. 
 
7.12 Flow	  cytometry	  and	  intracellular	  staining	  
7.12.1 Surface	  staining	  
Single cell suspensions of thymus and spleen were pre-incubated with 10 µg/ml Fc-block 
(CD16/31; 2.4G2; in-house production) in staining buffer (PBS, 2% FBS, 2 mM EDTA) for 
10 min at 4°C and stained with antibodies for 20 min at 4°C in staining buffer. Antibodies, 
listed in Table 5, were diluted according to the manufacturer’s suggestion. The PBS57-loaded 
CD1d Tetramer was kindly provided by the National Institutes of Health. 
For the CXCR5 staining, cells were incubated for 1 h at 4°C with rat anti-mouse CXCR5 
hybridoma supernatant in staining buffer followed by stainings with biotinylated mouse anti-
rat IgG and Streptavidin–APC or –PerCP.  
 
7.12.2 Intracellular	  staining	  
For intracellular cytokine staining, splenocytes or CD4+ T cells were stimulated either with 
PMA/ionomycin (20 nM and 1 µM, respectively) or antiCD3/antiCD28 (0.25 µg/µl and 
2.5 µg/µl, respectively) for 5 h adding BrefeldinA (10 µg/ml) for at least 2 h. After the 
surface staining, cells were fixed with 4% PFA and permeabilized with PBS containing 0.5% 
saponin and 1% BSA. This buffer was used for all following steps. The samples were pre-
incubated with Fc-block (10 µg/ml) for 10 min and antibody stained for 30 min at the 
concentration suggested by the manufacturer. IL-21 was detected by staining with a mIL-21R 
subunit FC chimera for 30 min at room temperature, followed by a FITC-conjugated anti-
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human IgG, Fcγ-specific antibody. Bcl6 (45 min) and Foxp3 (30 min) stainings were 
performed at RT using the Foxp3 staining kit (eBioscience).  
For intracellular staining of Roquin-1/2, an in-house-produced biotinylated antibody (3F12) 
against the amino-terminus of both proteins was used. After 20 min fixation with 2% 
formaldehyde, cells were permeabilized in PBS containing 0.5% saponin and 1% BSA. 3F12 
supernatant was applied for 1 h (dilution 1:50), followed by staining with Streptavidin–APC. 
Biotinylation of the 3F12 antibody was performed with the EZ-Link NHS-PEG Solid-Phase 
Biotinylation Kit (Thermo Scientific) according to the manufacturer’s instructions. 
Samples were acquired on a FACSCalibur, LSRII or LSRFortessa (BD Biosciences) and 
analyzed with FlowJo software (Tree Star). 
 
7.13 Co-­‐immunoprecipitation	  and	  immunoblotting	  
For co-immunoprecipitations MEFs were lysed on ice in an NP-40 lysis buffer, shock frozen 
in liquid nitrogen, thawed and the lysates were cleared by centrifugation (10,000 g, 4°C, 
10 min). Anti-Roquin-1/2 antibody (Q4-2, in-house production) coupled to magnetic beads 
(MyOne Tosylactivated Dynabeads, Invitrogen) was incubated for 4 h at 4°C with lysate 
containing 3–5 mg protein in the presence of 20 U RNasin. Beads were washed three times 
with lysis buffer. For protein elution the beads were taken up in lysis buffer containing SDS 
sample buffer and boiled at 95°C for 5 min. The supernatant was used for Western blotting.  
For Western blot lysates, cells were washed in PBS at 4°C and lysed in a minimum of 15 µl 
RIPA or Meister lysis buffer. Lysates were incubated for 15 min on ice, vortexed every 2 min 
and then centrifuged at 10,000 g, 4°C for 10 min. The protein amount in the supernatant was 
determined by the Bradford protein assay. Protein samples were boiled in SDS sample buffer 
for 5 min at 95°C and loaded into the slots of a SDS-polyacrylamide gel. In addition, a protein 
size maker (Precision Plus Protein All Blue Standards, Biorad) was loaded. The gels consisted 
of a lower separating and an upper stacking part. The separating part consisted of 8–12% 
acrylamide, 0.1% SDS, 0.1% APS and 0.06% TEMED in 375 mM Tris-HCl (pH 8.8). The 
stacking part contained 5% acrylamide, 0.1% SDS, 0.1% APS and 0.1% TEMED in 126 mM 
Tris-HCl (pH 6.8). After loading the samples, the electrophoresis was first run for 15 min at 
80 V and then for 1.5 h at 120 V. The proteins were blotted on methanol-activated PVDF 
membranes at 40 V over night in Western blot buffer using a wet gel blotting chamber 
(Biorad). For protein detection, membranes were first blocked in 5% milk dissolved in TBS 
for two hours at RT. The blocked membranes were washed with TBS-T (3 x 10 min) and the 
diluted primary antibody was applied for 2 h at RT or over night at 4°C. The membranes were 
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washed again and incubated with the secondary antibody, conjugated with horseradish 
peroxidase, for 1 h at RT. After three more washing steps (TBST-T, TBS, H2O for 10 min 
each) the blots were developed with ECL plus Western blotting reagent (GE healthcare) or 
quantified on an Odyssey infrared imaging system. 
 
7.14 Nuclear	  fractionation	  
For cytoplasmic and nuclear fractionation, cells were resuspended in 200 µl buffer A  
(Table 16), incubated 15 min on ice and dounced 10 times. After centrifugation (10 min, 4°C, 
20,000 g), the supernatant containing the cytoplasmic fraction was used for Western blotting 
as described. The pellet that contained the nuclear fraction was washed two times with buffer 
A and was lysed for 15 min on ice in RIPA buffer (Table 16) and applied to Western blotting. 
 
7.15 Histology	  
Spleens were shock-frozen in HBS solution (Hank’s Balanced Salt Solution w/o Phenol Red; 
Lonza) and 4 µm sections were processed. Stainings were performed with BOND-MAX 
M210871 (Leica) and pictures were taken on Olympus DP72. Antibodies used for staining the 
sections are given in Table 3. 
 
7.16 Quantitative	  real-­‐time	  PCR	  
RNA was isolated from Th1 cell lysates with Trizol (Invitrogen) and reverse transcribed with 
the Quantitect kit (Qiagen). Quantitative PCR (qPCR) assays were run on a Light Cycler 
480II device with the Light Cycler 480 SW 1.5 software. Primers and universal probes 
(Roche) are given in Table 12. 
 
7.17 Statistical	  analysis	  
Statistical analyses were performed with GraphPad Prism 5.0d and p values were calculated 
by Student’s t-test, one-way analysis of variance (ANOVA) or Tukey’s multiple comparisons 
test. 
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8 Results	  
8.1 Characterization	  of	  protein–RNA	  interactions	  in	  post-­‐transcriptional	  
gene	  regulation	  
Post-transcriptional gene regulation is a crucial element in the control of immune responses. 
Compared to regulation on the level of transcription, regulation on the post-transcriptional 
level can respond faster and quickly alter gene expression 121. A striking example of failed 
post-transcriptional control is the san/san mouse, in which a single point mutation (san 
mutation) in the ROQ domain of the protein Roquin-1 led to a severe autoimmune disease 39. 
Although it was demonstrated that Roquin-1 limited the abundance of the inducible co-
stimulator (Icos) transcript 119, the exact mechanism of this regulation could not be resolved. 
It had been proposed that Roquin-1-dependent Icos repression was mediated by miR-101, 
which contained a putative binding site in the 3’UTR of the Icos mRNA 119. However, recent 
studies using cells deficient for Dicer or Ago1–Ago4, which were devoid of miRNAs 149 or 
defective in miRNA-mediated gene silencing 154, clearly demonstrated that Roquin-1 was able 
to repress Icos independently of the miRNA pathway 149. We therefore investigated the 
possibility of direct Roquin-1 protein interaction with Icos mRNA as a crucial first step in the 
so far unknown mechanism of Roquin-1-mediated Icos repression. 
 
8.1.1 Roquin-­‐1	  is	  able	  to	  directly	  bind	  to	  RNA	  and	  has	  an	  intrinsic	  preference	  for	  
the	  3’UTR	  of	  ICOS	  mRNA	  
Direct interaction of Roquin-1 with the human ICOS mRNA was investigated in vitro using 
electrophoretic mobility shift assays (EMSA), in which in vitro transcribed ICOS mRNA was 
combined with purified recombinant Roquin-1 protein. It was important to test the interaction 
with ICOS full-length (FL) mRNA to avoid any bias by using only fragments of the ICOS 
mRNA. Recent studies showed that a region encompassing one-third at the end of the ICOS 
3’UTR responded to high Roquin-1 overexpression when transplanted into the context of a 
reporter gene 119. Within this fragment Roquin-1 was mapped to bind at a 47-nt sequence 
immediately adjacent to the miR-101 binding site mentioned above 155. Because of this 
correlation, the focus was laid on the 47-nt sequence in the investigation of direct protein–
RNA binding and functional response. However, Roquin-1 overexpression down-regulated 
the reporter construct containing the putative 47-nt response element to a lesser extent than 
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the larger construct containing the full last third of the ICOS 3’UTR 119. Bearing in mind that 
Roquin-1-mediated Icos repression was demonstrated to be independent of the miRNA 
pathway 149, it was crucial to investigate Roquin-1 binding to the entire ICOS mRNA. 
As the ICOS FL mRNA (nts 1–2540) was too large to run on polyacrylamide gels, EMSAs 
were performed on a standard agarose gel and RNA or RNA–protein complexes were 
visualized by staining the gel with ethidium bromide. For these experiments, ICOS mRNA 
constructs were in vitro transcribed and purified (Figure 5 A). Furthermore, a truncated 
recombinant Roquin-1 (aa 1–441) protein was generated, comprising the RING finger, the 
ROQ domain and the zinc finger (Figure 5 B and Figure 15 B showing the protein domain 
organization).  
 
 
Figure 5: In vitro transcribed ICOS mRNA and recombinant Roquin-1 (aa 1–441) protein. (A) In vitro 
transcribed and purified ICOS full-length (FL) or coding sequence (CDS) mRNA, analyzed on a 
denaturing agarose gel. (B) SDS polyacrylamide gel showing the purity of increasing amounts (pmol) of 
Roquin-1 (aa 1–441) after purification and desalting. 	  
In immunoprecipitation experiments from cell lysates, in which Roquin-1 mutants were 
overexpressed, this amino-terminal fragment of Roquin-1 had been shown to efficiently bind 
to ICOS mRNA, while the carboxy-terminus was not involved in ICOS mRNA binding 149. 
However, this interaction of the amino-terminus of Roquin-1 with the ICOS mRNA could 
also occur indirectly via binding of other factors present in these lysates. Testing the truncated 
recombinant Roquin-1 construct in the EMSA in vitro system would therefore constitute the 
first proof of a direct protein–RNA interaction via the amino-terminus of Roquin-1.  	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The band shift experiments demonstrated indeed that the amino-terminus of Roquin-1  
(aa 1–441 of full-length (FL) protein isoforms aa 1–1130 or 1–1121) was capable of directly 
binding to ICOS mRNA in vitro. The ICOS FL mRNA band only shifted in the presence of 
varying amount of Roquin-1 (5, 7.5 and 10 µg), but not in the presence of equal amounts of 
BSA protein (Figure 6 A). Furthermore, the Roquin-1-binding was specific for mRNA, as 
tRNA used as a competitor did not compete the observed band-shift (Figure 6 B).  
 
 
Figure 6: Roquin-1 interacts with ICOS mRNA. (A–B, D) EMSAs of Roquin-1 protein interacting with 
ICOS mRNA were performed in the presence of 65-fold excess competitor yeast transfer RNA (tRNA). 
Varying amounts of Roquin-1 (aa 1–441) (A, D) and unrelated protein (BSA=bovine serum albumin) (A) 
were incubated with ICOS FL mRNA. (C–D) The DNA template used for in vitro transcription and 
subsequently for EMSA, was linearized to produce mRNA with or without the T7-terminator sequence. 	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Nevertheless, the use of restriction sites behind the T7-terminator sequence to linearize the 
DNA template for in vitro transcription occasionally led to the in vitro transcription of the T7-
terminator sequence, which might allow Roquin-1 binding to the secondary structure of the 
T7-terminator sequence. To exclude this possibility, a restriction site was cloned behind the 
respective ICOS sequence, but before the T7-terminator sequence. Importantly, ICOS mRNA 
bands were equally well shifted when the DNA template for in vitro transcription was cut 
before or after the terminator sequence. Therefore, the binding was not dependent on the T7-
terminator sequence (Figure 6 C–D). 
As most trans-acting factors target cis-elements in the 3’UTR of mRNAs 121, the binding 
preferences of Roquin-1 were investigated. Roquin-1 bound effectively to RNA sequences 
from the ICOS FL or 3’UTR, while ICOS CDS mRNA was not well recognized in vitro 
(Figure 7 A). Furthermore, a band representing an artificial mRNA with a tandem repeat of 
the ICOS CDS was also not efficiently shifted in vitro (Figure 7 B). This excluded the 
possibility that binding depended solely on the length of the transcript. Moreover, this 
indicated that a specific cis-element for Roquin-1-binding was localized in the 3’UTR of 
ICOS mRNA. Roquin-1-specific binding of mRNA was shown by the complete absence of 
free mRNA and could be quantified by titration of different amounts of Roquin-1 protein.  
1 pmol of full-length ICOS mRNA could be fully shifted with 20 pmol protein, while ICOS 
CDS was not shifted below 160 pmol protein (Figure 7 C). This indicated an at least eightfold 
binding preference of Roquin-1 to the 3’UTR of ICOS mRNA compared to ICOS CDS 
mRNA. The continuous shifting upon higher protein concentrations might be due to 
cooperative binding of several Roquin-1 molecules at the same RNA. Notably, using higher 
protein concentrations even resulted in an excessive shift of ICOS FL and the disappearance 
of free ICOS CDS. This gel retardation might be caused by an additional low binding affinity 
of Roquin-1 to RNA in general, as was observed for the ICOS CDS. This suggested a 
bimodal binding kinetic with a high affinity binding at low molar protein concentrations and a 
low binding affinity of Roquin-1 to RNA in general at high protein concentrations. 
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Figure 7: Roquin-1 specifically binds to the 3’UTR of ICOS mRNA. (A–C) EMSA showing a titration of 
increasing amounts (0–200 pmol) of recombinant Roquin-1 (aa 1–441) protein, incubated with in vitro 
transcribed ICOS mRNAs (1 pmol per lane). The ICOS mRNAs contained either full-length mRNA (1–
2540), coding sequence only (1–600) or the 3’UTR only (601–2540). As an artificial mRNA, the CDS was 
cloned in tandem omitting a second start codon (B). 
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The band shift experiments above in addition to immunoprecipitation studies 149 demonstrated 
that the ROQ domain of Roquin-1 was essential for the direct binding to ICOS mRNA. 
Furthermore, the previous overexpression and immunoprecipitation experiments indicated 
that the zinc finger contributed to the binding 149. Therefore, the function of the zinc finger 
had also been studied in vitro using electrophoretic mobility shift assays. Recombinant 
Roquin-1 protein lacking the zinc finger (aa 1–414) showed a reduced gel-retardation of the 
ICOS FL mRNA compared to Roquin-1 (aa 1–441) (Figure 8 A). This difference could be 
interpreted as a reduced binding activity of Roquin-1 (aa 1–414). However, several proteins 
can interact with the same mRNA. Therefore, the alteration might equally be due to the 
reduced molecular weight of the Roquin-1 (aa 1–414)–ICOS mRNA complex. To 
discriminate between both possibilities, recombinant Roquin-1 (aa 1–441) was generated with 
a mutation of the first cysteine of the zinc finger. This protein fragment with equal mass but 
without zinc finger activity did not show decreased binding affinity to ICOS FL mRNA 
(Figure 8 B), explaining why addition of EDTA did also not interfere with Roquin-1 binding 
(EDTA was present in the EMSA in Figure 8 A, but not in B; also see section 7.10). The zinc 
finger therefore did not significantly contribute to the binding of ICOS FL mRNA in vitro, 
but may accomplish functions in vivo of so far unknown specificity. 
 
 
Figure 8: The zinc finger in Roquin-1 does not significantly contribute to RNA binding. (A–B) EMSA 
showing the binding of recombinant Roquin-1 to 1 pmol of ICOS FL mRNA. Recombinant Roquin-1 was 
generated with (aa 1–441) or without (aa 1–414) the zinc finger domain (A) or with a point mutation in the 
first cysteine of the zinc finger (C419R mutation) causing loss of zinc finger function (B). In (A) the 
original EMSA buffer with EDTA was used and in (B) the optimized binding buffer without EDTA was 
used (section 7.10).  
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Moreover, the carboxy-terminal part of Roquin-1 did not play a significant role in RNA 
binding, as full-length Roquin-1 (aa 1–1130) shifted ICOS mRNA only slightly better than 
the truncated version of Roquin-1 (aa 1–441) (Figure 9). This difference in the binding could 
equally be explained by the increased size of the Roquin-1 FL–ICOS mRNA complex 
compared to Roquin-1 (aa 1–441) binding to the ICOS mRNA. 
 
 
Figure 9: Both Roquin-1 FL (aa 1–1130) and Roquin-1 (aa 1–441) bind comparably well to the ICOS 
mRNA. EMSA of Roquin-1 proteins (0–40 pmol) with 1 pmol ICOS FL mRNA. 
 
Interestingly, the Roquin-1san protein (aa 1–441) with the M199R mutation did not show an 
altered binding behavior to ICOS FL mRNA (Figure 10 A). Roquin-1san had been proposed to 
bind to ICOS with higher affinity than Roquin-1 wild-type 155. However, these studies used 
PAGE and radioactively labeled RNA fragments for the investigation of the RNA-binding 
and therefore focused on the isolated 47-nt sequence in the ICOS 3’UTR, which correlated 
with the miR-101 complementary sequence 155. In contrast, agarose EMSAs allowed the 
unbiased investigation of full-length ICOS mRNA. In this system, binding differences 
between Roquin-1 wild-type (aa 1–441) and Roquin-1 M199R (aa 1–441) protein could not 
be reproduced even in a very fine titration of Roquin-1 M199R vs. wild-type Roquin-1 
protein (Figure 10 B).  
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Figure 10: Roquin-1 (aa 1–441) protein with the M199R mutation binds equally well to ICOS mRNA as 
wild-type protein. (A–B) EMSA of Roquin-1 (aa 1–441) protein with or without M199R mutation (0–160 
pmol) binding to 1 pmol ICOS FL mRNA. 
 
8.1.2 Roquin-­‐1	  binds	  to	  a	  specific	  cis-­‐element	  in	  the	  3’UTR	  of	  ICOS	  
To identify the specific cis-element for Roquin-1 binding, the 3’UTR of ICOS mRNA was 
sequentially shortened by 600 nucleotides (nts), starting from the 3’end. ICOS mRNA 
transcribed from all deletion constructs was shifted equally well by Roquin-1 (aa 1–441) 
protein compared to ICOS FL mRNA, with the shortest one containing the ICOS CDS plus 
additional 610 nts of the 3’UTR (ICOS 1–1210) (Figure 11 A). Importantly, Roquin-1  
(aa 1–441) bound to ICOS 1–1210 with higher affinity than to an irrelevant mRNA of 
comparable length (Figure 11 B). Similarly, the artificial construct with the tandem CDS of 
ICOS mRNA comprising 1200 nucleotides did not response to Roquin-1 binding  
(Figure 7 B), corroborating the observation that the band shift did not depend on the length of 
the RNA. 
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Figure 11: Roquin-1 specifically binds to a cis-element in the 3’UTR of ICOS mRNA. EMSA of increasing 
amounts (0–40 pmol) Roquin-1 (aa 1–441) protein with ICOS mRNAs (1 pmol per lane). (A) ICOS 
mRNAs were progressively shorted from the 3’end to investigate the binding preference of Roquin-1 to 
different parts of the ICOS mRNA. ICOS FL = 1–2540, ICOS CDS = 1–600. (B) FOXP3 CDS mRNA was 
used as a non-specific binding control compared to an ICOS mRNA fragment of similar size (nts 1–1210). 
 
Additional deletion constructs of ICOS mRNA were generated to localize the responsive cis-
element. ICOS 1–1210 was further shortened in a step-wise manner by 100 nts each. As the 
construct ICOS 1–800 was still effectively bound, but ICOS 1–700 was not, one crucial cis-
element could be assigned to 100 nts 3’ to the stop codon of the ICOS CDS (Figure 12).  
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Figure 12: A crucial cis-element for Roquin-1 binding is localized 100 nts 3’ to the stop codon. EMSA of 
increasing amounts (0–40 pmol) Roquin-1 (aa 1–441) recombinant protein with in vitro-transcribed ICOS 
mRNA. The 3’UTR of ICOS mRNA was progressively shortened from 900 bases (ICOS 1–900 mRNA) to 
700 bases (ICOS 1–700 mRNA) as indicated in the scheme. 
 
8.1.3 The	  RNA	  sequence	  in	  the	  ICOS	  cis-­‐element	  adopts	  a	  finger-­‐like	  structure	  
Trans-acting factors can either bind to specific sequences in their target mRNA, or recognize 
certain structural motifs 121. It can therefore be difficult to describe a valid cis-element just on 
the basis of a mapped sequence. The 3’UTR of the ICOS mRNA is unusually long and was 
found to contain six highly conserved regions 119. There are few conserved and several poorly 
conserved miRNA binding sites in the ICOS 3’UTR and miR-101 was initially proposed to 
play a role in Roquin-1-mediated Icos repression 119. However, as was shown thereupon in 
Dicer-deficient cells, Roquin-1 repressed Icos independently of miRNAs. Instead it directly 
bound to the 3’UTR of the ICOS mRNA (section 8.1.1, 8.1.2 and 149). 
The ICOS 3’UTR was then scanned for known RNA-binding motifs, using the IBT tool 
UTRscan. Beside the polyadenylation site at the end of the ICOS 3’UTR, the scan only 
revealed six putative Musashi binding elements. Musashi is a stem cell factor involved in the 
post-transcriptional control of early developmental processes 156. Despite this motif, there was 
no evidence for other sequence-specific motifs such as AU-rich elements. Therefore, the 
secondary structure of ICOS mRNA was determined to identify possible structures, which 
might play a role in Roquin-1/2 protein binding. The SHAPE assay (selective 2’-hydroxyl 
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acylation analyzed by primer extension) 153 was used to model structural motifs of the ICOS 
3’UTR. Electrophilic components, such as N-methylisatoic anhydride (NMIA), are attracted 
by the nucleophilic reactivity of 2’-hydroxyl groups of unpaired RNA nucleotides. Acylation 
of these groups by NMIA leads to a stop in a primer extension reaction. It is therefore 
possible to directly obtain the site, where nucleotides are present in an unpaired conformation. 
With this information, the secondary structure of an mRNA can be modeled at a single 
nucleotide resolution 153. As described in section 7.11, RNA was modified with NMIA or 
DMSO as a control and primer extension as well as sequencing reactions for nucleotide 
assignment were performed with radioactively labeled primers. As there is a limit to the 
length of the RNA that can be resolved on the gel, we focused on the mapped cis-element 
ICOS 700–800 as well as on two additional fragments 5’ (ICOS 600–700) and 3’ (ICOS 800–
900) to the cis-element (Figure 13 A–B). The intensity of the 32P-labeled nucleotides was 
determined for the NMIA and DMSO reaction (Figure 13 C) and the signal was normalized to 
the DMSO background levels (Figure 13 D). In Figure 13 D, yellow bars represent relative 
SHAPE reactivities above 0.2 and red bars above 0.3. However, background levels strongly 
vary. Therefore, we defined that relative SHAPE reactivities above 0.3 indicate possibly 
unpaired nucleotides, while relative SHAPE reactivities above 0.5 represent truly unpaired 
nucleotides. The strength of nucleotide pairing can be influenced by wobbly structures in the 
RNA. A single free nucleotide neighbored by two paired nucleotides could loosen the base 
pairing of its neighbors, which might be a reason why nucleotides appear as unpaired but 
might not truly be free.  
The additional information of unpaired nucleotides can be entered into the RNA folding form 
of “The mfold Web Server” program to model the secondary structure of the RNA. The 
platform offers the possibility to constrain the folding by certain formulas. Here, the formula 
P i 0 k was used with i being the first base that must not pair and k the number of consecutive 
bases that must not pair starting with i. 
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Figure 13: SHAPE analyses of ICOS mRNA fragments. (A) Scheme of ICOS mRNA indicating the 
analyzed fragments in blue. (B) DNA-sequencing gel for the ICOS fragments 600–700, 700–800 and 800–
900 showing reactions with NMIA (+) or with DMSO as a control (–). LMW=low molecular weight 
marker. (C) Intensity (PSL) of the radioactive nucleotides in the sequencing reaction of ICOS 700–800 
with (+, red) or without (–, green) NMIA. (D) Relative SHAPE reactivities indicating unpaired nucleotides 
of ICOS 700–800 normalized to the DMSO-control reaction. Primer extension and sequencing reactions 
as well as data analyses were done by Dr. Maximilian Hartl, Department of Biopolymers, Universität 
Bayreuth. 	  
For the analyzed fragments, only one or two thermodynamic stable structures were predicted 
(Figure 14 A–C). Both ICOS 600–700 (Figure 14 A) and ICOS 800–900 (Figure 14 C) 
displayed a long, stretched secondary structure with small loops, while ICOS 800–900 could 
also exert a structure with wider loops. However, only ICOS 700–800 exhibited an interesting 
two-finger-like structure, which might serve as a binding groove for Roquin-1 protein (Figure 
14 B, finger-like structure highlighted in blue).  
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Figure 14: Secondary structures of ICOS mRNA fragments. (A–C) Using the additional information of 
free, unpaired nucleotides determined in section 8.1.3 (cutoff >0.5), the secondary structure of ICOS 600–
700, ICOS 700–800 and ICOS 800–900 was modeled with “The mfold Web Server” program using the 
formula P i 0 k with i being the first base that must not pair and k the number of consecutive bases that 
must not pair starting with i. Only one thermodynamic stable conformation was predicted for (A–B) and 
two conformations were predicted for (C) with the same Gibbs free energy (dG) value. ICOS 700–800 was 
mapped in EMSAs to contain a crucial cis-element for protein binding. Data analyses were done by Dr. 
Maximilian Hartl, Department of Biopolymers, Universität Bayreuth. 
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This idea matched with the mapping of the region in the ICOS 3’UTR, which contained a 
crucial cis-element for Roquin-1 binding, approximately 100 nts 3’ to the stop codon of ICOS 
CDS (Figure 12). However, a limitation of this method is clearly the separated view onto 
distinct RNA constructs, which add up to the whole secondary structure of the ICOS mRNA. 
It is therefore reasonable to investigate overlapping segments of the sequence of interest to 
optimize the modeling procedure. 	  
8.1.4 Roquin-­‐2	  binds	  equally	  well	  to	  the	  3’UTR	  of	  Icos	  mRNA	  
Roquin-2, the paralog of Roquin-1, was first described as a membrane-associated nucleic 
acid-binding protein (Mnab) 151. The amino acid sequences of both proteins are highly 
conserved in the amino-terminal regions and less conserved in their carboxy-termini 
(Figure 15 A). Furthermore they share a similar domain organization with a RING finger, 
ROQ domain and zinc finger and similarly a proline-rich region in their carboxy-termini 
(Figure 15 B). Roquin-2 is the only other protein in the mouse containing this ROQ domain 
with 77% identity to the Roquin-1 ROQ domain-transcript and even 94% identity on the 
amino acid level. 
 
 
Figure 15: The paralogs Roquin-1 and Roquin-2 share sequence and domain organization. (A) Alignment 
of mouse Roquin-1 and the long isoform of mouse Roquin-2 (aa 1–1187) for amino-acid similarity. (B) 
Depiction of the domain organization in Roquin-1 and Roquin-2 with the RING finger, the ROQ domain, 
a zinc finger (Zn), a proline-rich region (Pro-rich) and a Coiled coil (CC) domain. 
 
To investigate the binding of Roquin-2 to RNA, specifically to the ICOS mRNA, a 
recombinant Roquin-2 protein (aa 1–438) was generated and tested in EMSAs, which was 
homologous to the amino-terminal fragment of Roquin-1 (aa 1–441). Interestingly, Roquin-2 
bound equally well to ICOS mRNA as Roquin-1 (aa 1–441) with an intrinsic preference to the 
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3’UTR of ICOS (Figure 16). This indicated that Roquin-2 might target the same or similar 
mRNAs, or might be able to substitute for Roquin-1. 
 
 
Figure 16: Roquin-1 and Roquin-2 bind equally well to the 3’UTR of ICOS mRNA. EMSA of varying 
amounts of recombinant Roquin-1 (aa 1–441) or Roquin-2 (aa 1–438) protein with 1 pmol ICOS FL or 
CDS mRNA. 	  
8.1.5 An	  array-­‐approach	  to	  identify	  new	  targets	  of	  Roquin-­‐1	  
ICOS mRNA was the first confirmed target of Roquin-1. Very recently IFN-γ had been 
proposed to be an additional Roquin-1 target, as indicated by increased half-life of IFN-γ 
mRNA in Rc3h1san/san mice 157. However, IFN-γ has not been functionally evaluated as a 
potential target in respect to direct protein–RNA interaction or direct repression by Roquin-1. 
The important function of Roquin-1 in the immune system necessitated the search for more 
targets, especially because Icos de-repression could not exclusively explain the massively 
disturbed phenotype of the Rc3h1san/san mouse. To address this question, Roquin-1 was 
knocked down in CD4+ T cells from mice bearing a transgene for a truncated human 
coxsackie adenovirus receptor (CAR). This receptor enabled the transfection of cells with a 
control or Roquin-1-knockdown adenovirus. The knockdown construct independently co-
expressed GFP as a marker and the 10% highest infected cells were sorted for RNA isolation. 
In three repeats a relatively small set of targets was identified. Knockdown of Roquin-1 
revealed 43 genes, which were de-repressed, while the expression of only 8 genes was 
reduced by the knockdown (Figure 17), indicating that Roquin-1 acted predominantly as 
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repressor of targets. As a knockdown control, Roquin-1 was efficiently down-regulated and 
the known target Icos was up-regulated. Interestingly, several other T cell co-stimulatory 
receptors were deregulated, including 4-1bb and Ox40. Additionally, the knockdown of 
Roquin-1 revealed several genes involved in oxidative stress, the glucose metabolism or 
diverse signaling pathways. 
 
 
Figure 17: Expression levels of putative Roquin-1 target mRNAs. In an array approach, Rc3h1 was 
adenovirally knocked down to search for deregulated targets. The color key indicates the fold-change as 
2x. Arrays were performed in three replicates and are ordered in the heat map according to similarity 
among each other. Gene expression analyses were done at the Laboratory for Functional Genome 
Analysis, Munich under the direction of Dr. Helmut Blum. The statistical analyses and heat map were 
done by Dr. Dirk Repsilber, Leibniz Institute for Farm Animal Biology, Dummerstorf. 	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Quantitative PCR was used to further validate several of the putative targets, which were 
identified in the knockdown approach. Expression levels of target mRNAs were determined 
in CD4+ T cells from Rc3h1fl/fl; CD4-Cre mice, which lacked Roquin-1 expression or as a 
control from wild-type mice. This approach confirmed seven targets of Roquin-1. Roquin-1 
acted therefore as repressor of Pim2, Kit, Ox40, Lfng, Ctla4, Icos and Ebi3 amongst other 
possible targets (Figure 18). 	  
 
Figure 18: De-repressed targets of Roquin-1. To validate targets unique to Roquin-1, RNA was prepared 
from wild-type CD4+ T cells or CD4+ T cells of mice deficient for Roquin-1. The mRNA expression levels 
of the indicated genes relative to YWHAZ were analyzed by qPCR. The qPCR analyses were performed by 
Dr. Kai Höfig. 
 
8.1.6 Roquin-­‐1	  binding	  to	  new	  mRNA	  targets	  
Based on the qPCR results, two very promising candidates of Roquin-1 binding are Ctla4 and 
Ox40, as they are both co-receptors on T cells. Furthermore, Ctla4 is structurally related to 
Icos 25. Both belong to the CD28 receptor family and interact with PI3K (section 5.1.2 and 25). 
However, they diversify in function as Icos provides positive co-stimulation whereas Ctla4 
exerts negative co-stimulation 158. Ox40 does not share a common structure with Icos, but is 
also an activation marker on T cells, providing co-stimulatory signals for cell division and 
survival 42. In EMSA experiments, Roquin-1 (aa 1–441) could actually bind to both mouse 
Ox40 and mouse Ctla4 FL mRNA (Figure 19). While the binding of ICOS or Ctla4 seemed to 
exhibit similar characteristics, Ox40 mRNA shifted higher than ICOS with the same protein 
concentration. These studies corroborate Ox40 and Ctla4 as new direct targets of Roquin-1. 
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Figure 19: Roquin-1 binds to ICOS, Ctla4 and Ox40 mRNA. EMSA showing binding of increasing 
amounts of recombinant Roquin-1 (aa 1–441) protein to 1 pmol ICOS, Ctla4 or Ox40 full-length (FL) 
mRNA. EMSA was performed by Gitta Heinz. 	  
8.2 Function	  of	  Roquin-­‐1	  and	  Roquin-­‐2	  in	  vivo	  
After analyzing the essential RNA-binding activity of Roquin-1 and Roquin-2 in vitro, the 
focus was laid on the function and mechanism of both proteins in vivo. Roquin-1 deficiency 
had already been analyzed at several levels (section 5.3) 120. In contrast to the Rc3h1san/san 
mouse, the conditional Roquin-1 knockout in T cells, B cells or in the hematopoietic system 
did not show signs of autoimmunity. However, Icos levels were uniformly elevated in all 
knockouts 120. This showed that de-repression of Icos was not sufficient to break tolerance 
and that other factors significantly contributed to the lupus-like autoimmune phenotype in 
san/san mice. This was also supported by a recent publication, which demonstrated that loss 
of Icos in the context of the sanroque alleles even increased splenomegaly and led to the 
predominant occurrence of anti-nuclear antibodies in Rc3h1san/san mice, which normally show 
anti-nuclear as well as anti-cytoplasmic autoantibodies 159. 
Furthermore, the striking homology of Roquin-1 and Roquin-2 (Figure 15), Roquin-2 binding 
to ICOS mRNA (Figure 16) as well as the mild phenotype in Rc3h1-deficient mice 120 
strongly suggested that Roquin-2 might be able to substitute for loss of Roquin-1 function in 
the knockout situation, but not when Roquin-1 is still present in its mutated form. Therefore, 
conditional knockout mice were analyzed to determine the redundant and non-redundant 
functions of Roquin-1 and Roquin-2 in vivo. 
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8.2.1 Expression	  levels	  of	  Roquin-­‐1	  and	  Roquin-­‐2	  in	  mouse	  tissues	  	  
First, the expression levels of both proteins were investigated. For that purpose, a monoclonal 
antibody was generated that detected both proteins with similar efficiency. The antibody was 
raised against the amino-terminal part of Roquin-1, which comprised highest sequence 
homology to Roquin-2. It recognized endogenous Roquin-1 and Roquin-2 proteins equally 
well as the recombinant protein fragments Roquin-1 (aa 1–441) and Roquin-2 (aa 1–438) 
(Figure 20 A). 
 
 
Figure 20: Roquin-1 and Roquin-2 are similarly expressed in different tissues. (A) To evaluate the 
antibody clone 3F12 against the amino-terminal part of Roquin-1 and Roquin-2, increasing amounts of 
recombinant Roquin-1 (aa 1–441) or Roquin-2 (aa 1–438) protein were spiked into wild-type MEF cell 
lysates. (B) Increasing amounts of purified recombinant Roquin-1 (aa 1–441) or Roquin-2 (aa 1–438) were 
analyzed by PAGE and protein was stained with Coomassie. (C) Protein expression levels of Roquin-1 and 
Roquin-2 in different mouse tissues with tubulin and GAPDH as loading controls (A–B) were performed 
by Nina Martin and (C) in cooperation with Claudia Lohs. 	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Figure 20 B shows a Coomassie staining of Roquin-1 and Roquin-2 proteins as a loading 
control. The expression levels of Roquin-1 and Roquin-2 were then studied in lysates with 
equal protein amount from different mouse tissues. Roquin-1 and Roquin-2 proteins showed 
highest expression levels in extracts from lymph nodes and thymus and significant levels in 
extracts from brain, lung and spleen. Both proteins were only weakly detectable in extracts 
from heart, muscle and kidney. Interestingly, in all tissues analyzed, Roquin-1 was present at 
higher protein levels than Roquin-2 (Figure 20 C). In MEF cells, however, both proteins were 
endogenously expressed to a similar extent (Figure 20 A). 	  
8.2.2 In	  CD4+	  T	  cells	  Roquin-­‐1	  localizes	  to	  P	  bodies	  
To investigate the expression of Roquin-1 in T cells, confocal microscopy was used to study 
localization of Roquin-1. Primary CAR-transgenic CD4+ T cells were transduced with 
adenoviruses expressing GFP-tagged Roquin-1. The GFP signal marking Roquin-1 
expression was found to co-localize with the helicase Rck, a P body marker (Figure 21, upper 
panel). Upon stress-induction by arsenite treatment, stress granules formed, which showed co-
expression of Roquin-1. In only 5.5% of these cells, Roquin-1 remained co-localized with 
Rck (Figure 21, lower panel).  
This demonstrated that Roquin-1 primarily localized to P bodies, but could translocate into 
stress granules, if the cell was subjected to stress. It had also been shown that Roquin-1 
directly interacted with Rck to induce the decay of its mRNA target 149. As both Roquin-1 and 
Roquin-2 can bind RNA and are similarly expressed in different tissues, we asked whether 
Roquin-2 was also restricted to P bodies. Indeed, co-localization of Roquin-1 and Roquin-2 
could be demonstrated by overexpression studies in A549 cells 150. Furthermore it was shown 
that there was no difference in the localization of Roquin-1, Roquin-1san and Roquin-2 155. 
Though Athanasopoulos et al. described localization of these proteins to stress granules 
instead of P bodies, this could be explained by the transient transfection systems they used, 
which tended to induce cell stress. 
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Figure 21: Roquin-1 co-localizes with Rck in P bodies. Confocal microscopy showing co-localization of 
Rck (blue) and FMRP (red) with GFP-tagged wild-type Roquin-1 (GFP-Roquin-1; green) in primary 
CD4+ T cells. Cells were stimulated for 48 h with plate-bound anti-CD3 and anti-CD28 antibodies and 
treated with (Arsenite treatment) or without (No stress) arsenite. White arrowheads indicate Rck-, GFP- 
and FMRP-marked foci, respectively. Zoom (far right) shows selective enlargement of the images on the 
left. Original magnification: x23 (main images) or x262 (enlarged images). 
 
8.2.3 Evaluation	  of	  the	  complete	  Roquin-­‐2	  knockout	  
To evaluate the function of Roquin-2 in vivo, conditional knockout mice were obtained with 
targeting exon 4 of Rc3h2. Targeting was confirmed by Southern blotting using standard 
procedures (EUCOMM mouse IKMC Project - ID: 30078, Figure 22 A–C). 
The complete absence of Roquin-2 was assessed by immunoblotting. For this, MEF cells 
were generated from crossings of mice with an Rc3h2+/neo genotype to obtain wild-type 
Rc3h2+/+, heterozygous Rc3h2+/neo or Rc3h2-deficient Rc3h2neo/neo MEF cells (Figure 22 D). 
The neomycin cassette (Neo) with a polyadenylation signal in the Roquin-2 targeting vector 
already created a null allele and completely eliminated Roquin-2 protein. The absence of 
Roquin-2 in Rc3h2neo/neo MEF cells could even be demonstrated by intracellular FACS 
staining with the 3F12 antibody (described in section 8.2.1), which recognized both Roquin-1 
and -2 in wild-type or only Roquin-1 in Rc3h2neo/neo MEF cells (Figure 22 E).  
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Figure 22: Targeting strategy of the Rc3h2 allele. (A) Schematic representation of the gene-targeting 
construct. (B) Position of the restriction sites used to validate the Rc3h2 gene-targeting. (C) Southern blot 
analysis showing the conversion to the Rc3h2tm1a(KOMP)Wtsi allele by using a probe to LacZ (left panel) and 
NeoR (right panel) after digestion with the indicated restriction enzymes (top). The genomic restriction 
sites are adjacent to the targeting vector arms. Expected sizes: 5’ EcoNI (12492 bp) and 3’ EcoRI (10385 
bp). Southern blots were performed by Dr. Joel Schick, Institute of Developmental Genetics, Helmholtz 
Zentrum München. (D) Western blot analysis of Roquin-2 and tubulin expression in Rc3h2+/+, Rc3h2+/neo 
and Rc3h2neo/neo immortalized MEF cells. (E) Intracellular FACS staining of Roquin-1/2 proteins with the 
3F12 antibody described in section 8.2.1 in MEF cells of the indicated genotype. Wild-type cells were also 
stained with an isotype control antibody. 	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Having confirmed correct targeting of Rc3h2, the consequences of Roquin-2 deficiency were 
investigated. The most obvious phenotype in Rc3h2neo/neo mice on a pure C57BL/6 
background was postnatal death. Though postnatal death in Rc3h2-deficient mice was clearly 
a non-redundant phenotype, Rc3h1-deficient mice similarly exhibited early death, only 
several hours after birth 120. The exact cause of death in Rc3h2neo/neo mice, however, could not 
be resolved yet. As lethality in Rc3h1-deficient mice could partially be rescued on an outbred 
strain genetic background, a similar strategy was used to rescue death in Rc3h2neo/neo mice. 
The higher genetic variance in mixed C57BL/6–NMRI-outbred strain mice was assumed to 
allow for compensatory mechanisms. Indeed, the viability of homozygous Rc3h2-deficient 
animals was restored in one single cross with mice from an NMRI outbred strain genetic 
background and a subsequent intercross of the F1 generation. The offspring was born at a 
Mendelian ratio and survived until weaning age (P21) and longer (Figure 23 A). Physically, 
the mice appeared normal, with decreased body weight only seen in male individuals. This 
difference in weight constituted 24–29% at each point of measure starting at day 1 after birth 
up to adulthood (Figure 23 B). 
 
 
Figure 23: Crossing Rc3h2neo/neo mice to an NMRI outbred strain background rescues lethality. (A) 
Genotype frequency of offspring from a heterozygous mating of Rc3h2+/neo mice on an NMRI outbred 
strain background. (B) Body weight curve of male or female Rc3h2+/neo and Rc3h2neo/neo mice on an NMRI 
outbred strain background. Weight reduction in male Rc3h2neo/neo mice was already significant at each 
point of measure starting at day 1 after birth. Statistical significances were calculated by Student’s t-test 
(***p < 0.001). 	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Surprisingly, further analysis of these mice did not reveal an obvious immune phenotype. 
There was no difference in total splenocyte (Figure 24 A) or thymocyte (Figure 24 B) 
numbers between Rc3h2 knockout, heterozygous or wild-type (WT) mice on a mixed 
background.  
 
 
Figure 24: Splenocyte and thymocyte numbers are normal in Rc3h2neo/neo (NMRI) mice. (A) Splenocyte 
numbers in mice with the indicated phenotypes. (B) To count thymocyte numbers, littermate mice with 
the indicated phenotypes were analyzed at an age of three weeks. The bar represents the mean value in 
each group. 
 
Additionally, different lymphocyte subsets were investigated. However, no abnormalities 
could be found in populations of CD4+, CD8+, Treg, B, NK, NKT or dendritic cells as well as 
in eosinophils, neutrophils and macrophages (Table 20). This clearly shows the importance of 
genetic variation. Introducing new alleles of various genes into Rc3h2-deficient C57BL/6 
mice was sufficient to rescue death and possible immune cell phenotypes. 	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Table 20: Phenotyping of Rc3h2neo/neo; NMRI mice. Absolute cell numbers with standard deviation of 
various cell types from Rc3h2+/+, Rc3h2+/neo and Rc3h2neo/neo mice, which were all bred to an NMRI 
outbred strain to rescue lethality. Statistical significances were calculated by one-way analysis of variance 
(ANOVA). 
 Rc3h2+/+ 
(NMRI) 
(n=5) 
Rc3h2+/neo 
(NMRI) 
(n=7) 
Rc3h2neo/neo 
(NMRI) 
(n=10) 
p value (one-
way ANOVA) 
Significance 
CD4+ T cells  
(CD4+) 
7.8*106 
±3.9*106 
7.3*106 
±4.4*106 
6.4*106 
±2.1*106 
0.7305 
 
ns 
 
CD8+ T cells  
(CD8+) 
3.0*106 
±1.6*106 
2.6*106 
±1.1*106 
2.3*106 
±1.0*106 
0.5164 
 
ns 
 
Treg  
(CD4+ Foxp3+) 
9.8*105 
±2.7*105 
9.0*105 
±4.2*105 
9.2*105 
±2.8*105 
0.9104 
 
ns 
 
B cells  
(B220+) 
7.0*106 
±3.2*106 
8.1*106 
±4.6*106 
8.9*106 
±3.7*106 
0.6707 
 
ns 
 
NKT  
(B220– TCRβint 
CD1d-PBS57+) 
4.4*105 
±3.0*105 
5.0*105 
±3.3*105 
4.0*105 
±2.1*105 
0.7489 
 
ns 
 
NK  
(B220– CD3– 
NK1.1+) 
6.4*105 
±6.1*105 
11.1*105 
±7.5*105 
9.2*105 
±8.3*105 
0.5876 
 
ns 
 
DC  
(CD11c+ MHCII+) 
3.3*105 
±1.8*105 
3.4*105 
±2.0*105 
4.0*105 
±1.7*105 
0.7212 
 
ns 
 
Eosinophils  
(SiglecF+ GR-1int) 
2.1*105 
±0.9*105 
1.8*105 
±0.7*105 
3.1*105 
±1.7*105 
0.1336 
 
ns 
 
Neutrophils  
(SiglecF– GR-1hi 
F4/80–) 
11.4*105 
±13.0*105 
8.6*105 
±5.7*105 
9.6*105 
±3.6*105 
0.8052 
 
ns 
 
Macrophages  
(SiglecF– GR-1int 
F4/80hi) 
1.4*106 
±0.8*106 
1.4*106 
±0.8*106 
1.8*106 
±0.8*106 
0.4147 
 
ns 
 
 
8.2.4 Conditional	  Roquin-­‐2	  knockout	  in	  T	  cells	  
As the mixed C57BL/6–NMRI-outbred strain genetic background might disguise immune 
phenotypes, Roquin-2 was conditionally deleted in T cells on a pure C57BL/6 background 
using CD4-Cre recombinase. The CD4-Cre recombinase is expressed as soon as CD4 is 
switched on in T cells. This occurs early in TCRαβ thymocyte development upon the 
transition of DN to DP thymocytes. Although the CD4 gene is silenced in immature DN 
thymocytes, the CD4 enhancer and promoter are already active in the DN3 precursor stage 160. 
This implies that CD8+ cells were also devoid of Roquin-2 in Rc3h2fl/fl; CD4-Cre mice, while 
the CD4 gene was later on silenced again in this lineage. 
Roquin-2 protein expression was completely absent in peripheral CD4+ T cells from 
conditionally targeted mice and already reduced in total thymocytes. In wild-type peripheral T 
cells and thymocytes, Roquin-2 was typically lower expressed than Roquin-1 (Figure 25 A). 
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Figure 25: Deletion of Roquin-2 in T cells does not affect T cell development and activation or Icos levels. 
(A) Western blot analysis of Roquin-1 and Roquin-2 expression in CD4+ T cells (left) or thymocytes 
(right). Representative contour plots showing the frequencies of CD4+ or CD8+ thymocytes (B) or the 
activation status of peripheral CD4+ or CD8+ T cells (C). (D) Relative median fluorescence intensity (MFI) 
of Icos in CD4+ CD8– or CD8+ CD4– thymocytes or peripheral T cells from Rc3h2fl/fl; CD4-Cre mice, 
normalized to the ICOS MFI in wild-type; CD4-Cre mice. The bar represents the median value of each 
column. (E–F) Representative contour plots of follicular helper T cells (PD-1hi CXCR5hi), pre-gated on 
CD4+ B220– (E) or germinal center B cells (GL-7hi CD95hi), pre-gated on B220+ (F) splenocytes. Genotypes 
are indicated in the figure and data are representative for 3 (A) independent experiments or 10 (B), 12 (C) 
and 5 (E–F) individual mice per genotype. 
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Infrared imaging quantification revealed that Roquin-1 protein was expressed 5 times more 
(5.3 ± 0.5 SD) than Roquin-2 in peripheral CD4+ T cells. Despite the fact that thymocytes had 
already reduced Roquin-2 levels, thymus development occurred normal in respect to absolute 
number and percentage of T cell populations (Figure 25 B). Furthermore, there was no defect 
in the development of peripheral T cells. Percentage and absolute number of naive (CD62Lhi 
CD44lo), effector-like (CD62Llo CD44hi) and memory-like (CD62Lhi CD44hi) T cells was not 
altered (Figure 25 C). This is in contrast to Rc3h1fl/fl; CD4-Cre T cells showing highly 
enhanced effector-like CD8+ T cells 120. These animals also displayed increased Icos levels on 
T cells, which could not be observed in Rc3h2-deficient thymocytes or peripheral T cells 
(Figure 25 D). The percentage of follicular helper T cells as well as germinal center B cells 
was also not altered (Figure 25 E–F). Altogether, no abnormal T cell phenotypes and no signs 
of autoimmunity could be detected, revealing any role for Roquin-2. 	  
8.2.5 Conditional	  Roquin-­‐2	  knockout	  in	  the	  hematopoietic	  system	  
Because the ablation of Roquin-2 in T cells did not reveal an immunological phenotype, 
Roquin-2 was deleted in the hematopoietic system using Vav-Cre recombinase. Deleting 
Roquin-2 in hematopoietic cells might reveal a new function of Roquin-2 in other cell types. 
However, similar to complete absence of Roquin-2 in mice with mixed C57BL/6–NMRI 
background, there was no significant change in total splenocyte (Figure 26 A) or thymocyte 
(Figure 26 B) numbers.  
 
 
Figure 26: Splenocyte (A) and thymocyte (B) numbers are not significantly altered in Rc3h2fl/fl; Vav-Cre 
mice compared to wild-type controls (WT; Vav-Cre). The bar represents the mean value of each column. 	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Furthermore, cell subsets defined by CD4, CD8, B, NK, NKT or dendritic cell markers as 
well as markers for eosinophils, neutrophils and macrophages did not reveal differences in 
frequency of absolute cell numbers (Table 21). 
 
Table 21: Phenotyping of Rc3h2fl/fl; Vav-Cre mice. Absolute cell numbers with standard deviation of 
various cell types from Rc3h2fl/fl; Vav-Cre and WT; Vav-Cre mice. Statistical significances were calculated 
by Student’s t-test (**p < 0.01). 
 WT; 
Vav-Cre 
(n=5) 
Rc3h2fl/fl; 
Vav-Cre 
(n=6) 
p value 
(Student’s  
t-test) 
Significance 
CD4+ T cells 
(CD4+) 
7.76*106 
1.48*106 
5.77*106 
1.87*106 
0.0669 
 
ns 
 
CD8+ T cells 
(CD8+) 
4.21*106 
0.27*106 
3.94*106 
1.02*106 
0.5346 
 
ns 
 
Treg 
(CD4+ Foxp3+) 
11.0*105 
1.61*105 
7.15*105 
1.65*105 
0.0026 
 
** 
 
B cells 
(B220+) 
22.5*106 
5.65*106 
17.4*106 
5.44*106 
0.1334 
 
ns 
 
NKT 
(B220– TCRβint CD1d-PBS57+) 
2.69*105 
0.72*105 
2.36*105 
0.63*105 
0.3295 
 
ns 
 
NK 
(B220– CD3– NK1.1+) 
8.06*105 
4.09*105 
7.02*105 
2.93*105 
0.6444 
 
ns 
 
DC 
(CD11c+ MHCII+) 
5.16*105 
2.15*105 
3.66*105 
1.36*105 
0.1504 
 
ns 
 
Eosinophils 
(SiglecF+ GR-1int) 
3.33*105 
1.93*105 
3.20*105 
1.67*105 
0.9675 
 
ns 
 
Neutrophils 
(SiglecF– GR-1hi F4/80–) 
6.84*105 
3.84*105 
7.03*105 
2.88*105 
0.9632 
 
ns 
 
Macrophages 
(SiglecF– GR-1int F4/80hi) 
5.74*105 
2.74*105 
7.48*105 
2.80*105 
0.4015 
 
ns 
 
 
Interestingly, peripheral Treg cell numbers were significantly decreased in Rc3h2fl/fl; Vav-Cre 
mice (Table 21 and Figure 27 A). This reduction in Treg cell numbers is most likely an 
indirect effect as Treg cells appeared unaltered in Rc3h2fl/fl; CD4-Cre mice (Figure 27 B). 
Furthermore, it contrasts the elevated Treg cell numbers in Rc3h1fl/fl; CD4-Cre mice 120. 
However, as this research project primarily focuses on Roquin-1/2 function in T cells, it 
remains to be elucidated which cell population is responsible for altered Treg cell numbers 
and what the functional consequences might be. 	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Figure 27: Frequencies of peripheral Treg cells in Rc3h2-deficient cells. (A–B) Representative contour 
plots of peripheral Treg cells, pre-gated on CD4+ splenocytes from mice deficient for Roquin-2 in 
hematopoietic cells (A) or T cells (B). Genotypes are indicated in the figure and data are representative for 
5 (A, wild-type) and 6 (A, knockout) as well as 2 (B) individual mice per genotype. 
 
8.2.6 Conditional	  knockout	  of	  Roquin-­‐1	  and	  Roquin-­‐2	  in	  T	  cells	  resembles	  
phenotypes	  of	  the	  Rc3h1san/san	  mouse	  
Until now, it had not been answered why the Rc3h1san/san mouse developed such a severe 
autoimmune disease, while mice deficient for Roquin-1 in T, B and hematopoietic cells 
display only a mild immune deregulation. Likewise, mice deficient for Roquin-2 in T and 
hematopoietic cells do not show a significant phenotype at all. Although the san mutation 
affects all cells in the mouse, some phenotypes such as the activation of T cells and de-
repression of Icos were T cell intrinsic 39. Therefore, T cell-specific ablation of Roquin-1 and 
Roquin-2 together was chosen to investigate functional redundancy of both paralogs. 
Complete absence of Roquin-1 and Roquin-2 protein was shown in T cell extracts from 
Rc3h1fl/fl; Rc3h2fl/fl; CD4-Cre (Rc3h1/2fl/fl; CD4-Cre) mice (Figure 28 A). Interestingly, all 
Rc3h1/2fl/fl; CD4-Cre mice developed splenomegaly and lymphadenopathy (Figure 28 B), 
already at an age of four weeks. Spleens increased in weight and total splenocyte numbers 
(Figure 28 C).   
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Figure 28: Combined deficiency of Roquin-1/2 in T cells causes splenomegaly and lymphadenopathy. (A) 
Western blot analysis confirming the ablation of Roquin-1 and Roquin-2 in CD4+ T cells. Tubulin was 
used as a loading control. (B) Spleen (left) and lymph node (right) sizes. (C) Mean splenic weight (left 
graph) and mean splenocyte number (right graph). Genotypes are indicated in the figure and data are 
representative for four (A) independent experiments. Significances are calculated by Student’s t-test (*p < 
0.05; **p < 0.01). (B–C) Data were collected in cooperation with Dr. Stephanie Edelmann. 
 
Analyzing the T cell compartment by flowcytometry, it was observed that all T cells were 
highly activated. CD4+ T cells displayed an increased frequency of effector-like (CD44hi 
CD62Llo) T cells. This was even exacerbated in CD8+ T cells, which lacked almost all naive 
(CD62Lhi CD44lo) T cells and had a reduced frequency of memory-like (CD62Lhi CD44hi) T 
cells. Furthermore, there was a reduction in absolute numbers of total CD4+ T cells as well as 
naive CD4+ and CD8+ T cells and a significant increase in CD8+ effector-like T cells (Figure 
29 A–B). The phenotype of Rc3h1/2-deficient mice exceeded that of Rc3h1fl/fl; CD4-Cre mice 
by far. Importantly, Roquin-1 and Roquin-2 expression levels were similar in CD4+ and CD8+ 
T cells and Roquin-2 was not altered in Rc3h1-deficient CD4+ or CD8+ T cells (Figure 29 C). 
Furthermore, peripheral regulatory T cells exhibited a marked increase in frequency, although 
absolute numbers were normal presumably due to the overall reduction in CD4+ T cells 
(Figure 29 D). The increase in effector-like CD4+ and especially CD8+ T cells resembles 
prominent phenotypes of the Rc3h1san/san mouse. Furthermore, Rc3h1/2fl/fl; CD4-Cre as well 
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as Rc3h1san/san mice develop splenomegaly and lymphadenopathy. Altogether, these data 
suggest functional redundancy of Roquin-1 and Roquin-2.  
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Figure 29: Combined ablation of Roquin-1 and Roquin-2 in T cells reveals functional redundancy. 
Representative contour plots (A) and corresponding cells numbers (B) from CD4+ (upper panel) or CD8+ 
(lower panel) T cells, showing CD62Lhi CD44lo, CD62Llo CD44hi or CD62Lhi CD44hi T cells from spleen. 
(C) Western blot analysis of Roquin-1 and Roquin-2 expression levels in CD4+ (left) or CD8+ (right) T 
cells. (D) Absolute cell number (left panel) or percentage (of CD4+ T cells, right panel) of peripheral Treg 
cells (CD4+ Foxp3+). Genotypes are indicated in the figure and data are representative for two (C) 
independent experiments. The number of mice analyzed in (A) is indicated in (B). Statistical significances 
were calculated by Tukey’s multiple comparisons test (B) or Student’s t-test (D) (*p < 0.05; **p < 0.01; 
***p < 0.001). (B, D) The bar represents the mean value of each column. (A–B, D) Data were collected in 
cooperation with Dr. Stephanie Edelmann and the Western blot (C) was developed with help of Claudia 
Lohs. 
 
8.2.7 Roquin-­‐1	  and	  Roquin-­‐2	  both	  repress	  ICOS	  mRNA	  
A hallmark of the autoimmune disease in Rc3h1san/san mice was elevated Icos levels on all T 
cells. Analysis of Icos levels in Rc3h1/2 double-deficient mice showed increased Icos 
expression on all CD4+ and CD8+ T cells. Icos protein levels were highest on effector-like 
(CD44hi CD62Llo) CD4+ or CD8+ T cells (Figure 30 A–B).  
 
 
Figure 30: Icos levels are extremely elevated in Rc3h1/2fl/fl; CD4-Cre mice. Representative histograms (A) 
and relative median fluorescence intensity (MFI) (B) of Icos in naive (CD62Lhi CD44lo), E-like (CD62Llo 
CD44hi) or Mem-like (CD62Lhi CD44hi) CD4+ (upper panel) or CD8+ (lower panel) T cells from Rc3h1/2fl/fl; 
CD4-Cre mice, each compared to an equal number of wild-type; CD4-Cre animals. The bar represents the 
median value of each column. (C) Histogram overlay of Icos levels on CD4+ T cells. Genotypes are 
indicated in the figure and data are representative for six (A) and two (C) independent experiments. Data 
were collected in collaboration with Dr. Stephanie Edelmann. 
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Interestingly, Icos levels were massively enhanced in double knockout CD4+ T cells 
compared to Roquin-1-single knockout cells 120. Expression levels seemed even higher than in 
the Rc3h1san/san mouse 39. Rc3h2-deficient cells showed normal wild-type levels of Icos 
expression (Figure 30 C). 
This difference in Icos expression between Rc3h1-deficient and Rc3h1/2 double-deficient 
mice could be explained by functional redundancy of both paralogs or by an indirect negative 
effect of Roquin-2. To address this question, biochemical analyses investigated and compared 
the molecular mechanism of Roquin-1 and Roquin-2. As shown in section 8.1, both proteins 
had a general binding affinity to RNA, but showed a specific binding preference for the 
3’UTR of ICOS mRNA. Indeed, Roquin-1 and Roquin-2 exhibited an identical binding 
behavior to the ICOS mRNA, inferred from the upshifting RNA band (Figure 16). 
In addition, direct repression of Icos expression was investigated by overexpressing Roquin-1 
wild-type (WT), an inactive version of Roquin-1 (aa 1–509) and two different isoforms of 
Roquin-2 (aa 1–1125 and 1–1187). To achieve sufficient overexpression of both proteins in 
CD4+ T cells, mice were generated bearing a truncated human CAR on CD4+ T cells (Heger 
and Schmidt-Supprian, unpublished). The CAR was only expressed after Cre-mediated 
recombination of a floxed stop-cassette. To reduce endogenous protein backgrounds, CD4+ T 
cells were isolated from Rc3h1fl/fl; CAG-CARstop-fl; CD4-Cre mice and transduced with 
adenovirus encoding the indicated proteins. Roquin-1/2 protein expression was analyzed by 
intracellular staining with a Roquin-1/2 specific antibody (clone 3F12). Icos levels were 
repressed by Roquin-1 wild-type and both isoforms of Roquin-2, but not by the inactive 
version of Roquin-1 (aa 1–509) (Figure 31 A–B).  
Furthermore, Roquin-1 had been demonstrated to interact with factors of the mRNA 
decapping pathway, such as Edc4 149. Immunoprecipitation experiments revealed that both 
proteins could independently and equally interact with Edc4 in MEF cell extracts deficient for 
Roquin-1 or Roquin-2. In extract from wild-type MEF cells, Edc4 was immunoprecipitated 
approximately twice as efficiently as in single-deficient cells. In double-deficient MEF cells, 
no Edc4 was immunoprecipitated by anti-Roquin-1/2 antibodies (Figure 31 C). 
In summary, both proteins could independently bind to a cis-element in the 3’UTR of ICOS 
mRNA and repressed Icos expression after overexpression on CD4+ T cells. They furthermore 
both interacted with Edc4, which is involved in mRNA decay. Therefore, Roquin-1 and 
Roquin-2 exhibited identical molecular characteristics, suggesting that they may function 
redundantly in guiding target mRNAs to the decapping pathway and inducing their decay.  
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Figure 31: Roquin-1 and Roquin-2 proteins interact with Edc4 protein and redundantly regulate Icos 
expression. (A) Adenoviral transduction of CD4+ T cells from Rc3h1fl/fl; CAG-CARstop-fl; CD4-Cre mice 
with adenovirus encoding an inactive Roquin-1 (aa 1–509), Roquin-1 wild-type (WT) or two isoforms of 
Roquin-2 (aa 1–1125 or aa 1–1187). (B) shows a histogram overlay of Roquin-1/2hi cells gated in (A). All 
blots in (A–B) are pre-gated on CAR+ cells. (C) Immunoprecipitation (IP) with magnetic beads coupled to 
an antibody, which recognizes both Roquin-1 and Roquin-2, of protein extracts from MEF cells. Edc4, 
Roquin-1 and Roquin-2 proteins were detected by Western blot analysis in IP and input. Genotypes are 
indicated in the figure and data are representative of three (A–B) and two (C) independent experiments. 
(C) IP was performed by Christine Wolf. 
 
8.2.8 Rc3h1/2-­‐deficient	  mice	  show	  increased	  follicular	  helper	  T	  and	  germinal	  
center	  B	  cells,	  but	  no	  auto-­‐antibodies	  
Similar to the Rc3h1san/san mouse, Rc3h1/2-deficient mice showed an increased frequency and 
number of follicular helper T cells, characterized by CXCR5hi and PD-1hi (Figure 32 A–B). 
Interestingly, double-deficient CD4+ T cells showed an overall increase in PD-1 expression, 
indicating either that more cells are about to adopt a Tfh cell phenotype or that the T cells are 
overall more activated (Figure 32 A, left). The functionality of CXCR5hi PD-1hi cells was 
further evaluated by staining the Tfh cell transcription factor Bcl6 (Figure 32 A, right).  
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Figure 32: Combined loss of Roquin-1 and Roquin-2 causes an increase in Tfh and GC B cells as well as 
immune dysregulation. (A) Representative contour plots of splenic Tfh cells (PD-1hi CXCR5hi), pre-gated 
on CD4+ with histogram overlays showing Bcl6 expression. (B) Percentage of Tfh cells (upper panel) or 
Tfh cell number (lower panel). (C) Representative contour plots of splenic germinal center B cells (GC B; 
GL-7hi CD95hi), pre-gated on B220+. (D) Percentage of GC B cells (of B220+ cells, upper panel) or GC B 
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cell numbers (lower panel). (E) Cell numbers of various cell types. The bar represent the mean value of 
each column and statistical significances were calculated by Tukey’s multiple comparisons test (B, D) or 
Student’s t-test (E) (*p < 0.05; **p < 0.01; ***p < 0.001). Genotypes are indicated in the figure and data 
are representative for 12 mice per genotype (A, C). Data were collected in cooperation with Dr. Stephanie 
Edelmann. 
 
Moreover, an increase in the frequency of germinal center B cells (B220+ GL-7+ CD95+) was 
observed (Figure 32 C–D). 
However, already in young Rc3h1/2fl/fl; CD4-Cre mice, total B cell numbers were drastically 
reduced (Figure 32 E). Hence, marginal zone B cells (MZB; B220+ CD23int CD21/35+) and 
follicular B cells (B220+ CD23hi CD21/35–) were also decreased in cell numbers  
(Figure 32 E), accompanied by slightly increased neutrophil numbers. Eosinophils and 
macrophages were not significantly affected by Roquin-1/2 deficiency (Figure 32 E).  
Despite the reduction in total B cells, the frequency and number of germinal center B cells 
was significantly increased (Figure 32 D). Rc3h1/2-deficient mice therefore reproduce one of 
the most important phenotypes of the Rc3h1san/san mouse with elevated Tfh and GC B cell 
numbers. Surprisingly, however, no anti-nuclear antibodies (ANAs) could be detected in the 
serum of young (6 weeks) and old (>6 months) mice.  
 
8.2.9 The	  spleen	  architecture	  in	  Rc3h1/2-­‐deficient	  mice	  is	  massively	  disrupted	  
Analyzing spleen sections of Rc3h1/2-deficient mice revealed that the splenic architecture 
was massively disturbed (Figure 33 A). Only few CD4+ T cells appeared to localize in a T cell 
zone of residual follicular structures, while CD8+ T cells were distributed randomly. The 
reduction in B cell numbers became obvious and only few B cells could be found to support a 
follicle-like structure. Metallophilic macrophages (MOMA-1+) no longer surrounded the 
follicle with a marginal zone and appeared dispersed (Figure 33 A). Furthermore, there was a 
strong reduction of white pulp, characterized by areas lacking F4/80+ cells (Figure 33 B–C). 
Such severe alteration might be caused by defective interaction and signaling of lymphocytes 
with accessory cells in the spleen. Those cells influence lymphocyte differentiation as well as 
tissue organization 161. ER-TR7+ reticular fibroblasts, representing T cell supporting stroma 
cells, appeared more dispersed in Rc3h1/2-deficient cells than in wild-type cells (Figure 33 
D). Follicular dendritic cells (FDC-M1+) on the other side, seemed slightly reduced in 
number, but were still able to form a central network (Figure 33 E). 
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Figure 33: Roquin-1/2 deficiency disrupts the splenic architecture. Consecutive cryo-sections from 
spleens, stained for CD4, CD8, B220 and MOMA-1 (A), for F4/80 and H&E (B), for IgD and ER-TR7 (D) 
and for CD4 and FDC-M1 (E) in adult mice. The black bar represents 100 µm. (C) Quantification of 
white/red pulp in the spleen. The bar represents the mean value of each column and statistical 
significances were calculated by Student’s t-test (***p < 0.001). Genotypes are indicated in the figure and 
data are representative for more than three different experiments. Cryo-sections and stainings were 
performed by Prof. Dr. Mathias Heikenwälder and Jessica Zöller, Institute for Virology, Technische 
Universität München/Helmholtz Zentrum München. 
 
In three-week-old mice, follicles start to develop. In such young Rc3h1/2-deficient mice, 
these structures appeared less disturbed than in older animals. However, intact follicular 
structures were already strongly reduced in young Rc3h1/2-deficient mice (Figure 34 A–C). 
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Consistently, B220+, CD4+ and CD8+ cells did no longer form T cell or B cell zones and 
appeared dispersed. Furthermore, accessory cells such as ER-TR7+ reticular fibroblast and 
FDC-M1+ follicular dendritic cells as well as MOMA-1+ macrophages were scattered and 
delocalized (Figure 34 D). Together these data suggest that in Rc3h1/2fl/fl; CD4-Cre mice, the 
splenic architecture is likely to be too disturbed to support auto-antibody production. 
 
 
Figure 34: Loss of Roquin-1 and Roquin-2 impairs follicular structure formation in the spleen. (A) 
Overview of B220+ follicles in the spleen (bar = 200 µm). (B) Number of follicular structures identified by 
a clear B and T cell and marginal zone. (C) Percentage of follicular structures compared to all visible foci. 
(D) Consecutive cryo-sections stained for B220, CD4, CD8, ER-TR7, FDC-M1 and MOMA-1 (bar = 100 
µm). All data show the analysis of an only 3-week old mouse and genotypes are indicated in the figure. 
Cryo-sections and stainings were performed by Prof. Dr. Mathias Heikenwälder and Jessica Zöller, 
Institute for Virology, Technische Universität München/Helmholtz Zentrum München. 
 
8.2.10 Roquin-­‐1	  and	  Roquin-­‐2	  control	  the	  transition	  point	  between	  Th1	  and	  Tfh	  cell	  
differentiation	  
Next, an adoptive transfer model was used to address whether Rc3h1/2-deficient cells could 
spontaneously support Tfh and GC B cell development in an intact spleen. For this, a system 
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was developed in which CD4+ T cells from Rc3h1/2fl/fl mice were treated with Cre-
recombinase in vitro, leading to acute deletion of both proteins.  
 
 
Figure 35: In vitro system for the deletion of Roquin-1 and Roquin-2. (A) Experimental outline displaying 
CD4+ T cell isolation, MSCV-Cre-Thy1.1-transduction and adoptive transfer of wild-type or Rc3h1/2fl/fl 
cells into Icos-/- mice. Expression of Cre (detected as Thy1.1) (B) or Icos (D) on the day of transfer. (C) 
Protein levels of Roquin-1/2 in Cre-transduced CD4+ T cells. (E) IFN-γ  and IL-21 production of PMA and 
ionomycin re-stimulated cells after MSCV-Cre-Thy1.1-transduction, analyzed at the day of the transfer. 
Genotypes are indicated in the figure and data are representative for five (B), six (C), four (D) and two (E) 
independent experiments. The in vitro system was developed by Dr. Stephanie Edelmann and evaluated in 
cooperation.  
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The recently described transitional stage between Th1 and Tfh cells 108 was motivation to 
expand the cells for transfer under Th1 differentiation conditions for 5–6 days. Wild-type or 
Rc3h1/2-deficient Th1 cells were transferred into Icos-deficient recipient mice to investigate 
the development of Tfh cells in the absence of endogenous Tfh cells in this niche (Figure 35 
A), because Icos-/- mice are almost devoid of Tfh cells 96. Functional deletion of Roquin-1 and 
Roquin-2 was demonstrated by staining for Thy1.1 expression, as a marker for Cre-
recombinase (Figure 35 B), and was shown by Western blotting (Figure 35 C). Consistently, 
Icos levels were elevated in cells after acute deletion of Roquin-1 and Roquin-2 compared to 
equally treated wild-type cells (Figure 35 D). In addition, there were more IL-21 single- and 
IL-21/IFN-γ double-producers after re-stimulation with PMA and ionomycin at the day of the 
transfer (Figure 35 E). This might indicate that the Rc3h1/2-deficient cells already adopt Tfh 
cell characteristics, because IL-21 is expressed by Tfh cells and important for their function. 
However, it is important to note that IL-21 expression is not distinctive for Tfh cells, as other 
cells such as Th17 cells can also express IL-21 94. The increased IL-21 expression after 
deletion of Roquin-1/2 could also be induced via Icos up-regulation and its activation of the 
transcription factor c-Maf 30.  
Six, seven and eight days after transfer, the mice were analyzed for spontaneous Tfh and GC 
B cell development. Indeed, only Th1 cells deficient for Roquin-1 and Roquin-2 (CD4+ 
Thy1.1+) gave rise to large numbers of follicular helper T cells, which were reduced to wild-
type levels in the course of the next two days (Figure 36 A–B). The transferred double-
deficient cells proliferated heavily (Figure 36 C). We assume that these highly activated cells 
died, since the transferred cells were no longer detected after eight days, as seen for total 
numbers of Tfh cells (Figure 36 B). Notably, the transferred cells were also not detected in 
other organs like lung, liver or kidney (data not shown). Despite of the rapid disappearance of 
the transferred cells, the Rc3h1/2-deficient Tfh cells functionally initiated the development of 
endogenous germinal center B cells, which accumulated from day 6 to day 8 (Figure 36 D–E). 
These effects could not be observed after transfer of equally treated wild-type cells.  
These data demonstrate that Roquin-1 and Roquin-2 directly control the differentiation of Tfh 
cells. Consequently, loss of Roquin-1/2 proteins led to spontaneous accumulation of Tfh cells 
in Rc3h1/2fl/fl; CD4-Cre mice (Figure 32). Roquin-1/2 might even control a transition point 
between Th1 and Tfh cells, as demonstrated by adoptive transfer (Figure 36).  
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Figure 36: Roquin-1 and Roquin-2 control the differentiation from Th1 to Tfh cells. (A–B) Frequencies  
(A) and cell numbers (B) of Tfh cells (CD4+ Thy1.1+) at day 6 (A) or day 6, 7 and 8 (B) after transfer of 
MSCV-Cre-Thy1.1-transduced wild-type or Rc3h1/2fl/fl cells (Th1-differentiated) into Icos-/- mice. (C) 
Proliferation of cells (CD4+ Thy1.1+) at day 6 after transfer. Frequency (D) or cell numbers (E) of GC B 
cells (B220+) at day 8 (D) or day 6, 7 and 8 (E) after transfer. Genotypes are indicated in the figure and 
data are representative for five experiments with two (A–B, D–E) and three (C) mice per group. Transfer 
experiments were established by Stephanie Edelmann and conducted in cooperation. 	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Plasticity among helper T cell subsets is generally accepted. Among those, the Tfh cell 
population seems to be one of the most flexible Th cell populations, by displaying features 
which overlap with other Th cell subsets 162. Furthermore, Lu et al. propose that several T 
helper subsets still maintain the potential to display Tfh cell characteristics 163.  
Therefore, naive CD4+ T cells were transferred into CD45.1; CD45.2 wild-type mice to 
investigate their potential to differentiate into Tfh cells without being previously activated. 
For the transfer, CD4+ T cells from wild-type; CD4-Cre or Rc3h1/2fl/fl; CD4-Cre mice were 
purified using magnetic beads and subsequently FACS sorted for CD4+ CD25– CD62L+ 
CD44– T cells (Figure 37 A, upper panel). Eight days after transfer, the mice were analyzed 
for the development of Tfh cells from transferred CD45.2+ cells. Interestingly, although 
transferred with a naive phenotype, Rc3h1/2-deficient cells were highly activated. Almost 
90% of the transferred Rc3h1/2fl/fl; CD4-Cre cells lost their naive state and expressed the 
activation marker CD44. Conversely, 90% of transferred wild-type cells stayed in the naive 
state (Figure 37 A, lower panel). Beside the potential of being highly activated, Rc3h1/2-
deficient cells also spontaneously differentiated into CXCR5hi PD-1hi Tfh cells, while 
transferred wild-type cells did not up-regulate these markers (Figure 37 B). This transfer 
experiment further corroborates the finding that Roquin-1 and Roquin-2 control the 
differentiation of Tfh cells. Roquin-1 and Roquin-2 seem to play a suppressing role in this 
differentiation program, which seems to be switched on as a default program if Roquin-1 and 
Roquin-2 are missing. These proteins might therefore be crucial in preventing germinal 
center-derived autoimmune diseases and potentially lymphoid cancers by repressing certain 
co-stimulatory molecules. 
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Figure 37: Naive CD4+ T cells from Rc3h1/2-deficient mice spontaneously become Tfh cells. For transfer 
experiments, naive CD4+ T cells from wild-type; CD4-Cre or Rc3h1/2fl/fl; CD4-Cre mice were sorted for 
CD4+ CD25– CD62L+ and CD44– (A, upper panel) and were i.v. injected into CD45.1+ CD45.2+ expressing 
recipient mice. Eight days after injection the transferred cells were analyzed for the expression of CD62L 
and CD44 markers (A, lower panel) or the spontaneous conversion into Tfh cells (B). 	  
8.2.11 Roquin-­‐1/2	  reciprocally	  influence	  Th17	  and	  Treg	  differentiation	  
The transfer experiments in section 8.2.10 clearly demonstrated that Roquin-1 and Roquin-2 
play a crucial role in Tfh cell differentiation. Therefore, their role in other differentiation 
programs was investigated. Wild-type or Rc3h1/2-deficient CD4+ T cells were activated in 
vitro under Th0, Th1, Th2, Th17 and Treg polarizing conditions. As Rc3h1/2-deficient CD4+ 
T cells were highly activated ex vivo, naive CD4+ T cells (CD4+ CD25– CD62L+ CD44–) were 
purified as described in section 8.2.10, to avoid any bias. Activating naive T cells with  
anti-CD3 and anti-CD28 under Th0 conditions was not sufficient to induce IFN-γ or IL-4 
production (Figure 38 A, upper panel). Furthermore, Rc3h1/2-deficient cells did not produce 
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significantly more IFN-γ than wild-type cells under Th1 conditions as judged by the MFI of 
IFN-γ in these cells and there were also similar frequencies of cells expressing IFN-γ  
(Figure 38 A, middle panel). Furthermore, IL-4 production under Th2-skewing conditions 
was not altered (Figure 38 A, lower panel). Interestingly, loss of Roquin-1 and Roquin-2 
under Th17-conditions, led to a significant increase in IL-17-producing cells (Figure 38 B, 
upper panel), while Treg cell differentiation marked by Foxp3 expression was strongly 
reduced (Figure 38 B, lower panel). This is consistent with the notion that Th17 and Treg 
cells originate from reciprocal differentiation programs 86,87. Roquin-1 and Roquin-2 were 
therefore not only involved in the development of Tfh cells, but probably also in navigating 
Th17/Treg decisions. 
 
 
Figure 38: Loss of Roquin-1 and Roquin-2 reciprocally influences Th17 and Treg differentiation. For 
differentiation experiments, CD4+ T cells from wild-type; CD4-Cre or Rc3h1/2fl/fl; CD4-Cre mice were 
enriched with CD4+ dynabeads and naive T cells (CD4+ CD25– CD62L+ CD44–) were sorted on a FACS 
AriaIII Cell Sorter. Cells were stimulated with anti-CD3/anti-CD28 antibodies, coupled to magnetic 
beads, under Th0, Th1, Th2 (A), Th17 or Treg (B) differentiation conditions (Table 19). Contour plots are 
representative for four independent experiments. Experiments were performed in cooperation with 
Sebastian Warth, who accomplished the T cell differentiation after cells had been isolated and sorted. 
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Interestingly, IFN-γ had been proposed as a target of Roquin-1, only on the basis though of 
increased Ifng mRNA half-life in T cells from san/san mice 157. However, by evaluating  
IFN-γ protein levels in the differentiation experiments above (Figure 38), we cannot confirm 
IFN-γ as a direct target of Roquin-1/2 proteins. Roquin-1/2 deficiency did neither 
significantly enhance the MFI of IFN-γ nor the number of IFN-γ-producing cells under Th1 
skewing conditions. Nevertheless, IFN-γ certainly plays an important role in the disease 
progression of san/san mice. Prolonged half-life of IFN-γ mRNA in Rc3h1san/san mice led to 
the massive accumulation of short-lived effector CD8+ cells (SLECs) in these mice. This 
phenotype was attenuated by crossing the san/san mice to IFN-γR knockouts 157.  
We therefore speculated that IFN-γ might be more deregulated in CD8+ than in CD4+ cells. 
To evaluate IFN-γ expression by CD4+ and CD8+ T cells, total splenocytes were stimulated 
with antiCD3/antiCD28 for five hours. Interestingly, CD4+ cells from Rc3h1/2fl/fl; CD4-Cre 
mice exhibited only marginally enhanced IFN-γ expression, while CD8+ T cells produced 
enormous amounts of IFN-γ (Figure 39). Notably, by stimulating total splenocytes, the initial 
differences in the activation status between Rc3h1/2fl/fl; CD4-Cre and wild-type cells as well 
as CD4+ and CD8+ T cells have to be taken into account. CD8+ T cells from double-deficient 
mice were more activated than CD4+ T cells and both T cell lineages were more activated 
compared to wild-type cells (Figure 29). This might explain why CD8+ T cells from 
Rc3h1/2fl/fl; CD4-Cre mice produced such excessive amounts of IFN-γ. Nevertheless, it is 
likely that the elevated IFN-γ levels could indeed have a positive feedback effect, by driving 
the accumulation of effector CD8+ T cells in Rc3h1/2fl/fl; CD4-Cre mice similar to Rc3h1san/san 
mice. IFN-γ might also contribute to other phenotypes in Rc3h1/2fl/fl; CD4-Cre mice such as 
the disrupted splenic architecture. However, IFN-γ is most probably not a direct target of 
Roquin-1/2 proteins, as implied by the differentiation experiment above (Figure 38). 
Enhanced IFN-γ expression could as well be caused by increased co-stimulation of effector 
cells, which can indeed stabilize the mRNA of cytokines such as IFN-γ 164. Therefore, the 
exact mechanism of IFN-γ deregulation in Rc3h1san/san and Rc3h1/2fl/fl; CD4-Cre mice 
remains to be specified. 
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Figure 39: Loss of Roquin-1/2 causes elevated IFN-γ  levels in CD8+ T cells. Total splenocytes from wild-
type; CD4-Cre or Rc3h1/2fl/fl; CD4-Cre mice were stimulated with antiCD3 and antiCD28 for 5 h adding 
Brefeldin A for 2 h. Cells were stained for IFN-γ  cytokine expression in CD4+ (left panel) or CD8+ (right 
panel) T cells. 
 
8.2.12 The	  NF-­‐κB	  pathway	  is	  activated	  in	  Rc3h1/2-­‐deficient	  cells	  	  
Th17 and Tfh cell differentiation share Irf4 as an essential transcription factor 90,165, 
suggesting that loss of Roquin-1/2 could induce Tfh and Th17 cell differentiation via 
increased Irf4 signaling. In addition to Irf4, also up-regulation of Bcl6 could explain that 
Rc3h1san/san and Rc3h1/2fl/fl, CD4-Cre mice developed spontaneous Tfh and germinal center B 
cells (39 and Figure 32, respectively). Therefore, the expression of the Tfh cell transcription 
factors Bcl6 68-70 and Irf4 103,104 was investigated. The expression levels of Bcl6 were not 
markedly altered in Rc3h1/2-deficient Tfh cells (Figure 32 A, right). However, analyzing Irf4 
expression levels after acute deletion of Roquin-1 and Roquin-2 in Th1 cells and in CD4+ T 
cells from Rc3h1/2fl/fl; CD4-Cre mice revealed significantly increased Irf4 protein amounts 
(Figure 40 A–D).  
As Irf4 is a down-stream transcriptional target of NF-κB, activation of the canonical and 
alternative NF-κB pathway was investigated. The canonical pathway did not seem to be 
strongly affected. However, there was a slight increase in p65 and IκBα phosphorylation 
(Figure 40 B), while IκBα itself was not degraded. On the contrary, the alternative NF-κB 
pathway was highly activated. This became apparent by increased expression of p100 and p52 
as well as enhanced processing of p100 to p52 in Th1-cultured cell as well as ex vivo isolated 
CD4+ T cells from Rc3h1/2fl/fl; CD4-Cre mice (Figure 40 C–D). Functionally active nuclear 
p52 was detected in cell fractionation experiments (Figure 40 E). 
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Figure 40: Roquin-1/2 deletion up-regulates Irf4 and leads to activation of the NF-κB pathway. Western 
blot analysis of protein lysates from wild-type or Rc3h1/2fl/fl CD4+ T cells after Cre-transduction, showing 
Irf4 levels (A) and factors involved in the canonical (B) or alternative NF-κB pathway (C), each 
representing an independent experiment. (D) Western blot analysis of purified CD4+ T cells, showing 
factors of the alternative NF-κB pathway. (E) Western blot analysis of cytoplasmic and nuclear extracts 
from wild-type or Rc3h1/2fl/fl CD4+ T cells after Cre-transduction. Data are representative for four (D) 
and three (E) experiments. (A–C) Western blotting was accomplished by Claudia Lohs. 
 
8.2.13 Ox40	  activates	  the	  NF-­‐κB	  pathway	  and	  is	  a	  novel	  target	  of	  Roquin-­‐1	  and	  -­‐2	  
Activation of the NF-κB pathway could be caused by Roquin-1/2 targets, which were de-
repressed in the knockout situation. Therefore, different mRNAs were tested by quantitative 
PCR, which were involved in the activation of NF-κB. In three biological replicates, no 
significant increase could be seen for Ikkα, Ikkβ, Ikkγ, NIK, Ciap1, Ciap2, Traf2, Traf3 and 
Tradd gene expression. Interestingly, Icos, RelB, Irf4 and Ox40 mRNA levels were elevated 
(Figure 41). 
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Figure 41: Loss of Roquin-1 and Roquin-2 de-represses Ox40. (A) Quantitative PCR analysis of factors 
involved in NF-κB signaling. Data are representative for three biological replicates from wild-type or 
Rc3h1/2fl/fl CD4+ T cells after Cre-transduction. (B) Relative median fluorescence intensity (MFI) of Ox40 
in CD4+ T cells from knockout mice, all normalized to an equal number of wild-type; CD4-Cre mice. (C) 
Western blot of Th1-differentiated T cell lysates from C57BL/6 mice, treated with 10 µg/ml isotype 
control antibody or anti-Ox40 (OX86) for three days, showing factors of the alternative NF-κB pathway. 
Genotypes are indicated in the figure and data are representative for three (C) experiments. Bars 
represent the median value of each column and statistical significances were calculated by Tukey’ 
multiple comparisons test (*p < 0.05). (A) qPCR was performed by Claudia Lohs. 
 
Ox40 was included as a candidate gene, because it was shown to activate the NF-κB 
pathway 166. Furthermore, as described in section 8.1.5 and 8.1.6, array approaches identified 
Ox40 as a promising new target of Roquin-1. Consequently, Ox40 protein levels were 2-fold 
increased in CD4+ T cells from Rc3h1fl/fl; CD4-Cre mice, and even higher increased in 
Rc3h1/2-deficient CD4+ T cells compared to wild-type or Rc3h2fl/fl; CD4-Cre CD4+ T cells 
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(Figure 41 B). Furthermore, cultivating Th1 cells in the presence of an agonistic anti-Ox40 
antibody (Ox86) was sufficient to activate the alternative NF-κB pathway with increased 
processing of p100 to p52. However, the stimulation was not effective to up-regulate Irf4 
expression compared to the isotype control (Figure 41 C). In these experiments, Irf4 was 
expressed after 1 h, 5 h, 48 h and 72 h of activation and completely vanished after six days. 
The presence of the anti-Ox40 antibody, though, had no influence on Irf4 expression levels. 
We nevertheless hypothesize that Ox40 co-stimulation in combination with additional signals 
could increase Irf4 expression. 
Moderately elevated Ox40 levels in Rc3h1fl/fl; CD4-Cre mice compared to significantly 
increased Ox40 expression in Rc3h1/2fl/fl; CD4-Cre mice were reminiscent of the extent of 
Icos deregulation in these mice (Figure 30). Furthermore, Roquin-1 was shown to directly 
bind to Ox40 mRNA (Figure 19). Therefore we tested redundant functions of Roquin-2 in 
respect to this novel target of Roquin-1. Indeed, Roquin-2 (aa 1–438) could equally well bind 
to full-length Ox40 mRNA (Figure 42 A). Furthermore, direct repression of Ox40 was 
investigated in vitro by transduction of CAR-transgenic CD4+ T cells deficient for Roquin-1 
with adenovirus expressing Roquin-1 and Roquin-2 proteins. Roquin-1 wild-type and both 
isoforms of Roquin-2 (aa 1–1125 and 1–1187) down-regulated Ox40 to the same extent 
(Figure 42 B), whereas the inactive form of Roquin-1 (aa 1–509) could not repress Ox40. 
These data support the conclusion that Ox40 is a novel target of Roquin-1 and Roquin-2, 
which was de-repressed in Rc3h1fl/fl; CD4-Cre and Rc3h1/2fl/fl; CD4-Cre mice. Furthermore, 
both proteins could independently bind to the Ox40 mRNA and repress Ox40 expression in 
vitro. 
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Figure 42: Roquin-1 and Roquin-2 redundantly control Ox40 expression. (A) EMSA with 1 pmol Ox40 
full-length mRNA and 0–20 pmol of recombinant Roquin-1 (aa 1–441) or Roquin-2 (aa 1–438). (B) Ox40 
levels after adenoviral transduction of CD4+ T cells from Rc3h1fl/fl; CAG-CARstop-fl; CD4-Cre mice with an 
inactive Roquin-1 (aa 1–509), Roquin-1 wild-type (WT) or two isoforms of Roquin-2 (aa 1–1125 or  
aa 1–1187), with histogram overlay of Roquin-1/2hi cells (below). All plots in (A) are pre-gated on CAR+ 
cells. Data are representative for two (A) and three (B) experiments. (A) EMSA was performed by Gitta 
Heinz. 
 
8.2.14 Loss	  of	  Roquin-­‐1/2	  drives	  Tfh	  cell	  differentiation	  independently	  of	  Icos	  
Having established Ox40 as a new target of Roquin-1 and Roquin-2, we hypothesized that the 
de-regulation of both co-stimulatory receptors might contribute to the phenotypes observed in 
Rc3h1/2fl/fl; CD4-Cre mice. To assess the role of Icos in these animals, triple knockout (TKO) 
mice were generated, which were deficient for Roquin-1 and Roquin-2 in the T cell 
compartment and overall deficient for Icos (Rc3h1/2fl/fl; CD4-Cre; Icos-/-). Icos expression 
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was reduced in Rc3h1/2fl/fl; CD4-Cre mice heterozygous for Icos and was indeed absent in 
Rc3h1/2fl/fl; CD4-Cre; Icos-/- mice (Figure 43 A). Ox40 levels were still up-regulated in these 
mice, although Icos ablation led to a slight reduction in Ox40 overexpression levels (Figure 
43 B). 
 
 
Figure 43: The absence of Icos in Rc3h1/2fl/fl; CD4-Cre mice does not revert the effector-like phenotype of 
the double knockout. (A–B) Mean value of the relative median fluorescence intensity of Icos (A) or Ox40 
(B) in CD4+ T cells from knockout mice, all normalized to an equal number of Icos-/- mice. (C) 
Representative contour plots of CD4+ (upper panel) or CD8+ (lower panel) splenocytes expressing the 
markers CD62L and CD44. Genotypes are indicated in the figure and data are representative for 4 (C) 
mice per genotype. 
 
We then analyzed the most important phenotypes of the Rc3h1/2fl/fl; CD4-Cre mice in the Icos 
TKOs. Surprisingly, loss of Icos did not alter the massive increase of effector-like CD4+ and 
CD8+ T cells in the double knockout situation (Figure 43 C), implying that other signals than 
Icos, such as Ox40 for example, play a dominant role in the activation of T cells from 
Rc3h1/2fl/fl; CD4-Cre mice. Furthermore, Icos TKOs were still able to spontaneously form 
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Tfh cells (Figure 44 A), although Icos was thought to be crucial in Tfh cell differentiation 96. 
All four mice analyzed exhibited clearly increased frequencies of Tfh cells compared to wild-
type or Icos-/- animals. Examining B cells in these mice revealed markedly reduced B220+ B 
cells (Figure 44 B). Two mice appeared unhealthy and were completely devoid of B cells. 
Consequently they did not develop GC B cells, while in the other two mice only the older one 
(17 weeks) exhibited spontaneous GC B cell development, while the younger one (12 weeks) 
did not (Figure 44 C). 
 
 
Figure 44: Loss of Roquin-1/2 proteins causes spontaneous Tfh and GC B cell formation even in the 
absence of Icos. (A–C) Representative contour plots of splenic Tfh cells (PD-1hi CXCR5hi), pre-gated on 
CD4+ (A), of B220+ cells (B) and of germinal center B cells (GL-7hi CD95hi), pre-gated on B220+ (C). All 
genotypes are indicated in the figures. Data are representative for four (A) and two of four mice, which 
still contained B220+ cells (B–C, also see section 8.2.14) mice. 
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Thus, combined loss of Roquin-1 and Roquin-2 seemed to override the need for Icos co-
stimulation in the generation of Tfh cells and probably also GC B cells. 
Remarkably, spleen sections from two mice analyzed revealed close to normal splenic 
architecture with follicle-like structures and marginal zones. Furthermore, the network of 
follicular dendritic cells (FDC-M1+) clearly spanned across the follicle structures  
(Figure 45 A). Loss of Icos signaling obviously normalized the development of the splenic 
architecture. 
 
 
Figure 45: Rescue of splenic architecture supports auto-antibody formation in Icos TKOs. (A) 
Consecutive cryo-sections from spleens, stained for B220, MOMA-1, FDC-M1 and CD4. The black bar 
represents 100 µm. Cryo-sections and staining were performed by Prof. Dr. Mathias Heikenwälder and 
Jessica Zöller, Institute for Virology, Technische Universität München/Helmholtz Zentrum München. (B) 
Indirect immunofluorescence for antinuclear antibodies (HEp-2). Each panel represents one animal with 
the indicated phenotype.  
 
As described in section 8.2.9, loss of Roquin-1/2 in T cells led to a complete destruction of 
the splenic architecture, impeding auto-antibody formation. The intact follicle structure in the 
Icos TKO and enhanced Tfh cell frequency might actually support auto-antibody formation. 
Indeed, auto-antibodies (ANAs) were detected in serum from a 17 weeks old male mouse. 
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Although only few animals were analyzed so far, ANAs appeared to be formed with age, as 
auto-antibodies started to occur in a male mouse at 15 weeks of age (Figure 45 B). Comparing 
these data with the frequency of Tfh and GC B cells in the respective animal revealed that 
only the older mouse (17 weeks) had auto-antibodies and GC B cells. The younger mouse (11 
weeks) did not spontaneously develop GC B cells, while the 15 weeks old mouse was not 
analyzed for GC B cells. We therefore assume that spontaneous GC B cell development as 
well as the occurrence of ANAs could manifest with age in these Icos TKOs. We furthermore 
speculate that Ox40 expression, which was still elevated in Icos TKOs, might even be able to 
substitute for Icos deficiency in Tfh cell and germinal center formation. Considering a recent 
publication, which demonstrated that the level of PIP3 generated by PI3K controlled the 
magnitude of the germinal center reaction 167, it would be interesting to address the possibility 
that Ox40 signaled via PI3K to influence the germinal center reaction. 
Taken together, these data demonstrated that loss of Roquin-1 and Roquin-2 caused 
spontaneous Tfh and GC B cell development even in the complete absence of Icos, which 
subsequently led to the formation of auto-antibodies in an almost intact splenic environment. 
Loss of Icos signaling on the one hand reversed the disruption of the splenic architecture, 
which could allow for the development of auto-antibodies in intact follicle structures. A 
recent study, however, demonstrated that ablation of Icos in san/san mice, which had intact 
spleens and spontaneous germinal centers, did not prevent ANA development, but even led to 
the occurrence of homogenous anti-nuclear antibodies in Rc3h1san/san mice 159. Loss of Icos 
signaling thus seems to correlate with the development of auto-antibodies in the absence of 
functional Roquin proteins in Rc3h1san/san and Rc3h1/2fl/fl; CD4-Cre mice. 
 
8.2.15 Reducing	  IFN-­‐γ 	  levels	  in	  Rc3h1/2-­‐deficient	  mice	  rescues	  splenic	  architecture	  
but	  not	  effector-­‐like	  phenotype	  
Very recently it had been described that loss of IFN-γ signaling reversed the phenotype of 
short-lived effector CD8+ T cells, characterized by a CD62Llo KLRG1hi phenotype 157. 
Crossing Rc3h1san/san mice to IFN-γR knockout mice reduced SLEC numbers to wild-type 
levels and total CD44hi CD8+ T cells declined to only 3-fold above wild-type levels compared 
to 9-fold in the Rc3h1san/san mice. Therefore, Rc3h1/2fl/fl; CD4-Cre, IFN-γ-/- mice (IFN-γ TKO) 
were generated to assess the effect of IFN-γ signaling on the double knockout phenotype. 	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Total splenocytes from IFN-γ-deficient mice with or without additional deletion of Rc3h1/2 
genes, did not produce IFN-γ after 5 h of PMA and ionomycin stimulation (Figure 46 A). 
Surprisingly however, the effector-like phenotype of Rc3h1/2-deficient mice was not reversed 
or reduced as in the san/san mouse upon loss of IFN-γ signaling. In contrast, even more CD4+ 
T cells seemed to adopt a CD44hi CD62Llo phenotype in the few IFN-γ TKOs analyzed, 
compared to Rc3h1/2-deficient mice (Figure 46 B, compare to Figure 29 A). 
 
 
Figure 46: IFN-γ  is not responsible for the effector-like T cell phenotype caused by loss of Roquin-1/2. (A) 
Representative contour plots showing IFN-γ  production after stimulation of total splenocytes for 5 h with 
PMA and ionomycin. (B) Representative contour plots from CD4+ (upper panel) or CD8+ (lower panel) 
splenocytes, showing naive (CD62Lhi CD44lo), effector-like (CD62Llo CD44hi) or memory-like (CD62Lhi 
CD44hi) T cells. Genotypes are indicated in the figure and data are representative for two (A), three (B, 
control) and four (B, IFN-γ  TKO) individual mice per genotype. 	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Although IFN-γ played a more dominant role in the development of effector T cells in the 
san/san mouse compared to Icos signaling 157,159, the ablation of neither IFN-γ nor Icos was 
able to rescue the activation phenotype in Rc3h1/2fl/fl; CD4-Cre mice. This suggests that other 
factors are causing this aberrant T cell activation in Rc3h1/2fl/fl; CD4-Cre mice. However, loss 
of Roquin-1 and Roquin-2 might also reduce the activation threshold of CD4+ and CD8+ T 
cells rendering them sensitive to even low stimuli, which might lead to constant activation. 
 
Similar to the Icos TKOs, all IFN-γ TKOs showed enhanced frequencies of Tfh cells without 
immunization. Two of four animals were able to spontaneously generate GC B cells (Figure 
47 A–B). However, the ability to induce GC B cells did not correlate with age. Consecutive 
cryo-sections of spleens from IFN-γ TKOs were then analyzed to compare the degree of 
destruction in spleens of Rc3h1/2-deficient mice. Interestingly, also reducing IFN-γ signaling 
was sufficient to largely rescue the splenic architecture (Figure 47 C). In some but not all 
animals, B220+ cells formed a clear B cell zone, surrounded by metallophilic macrophages 
(MOMA-1+). The B cells, however, did not fully localize in the marginal zone. Furthermore, 
IFN-γ TKOs clearly developed ANAs, correlating with the rescue in the splenic architecture, 
as could similarly be seen in Icos TKOs. In contrast to Icos TKOs, however, all IFN-γ TKOs 
developed auto-antibodies with an age of only 11 weeks (Figure 47 D). 
Although these investigations included only few mice of the respective genotypes, the 
phenotypes of the analyzed individuals indicated that loss of IFN-γ was sufficient to rescue 
the follicular organization in the spleen of IFN-γ TKOs. In an almost intact splenic 
environment, loss of Roquin-1 and Roquin-2 indeed caused auto-antibody formation by 
increasing Tfh and GC B cells. However, reducing IFN-γ signaling did not reverse other 
double knockout phenotypes such as increased numbers of effector-like T cells (CD62Llo 
CD44hi) and reduced numbers of naive T cells (CD62Lhi CD44lo) (Figure 29). Although IFN-γ 
and Icos signaling (section 8.2.14) contributed to several phenotypes, which developed due to 
loss of Roquin protein function, the molecular origin of these phenotypes is probably caused 
by a complex interaction of several deregulated signaling pathways. 
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Figure 47: Rescue of splenic architecture supports auto-antibody formation in IFN-γ  TKOs. (A–B) 
Representative contour plots of splenic Tfh cells (PD-1hi CXCR5hi), pre-gated on CD4+ (A) and of splenic 
germinal center B cells (GL-7hi CD95hi), pre-gated on B220+ (B). (C) Consecutive cryo-sections from 
spleens, stained for B220 and MOMA-1. The black bar represents 500 µm. Cryo-sections and stains were 
performed by Prof. Dr. Mathias Heikenwälder and Jessica Zöller, Institute for Virology, Technische 
Universität München/Helmholtz Zentrum München. (D) Indirect immunofluorescence for antinuclear 
antibodies (HEp-2). Each panel represents one animal with the indicated phenotype. 
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9 Discussion	  
In this research project, the roles of Roquin-1 and Roquin-2 were investigated in vitro and in 
vivo. An important finding was the discovery of a cis-element in the 3’UTR of ICOS mRNA 
for effective Roquin-1 and Roquin-2 protein binding. Furthermore, the work addressed the 
functions of Roquin-1 and Roquin-2 in vivo by investigating loss of function in mice with 
conditional deletions. These studies revealed functional redundancy of Roquin-1 and -2 in the 
control of the co-stimulatory molecules Icos and Ox40, the latter one being a novel mRNA 
target of both proteins. Combined deletion of Roquin-1/2 proteins augmented Ox40 co-
stimulation through the alternative NF-κB pathway and increased Irf4 transcription factor 
levels. This work further demonstrated a crucial role for Roquin-1 and Roquin-2 proteins in 
the prevention of autoimmunity and the maintenance of tolerance by impeding inappropriate 
T cell activation and Tfh cell differentiation. 
 
9.1 The	  RNA-­‐binding	  of	  Roquin-­‐1	  and	  Roquin-­‐2	  
As described in the introduction (section 5.2.1) RNA-binding proteins recognize specific cis-
elements mostly in the 3’UTR of their target mRNAs and interact with the mRNA via special 
RNA-binding domains such as zinc fingers. Recently, the newly defined ROQ domain in 
Roquin-1 had been proposed to be involved in RNA binding. Although immunoprecipitation 
experiments showed that the ROQ domain was important in the interaction of Roquin-1 with 
ICOS mRNA 149, the results could not exclude an indirect contribution such as the binding via 
cellular co-factors. Furthermore, the nature of the recognition motif for protein–RNA 
interaction remains to be identified. This research work therefore addressed the role of the 
ROQ domain in direct protein–RNA interaction, which is discussed below. Furthermore, the 
search for recognition elements in the ICOS mRNA revealed remarkable insights into the 
structure- and sequence-requirements for protein–RNA interaction, as described in the 
following sections. 
 
9.1.1 Roquin-­‐1	  recognizes	  a	  cis-­‐element	  in	  the	  3’UTR	  of	  ICOS	  mRNA	  	  
The repression of ICOS mRNA by Roquin-1 and -2 proteins depends on the presence of the 
3’UTR, as ICOS CDS alone does not respond to Roquin-1 regulation 149. Scanning the 3’UTR 
for conserved protein-binding sites, however, did not reveal recognition motifs such as AREs, 
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albeit six regions in the 3’UTR of ICOS were highly conserved between mouse and 
human 119. Therefore, previous studies tested the response of three larger regions of the 
3’UTR in the context of a reporter construct to Roquin-1 overexpression. The last part of the 
3’UTR, containing a putative miR-101 binding site, was well repressed by Roquin-1. 
However, a shortened 47-nt sequence containing this miR-101 binding site was only 
moderately repressed by Roquin-1. Mutating the miR-101 binding site led to a non-significant 
residual repression 119. Due to this correlation, a mechanism was suggested, in which 
Roquin-1 repressed ICOS mRNA by interacting with miR-101 to induce mRNA decay. 
However, subsequent studies in cells, which were devoid of mature miRNAs and therefore 
impaired in miRNA-mediated gene silencing, clearly demonstrated that Roquin-1-mediated 
repression of ICOS mRNA functions independently of the miRNA pathway 149. We therefore 
assumed that direct Roquin-1 protein interaction with the ICOS mRNA might be the first step 
in the targeting and regulation of ICOS. Indeed, I could demonstrate in EMSAs that 
recombinant Roquin-1 protein directly binds to in vitro transcribed ICOS mRNA, exhibiting a 
binding preference for the ICOS 3’UTR (Figure 7). Furthermore, I showed that Roquin-1 
binds to an element of so far unknown sequence or structure, located between 100 and 200 
nucleotides downstream of the stop codon in the ICOS 3’UTR (Figure 11 and Figure 12). 
Interestingly, we noticed that Roquin-1 had a general affinity for mRNA, as indicated by the 
disappearance of free ICOS CDS mRNA at very high protein concentrations (Figure 7). Such 
a behavior could be explained by a bimodal binding kinetic, in which Roquin-1 generally 
binds to mRNA with a low binding affinity, but has higher affinity for its responsive cis-
element within a target mRNA. In addition, specific binding seemed to occur in a cooperative 
manner by sequential binding and shifting of the mRNA with increasing protein 
concentrations. This raises the possibility that Roquin-1 has more than one binding site in the 
ICOS 3’UTR, which is also in line with previous studies, mapping a Roquin-1 binding site at 
the 3’end of the UTR, adjacent to the miR-101 binding site 155. It might be deceptive to focus 
on the 47-nt sequence, containing the miR-101 binding site, while ICOS repression did not 
depend on the miRNA pathway. Nevertheless, the last part of the 3’UTR containing the 47-nt 
element as well as the element mapped in the present work (Figure 12) could both be 
independently bound and be regulated by Roquin-1 119,149,155. The fact that the 47-nt element 
on its own was much less repressed than the larger region containing the 47-nt element 
implies that additional co-factors might recognize sites, which are not present in these 47 nts. 
Indeed, some cell lines are unable to support Roquin-1-mediated ICOS repression in 
overexpression experiments, indicating a need for co-factors, which are not present in these 
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cell lines (unpublished observation). It is therefore very likely that Roquin-1 requires 
additional factors in vivo, which bind to further cis-elements in the 3’UTR of ICOS and 
contribute to efficient ICOS repression.  
Importantly, I could find that Roquin-1 binding to the ICOS mRNA containing a cis-element 
did not depend on the length of the transcript (Figure 7 and Figure 11). While sequences of 
the 3’UTR, which were mapped for binding, confer a basal level of repression, the efficiency 
of repression increased upon extending the 3’UTR further 149. On the one hand, this could 
reflect the need for co-factor binding, which essentially contributes to ICOS repression. On 
the other hand, the presence of several cis-elements in the extensively long 3’UTR of the 
ICOS mRNA seems physiologically reasonable, given that cooperation of a number of cis-
elements together determine the rate of mRNA decay 123. ICOS is a factor especially needed 
upon activation of T cells and proliferating cells express mRNAs with shortened 3’UTRs 129. 
The expression of short 3’UTR devoid of any cis-elements seems to be a suitable mechanism 
to avoid repression, in a setting of acute T cell activation when there is need for ICOS 
signaling. In resting cells, Roquin-1 might be able to fully repress ICOS by cooperating with 
other trans-acting factors or by occupying several binding motifs to induce effective mRNA 
decay. 
 
9.1.2 Characterizing	  the	  cis-­‐element	  in	  the	  ICOS	  3’UTR	  further	  
Despite localizing a crucial Roquin-1 recognition element to 100 nucleotides in the ICOS 
3’UTR (Figure 12), we still do not know the sequence or structure characteristics of this 
element. Identifying the exact cis-element is important for the understanding of the protein–
RNA interaction and will facilitate the identification and characterization of new targets, 
specified by the presence of the Roquin-1 cis-element. Therefore, a new research project has 
been started by a colleague to address these open questions and to further examine the 
characteristics of the cis-element by crosslinking Roquin-1 to the mRNA in vitro and in cells. 
Moreover, it is important to functionally test the minimal response element. It is necessary 
therefor to inhibit functional responses by mutating essential nucleotides. However, the 
binding may not only involve a certain sequence but also structure determinants, hampering 
the mutagenesis approach. 
Computational tools cannot reliably predict potential secondary structures larger than 100 nts. 
Therefore we applied SHAPE 153 for obtaining the preferred secondary structure of 100-nt 
fragments of the ICOS mRNA, to set the molecular basis for future mutagenesis studies. We 
focused on three fragments of the ICOS mRNA, including the 100-nt binding element  
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(700–800) mapped in EMSAs (Figure 12) and two 100-nt long sequences 5’ (600–700) and 3’ 
(800–900) to the mapped element. Interestingly, all computational predictions were slightly 
different from the structures revealed by SHAPE, except for one of the suggested foldings for 
the 700–800 cis-element, which was identical to the SHAPE result. Furthermore, only the 
700–800 cis-element exhibited a two-finger-like structure with a shorter (15 nts) and a longer 
(39 nts) hairpin, while the other fragments folded in long or bulgy structures (Figure 14). 
Together these still preliminary data strongly suggest that the two-finger-like configuration of 
the 700–800 cis-element might constitute a novel structural cis-element for protein 
recognition and binding. 
 
9.1.3 The	  ROQ	  domain	  is	  a	  new	  RNA-­‐binding	  domain	  
In this research work, I could demonstrate that the amino-terminus of Roquin-1, comprising 
RING finger, ROQ domain and zinc finger, can directly bind to its mRNA target  
(section 8.1). As will be discussed below, the zinc finger does not play an essential role in 
RNA binding and immunoprecipitation experiments did not reveal an important role for the 
RING finger in RNA binding 149. I therefore conclude that the ROQ domain is a novel RNA 
binding domain, indispensable for the binding and subsequent repression of Roquin-1 mRNA 
targets. Nevertheless, the RING and zinc fingers may help in ICOS mRNA binding or 
regulation. 
Deletion of the zinc finger in Roquin-1 led to a marked decrease in protein–RNA interaction 
in overexpression studies, while point mutations in the zinc finger cause only a mild negative 
effect on ICOS mRNA repression 150. In vitro, the mutation of the zinc finger did not 
significantly affect the binding affinity in EMSA experiments (Figure 8 B). We therefore 
assume that the zinc finger can contribute to RNA-binding, but is not essential. Such zinc 
finger modules normally act in tandem to exert RNA-binding activity. The presence of only 
one zinc finger in Roquin-1 and Roquin-2 might therefore exert slightly different functions. It 
might help to bind multiple Roquin-1 protein molecules to the same ICOS mRNA. A modular 
structure with more than one RNA-binding domains is common to many RNA-binding 
proteins 168. Such modules enable the protein to bind to its target mRNA with higher affinity, 
thereby increasing the specificity for a substrate among an enormous diversity of mRNAs 168. 
Although the zinc finger mutations in Roquin-1 did not alter the RNA binding affinity in vitro 
(Figure 8 B), it might specify the function of Roquin-1 in vivo. 
Roquin-1 and Roquin-2 also contain a RING finger 3’ to the ROQ domain and the zinc finger. 
The molecular function of the RING finger had been investigated, however, the exact role of 
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the RING finger has not been defined yet. Auto-ubiquitination could not be observed, which 
indicates that the RING finger might not exert E3 ligase activity on Roquin-1 itself 150. Still, 
deletion of the RING finger in Roquin-1 clearly reduced ICOS protein repression 149. One 
possibility, which has not been addressed so far, is the involvement of the RING finger in 
RNA-degradation. Only recently, the turnover of AU-rich cytokine mRNAs had been linked 
to ubiquitination. The impairment of protein ubiquitination inhibited ARE-mediated decay 169. 
Moreover, a new ubiquitin ligase (MEX-3C) was shown to directly bind the HLA-A2 mRNA 
and to post-transcriptionally regulate the mRNA stability, while it also repressed HLA-A2 
protein expression 170. This suggests that mRNA decay and down-regulation of target proteins 
are two processes that are linked. 
Finally, NMR (Nuclear magnetic resonance) or crystal structures of Roquin-1 would further 
elucidate the relation and functional dependence of the single protein domains to each other. 
 
9.2 Roquin-­‐1	  and	  Roquin-­‐2	  serve	  redundant	  functions	  
Recent work has contributed a lot to the understanding of Roquin-1 function in the immune 
system. The functions of its paralog Roquin-2, however, were largely unknown. Roquin-2 is 
typically expressed at lower levels than Roquin-1 in different tissues and importantly in T 
cells (Figure 20 and Figure 25), and Roquin-2 was therefore assumed to play a minor role in T 
cell homeostasis. However, this work demonstrates a critical importance of Roquin-2 as an 
evolutionary safeguard against autoimmunity, compensating Roquin-1 function in post-
transcriptional gene regulation. 
 
9.2.1 Redundancy	  and	  lateral	  inhibition	  of	  Roquin-­‐1	  and	  Roquin-­‐2	  
The severe lupus-like autoimmune phenotype in Rc3h1san/san mice 39 conflicts with the normal 
immune system of Rc3h2fl/fl; CD4-Cre mice (section 8.2.4) and the relatively mild immune 
phenotypes of Roquin-1 deficiency in T, B and hematopoietic cells 120. We therefore 
speculated that the highly conserved Roquin-2 paralog substitutes for loss of Roquin-1 in 
Rc3h1fl/fl; CD4-Cre mice, while the presence of Roquin-1san protein might hinder Roquin-2 in 
rescuing autoimmune phenotypes.  
Indeed, I could show in vitro that Roquin-2 is fully capable of and equally efficient in 
performing key functions of Roquin-1. Roquin-2 could bind to ICOS and Ox40 mRNA 
independently of Roquin-1 (Figure 16 and Figure 42) and exhibited the same preference for 
binding to the 3’UTR of ICOS mRNA (Figure 16). Direct RNA binding may be the first step 
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in Roquin-1-dependent ICOS mRNA repression. Roquin-1 further interacts with members of 
the decapping machinery such as Edc4 to induce ICOS mRNA decay 149. Likewise, Roquin-2 
was able to directly interact with Edc4 independently of Roquin-1, as shown by 
immunoprecipitation experiments in MEF cells deficient for Rc3h1, Rc3h2 or both genes 
(Figure 31). Furthermore, both paralogs co-localized to P bodies, as shown by overexpression 
in A549 cells (150 and Figure 21). Finally, overexpression of both proteins in primary CD4+ T 
cells demonstrated that both proteins could equally well down-regulate ICOS or Ox40 
expression levels (Figure 31 and Figure 42). Thus, Roquin-2 resembles Roquin-1 in direct 
target mRNA binding, localization and interaction with the decapping factor Edc4 to repress 
target gene expression. 
However, functional compensation of Roquin-2 cannot completely explain the phenotypes 
observed in the different mouse models. We therefore propose a model that includes an 
inhibitory regulation of Roquin-1/2 proteins to explain the observed compensation of partial 
loss-of-function in some mouse models (Figure 48). This inhibitory effect is apparent when 
comparing the levels of the post-transcriptional target Icos on T cells from  
Rc3h1fl/fl; CD4-Cre mice, Rc3h2fl/fl; CD4-Cre mice, Rc3h1/2fl/fl; CD4-Cre mice or Rc3h1san/san 
mice. Notably, the protein levels of Roquin-1, Roquin-1san or Roquin-2 were not altered in T 
cells from mice with the different genotypes (Figure 29, 157 and Figure 25, respectively) and 
Roquin-1 as well as Roquin-1san proteins were five times more abundant than Roquin-2  
(section 8.2.4 and 157). 
The removal of Roquin-2 protein had no effect on Icos expression. Surprisingly however, the 
ablation of Rc3h1 caused only a moderate up-regulation of Icos, although it removed five 
times more Roquin protein. Combined loss of Roquin-1/2 on the other hand greatly enhanced 
Icos expression levels. This indicates that in wild-type cells Roquin-2 does not contribute to 
Roquin-1/2 function. Instead its function appears either inhibited or the protein cannot 
compete with the much greater amount of Roquin-1 protein. However, in Rc3h1-deficient 
cells, Roquin-2 displays an increased activity, as it is not inhibited anymore. It is now able to 
compensate for most of the Roquin-1 loss-of-function and thereby prevents major phenotypes 
of autoimmunity. Interestingly, in T cells from Rc3h1san/san mice, Icos was expressed at higher 
levels compared to T cells from Rc3h1fl/fl; CD4-Cre mice but at lower levels compared to T 
cells from Rc3h1/2fl/fl; CD4-Cre mice (as judged from 39). This effect can be explained with 
the Roquin-1san protein retaining the inhibitory regulation of Roquin-2 function at a similar or 
reduced extent. At the same time, the Roquin-1san protein loses most of its activity in post-
transcriptional gene regulation, as exemplified by the high levels of Icos. Therefore, Roquin-2 
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protein cannot complement the hypomorphic function of the Roquin-1san protein 39,119, which 
is still present at five-fold levels compared to Roquin-2. The nature of the inhibitory effect is 
currently unclear, but a competitive, dominant negative or negative feedback mechanism 
would be possible. 
 
 
Figure 48: Roquin-1 impairs Roquin-2 function. This conclusion is based on the analyses of mice deficient 
for Roquin-1 120, Roquin-2 or both proteins (section 8.2.4 and 8.2.6) as well as Roquin-1san/san mice 39. The 
conservation of both proteins implies that Roquin-2 could also impair Roquin-1 function, but to a minor 
extent, because of low Roquin-2 protein expression levels. Consequently, Roquin-2 can only exert its 
function in the absence of Roquin-1 constituting an important safety mechanism in the prevention of 
autoimmunity. 
 
9.2.2 Evolutionary	  role	  of	  Rc3h1	  gene	  duplication	  
Low Roquin-2 expression levels in peripheral T cells were sufficient to suppress those 
alterations in Rc3h1fl/fl; CD4-Cre mice that developed in Rc3h1san/san or Rc3h1/2fl/fl; CD4-Cre 
mice. These include that T cells become excessively activated and that CD4+ T cells are 
driven towards a Tfh cell phenotype, causing ANA formation in san/san mice even in the 
absence of immunization. This indicates that the Rc3h1/Rc3h2 gene duplication ensures tight 
control of T cell activation and Tfh cell differentiation to prevent autoimmunity.  
However, full redundancy is presumably unstable in evolution due to the lack of selective 
pressure. Novak et al. therefore have established several assumptions under which genetic 
redundancy can persist in evolution 171. In the light of functional redundancy of Roquin-1 and 
Roquin-2 as well as lower expression levels of Roquin-2 compared to Roquin-1 the 
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evolutionary advantage of gene duplication may not involve diversification of both proteins in 
the immune system, but rather improve adaptation of protein expression levels. In this 
scenario, Roquin-2 can only persist in evolution, if the mutation rate is lower in Roquin-2 
than in Roquin-1. We have detected a non-redundant role of Roquin-2 though: complete lack 
of Roquin-2 causes postnatal death in mice (section 8.2.3). Therefore, selective pressure is 
high to maintain Roquin-2. In regard to Roquin-2-function this could imply that Roquin-2 
does exert – so far unknown – essential molecular functions outside the immune system, 
which ensures evolutionary stability. Functional diversification might have occurred in the 
carboxy-terminal region, which is less conserved between Roquin-1 and Roquin-2  
(Figure 15). In addition, Roquin-2 comprises functions in the immune system redundant to 
Roquin-1. Here, Roquin-2 plays a minor role in healthy mice. However, in the case of loss of 
Roquin-1-function (Rc3h1fl/fl; CD4-Cre), Roquin-2 can substitute for Roquin-1 and prevent 
the onset of autoimmunity. 
 
9.3 Role	  of	  Roquin-­‐1	  and	  Roquin-­‐2	  in	  autoimmune	  disease	  
Autoimmune diseases can be classified into organ-specific and systemic diseases. Systemic 
diseases such as SLE often display multiple characteristics and are initiated by many different 
triggers. Due to these diverse phenotypes, it was generally assumed that SLE might never be 
caused by just one single genetic mutation 117. The san/san mouse is an outstanding counter-
example and ascribes enormous importance to Roquin-1 and Roquin-2 in the control of 
autoimmune disease by directing T helper cell differentiation. 
 
9.3.1 Do	  Roquin-­‐1	  and	  Roquin-­‐2	  intrinsically	  control	  Tfh	  cell	  differentiation?	  
We found that combined loss of Roquin-1 and Roquin-2 in T cells led to the spontaneous 
formation of Tfh and GC B cells (Figure 32). The increase of germinal center B cells in 
Rc3h1/2fl/fl; CD4-Cre mice is induced via cell-extrinsic mechanisms such as cytokines or 
increased co-stimulation by Tfh cells, since we investigated T cell-specific loss of function. 
Likewise, also the development of GC B cells in san/san mice was mostly due to cell-extrinsic 
mechanisms, although the san-mutation is not restricted to T cells 118. In contrast, Tfh cells in 
Rc3h1san/san mice accumulated in a T cell intrinsic manner 111. 
Nakayamada et al. recently described a transitional stage between Th1 and Tfh cells 108. As 
plasticity of T helper cell subsets seems to be an important feature in immune responses, we 
wanted to investigate the role of Roquin-1 and Roquin-2 in controlling the cellular transition 
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point between Th1 and Tfh cells. Adoptive transfer experiments showed that Th1 cells 
lacking Roquin-1/2 proteins proliferated heavily and were indeed able to convert into Tfh 
cells, while wild-type Th1 cells could not (Figure 36). Furthermore, these pre-activated T 
cells deficient for Roquin-1/2 were actually potent to induce a concomitant increase in GC B 
cells (Figure 36). However, previous publications have shown that in vitro cultured cells in a 
variety of conditions could adopt Tfh cell differentiation after immunization 163. Thus, it 
remains to be investigated, if loss of Roquin-1/2 proteins also drives cells from other T helper 
cell subsets into a Tfh cell phenotype. 
Importantly, the spontaneous differentiation into Tfh cells did not require ex vivo T cell 
activation, since it was also observed after adoptive transfer of sorted naive CD4+ T cells from 
Rc3h1/2fl/fl; CD4-Cre mice (Figure 37). Interestingly, almost all transferred naive cells 
deficient for Rc3h1/2 up-regulated the activation marker CD44, while transferred wild-type 
cells stayed predominantly naive (CD62L+). This indicates that loss of both Roquin-1 and 
Roquin-2 led to an enormous reduction of the activation threshold of these T cells, notably in 
the absence of antigen.  
Collectively, these data suggest a model in which the combined loss of Roquin-1/2 proteins or 
the impaired function of Roquin-1san protein triggers Tfh cell differentiation. Within this 
differentiation a de-repression of several known and unknown Roquin-1/2 targets may 
functionally cooperate. We envision a concept of inappropriate co-stimulation at the naive T 
cell stage, via the increased expression of Icos and Ox40 due to loss-of-function of Roquin 
proteins, which initiate the Tfh cell differentiation. These two co-stimulatory receptors 
normally expand activated T cells and control the size of the effector T cell pool. 
Inappropriate co-stimulation may therefore select those T cells for effector T cell 
differentiation that receive increased TCR-signals due to a certain degree of self-reactivity. 
The cooperation of the self-reactive TCR and inappropriate co-stimulation signals may then 
lead to aberrant T cell activation and subsequent Tfh cell differentiation.  
 
9.3.2 How	  can	  increased	  co-­‐stimulation	  drive	  Tfh	  cell	  commitment?	  
To identify the molecular cause for the spontaneous development of follicular helper T cells 
in Rc3h1/2fl/fl; CD4-Cre mice, we examined the expression of Bcl6 and Irf4, two critical 
transcription factors involved in Tfh cell differentiation 69-71,105. While the expression of Bcl6 
is not considerably affected in the double knockout situation (Figure 32), Irf4 levels were 
markedly elevated in cells deficient for Roquin-1/2 proteins (Figure 40). Increased Irf4 
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activity may augment Tfh cell numbers, since Irf4-deficient T cells are greatly impaired in 
this differentiation program 104,105.  
Irf4, however, is not only involved in Tfh cell differentiation but also drives Th17 cell 
commitment 90,104,105. The observed increased Tfh and Th17 differentiation in Rc3h1/2-
deficient cells is therefore a likely consequence from the up-regulation of Irf4 protein levels 
(Figure 38). It is furthermore described that the Th17 cell differentiation program reciprocally 
influences Treg differentiation 86,87 and that Irf4 might even be involved in the conversion of 
Treg cell into Tfh cells 66. Irf4 can also directly bind to the promoter of Icos and induce its 
expression 91, which could additionally explain the exceedingly high Icos levels in Rc3h1/2-
deficient T cells. Interestingly, the Irf4-binding protein Def6 was shown to negatively regulate 
Irf4 172 and deficiency of Def6 correlated with systemic lupus-like autoimmunity, 
characterized amongst others by the accumulation of effector T cells 173. In Def6-deficient 
mice these activated T cells are impaired to undergo apoptosis, which would be crucial to 
maintain T cell homeostasis.  
Importantly, Irf4 is a target of NF-κB signaling 55 and we could demonstrate spontaneous 
activation of the NF-κB pathway in Rc3h1/2fl/fl; CD4-Cre mice (Figure 40). Loss of  
Roquin-1/2 proteins especially induced the alternative NF-κB pathway (Figure 40 C–D), 
presumably via de-repressed levels of the novel mRNA target Ox40. Ox40 was potent to 
induce p100 to p52 processing but not an increase in Irf4 expression after stimulation of wild-
type cells with an agonistic antibody against Ox40 (Figure 41 C). It is nevertheless likely that 
Irf4 levels are increased due to Ox40 in combination with other signals in Rc3h1/2-deficient 
cells. At this point it is not clear whether Irf4 is also a direct target of Roquin-1/2 proteins. 
In addition, Ox40 has been implicated in a large number of autoimmune and inflammatory 
diseases like experimental autoimmune encephalomyelitis, arthritis or diabetes 42. A single 
dose of an agonistic antibody against Ox40 was even sufficient to break existing tolerance in 
CD4+ T cells and to restore T cell function 45. While deletion of Ox40 together with CD30 
rescued lethal autoimmunity in Foxp3-deficient mice 174, transgenic mice expressing OX40L 
on dendritic cells strongly increased the appearance of CD4+ T cells with a CD62Llo 
phenotype, presumably being Tfh cells, which accumulated in germinal centers after 
immunization 175. Another early study linked failure of CXCR5 up-regulation to the 
compromised function of Ox40 in CD28-deficient mice 16. This study, however, did not 
address a possible contribution of Icos to the up-regulation of CXCR5 expression that was 
recently proposed 96.  
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Ox40 may therefore play a critical role in the development of Tfh cells, especially as both 
Icos and Ox40 overlap in down-stream signaling 25. Icos and Ox40 activate the PI3K 
signaling pathway, while Ox40 additionally induces the NF-κB pathway 166,176,177. Not only 
the NF-κB pathway and Irf4 activation are linked to Tfh cell development. Remarkably, it 
was recently demonstrated that the amount of PIP3 generated by PI3K in an immune response 
determined the magnitude of the germinal center reaction 167. Together these data imply that 
both Icos and Ox40 co-stimulation can induce Tfh differentiation and effector T cells in 
Rc3h1/2–deficient CD4+ T cells, via redundant and cooperative down-stream signaling. 
 
9.3.3 Which	  factors	  cause	  the	  splenic	  disorder	  in	  Rc3h1/2-­‐deficient	  mice?	  
Spontaneous formation of Tfh and GC B cells in san/san mice is accompanied by the 
development of anti-nuclear antibodies 39. We show that combined Roquin-1 and Roquin-2 
deficiency in T cells led to spontaneous Tfh and GC B cell differentiation, but did not induce 
anti-nuclear antibodies (section 8.2.8). This can be due to several reasons. On the one hand 
the observed changes in san/san mice may require the presence of the mutation in cells 
outside of the T cell compartment. On the other hand, we propose that profound perturbation 
of the splenic microarchitecture in Rc3h1/2fl/fl; CD4-Cre mice may no longer permit 
progression towards a lupus-like disease (Figure 33 and Figure 34). We demonstrated that 
already in young (3 weeks) mice, follicular structures were greatly diminished and intact 
follicular structures were hardly detectable (Figure 34). Furthermore, stromal cells such as 
ER-TR7+ reticular fibroblasts were delocalized across the spleen in young animals and 
somewhat dispersed in older ones. In addition, the white pulp was strongly reduced in the 
spleen (Figure 33 B and C). The organization of stromal cells in the white pulp is indeed 
crucial for T and B cell homing, survival and co-stimulation 178. 
However, at this point we do not know which trans-acting factor interferes with the follicular 
organization. We assume that inaccurate co-stimulation accompanied with altered cytokine 
production by chronically activated T cells may contribute to the splenic disorder, as will also 
be discussed in the following sections. It is furthermore likely that the decreased numbers of 
B cells in Rc3h1/2fl/fl; CD4-Cre mice (Figure 32 E) do not provide sufficient lymphotoxin 
signals. Lymphotoxin receptor signaling is required for the development and maintenance of 
the microarchitecture in the white pulp 161. Testing those factors, which are crucial for the 
splenic organization, will certainly reveal the molecular cause for the disrupted splenic 
architecture in Rc3h1/2fl/fl; CD4-Cre mice. 
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9.3.4 Can	  loss	  of	  Icos	  reverse	  the	  Roquin-­‐1/2-­‐knockout	  phenotype?	  
Deregulated Icos levels and spontaneous formation of Tfh cells are two hallmark phenotypes 
observed in the san/san mouse. Both Icos and its paralog CD28 are essential for the GC 
reaction 22,23,96, but are temporally separated in their expression and function (section 5.1.2). 
While loss of CD28 co-stimulation partially corrected sanroque-dependent Tfh cell 
accumulation, the sanroque alleles in CD28-/- mice restored Tfh formation upon 
immunization comparable to wild-type levels. These effects were reverted upon additional 
ablation of the Icos ligand, and Rc3h1san/san mice deficient for both CD28 and Icos ligand no 
longer mounted a proper GC response upon SRBC (sheep red blood cells) immunizations 118. 
This implied that Roquinsan broke the compartmentalization of CD28 and Icos signaling and 
that de-repressed Icos levels contributed to the Tfh-induced pathology of Rc3h1san/san mice. 
However, it is very likely that factors other than Icos critically contributed to the phenotypes 
of Rc3h1san/san mice, since Icos deficiency did not prevent the development of autoimmunity. 
Recent work demonstrated that complete loss of Icos in Rc3h1san/san mice did not rescue but 
led to the occurrence of whole anti-nuclear antibodies in Rc3h1san/san mice 159. Icos deficiency 
in Rc3h1san/san mice also failed to rescue the expansion of effector-like T cells 159. 
Similarly, ablation of Icos in Rc3h1/2fl/fl; CD4-Cre mice did not reverse the activation 
phenotype of CD4+ and CD8+ T cells (Figure 43). Strikingly, loss of Icos signaling did also 
not impede the spontaneous development of Tfh cells (Figure 44). This remarkable finding is 
the first evidence of a possible bypass mechanism to avoid the dependence on Icos signaling 
for the development of Tfh cells. We speculate that elevated Ox40 levels in the Icos TKO 
may substitute for loss of Icos. These assumptions are supported by the fact that both Icos and 
Ox40 signal share the down-stream PI3K signaling pathway 176,177. As had been mentioned 
before, the amount of PIP3 generated by PI3K seemed to be detrimental for the extent of the 
germinal center response 167 and Ox40 was also shown to be involved in a number of 
autoimmune diseases 42. In addition, both Icos and Ox40 are important for the survival of 
effector T cells 43,179 and constitutive Ox40 triggering through transgenic expression of the 
Ox40 ligand on T cells leads to massive induction of effector-like CD4+ but not CD8+ T 
cells 44. This implies that Ox40 signaling may strongly contribute to the effector like 
phenotype at least of CD4+ T cells. It would be exciting to investigate loss of Ox40 signaling 
in the Roquin-1/2 double knockout situation. The results would elucidate the effect of Ox40 
especially in regard to the T cell activation phenotype. 
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9.3.5 What	  is	  the	  role	  of	  IFN-­‐γ 	  in	  Rc3h1/2-­‐deficient	  mice?	  
In addition to Icos and Ox40 mRNA, Ifng mRNA was recently proposed to be a potential new 
target of Roquin-1. In Rc3h1san/san mice, IFN-γ was shown to enhance short-lived effector 
CD8+ T cells (SLECs) with increased effector function 157. However, investigating IFN-γ 
protein levels in Th1 differentiation experiments, we cannot readily confirm IFN-γ as a direct 
target of Roquin proteins. Loss of Roquin-1/2 did neither enhance IFN-γ levels nor the 
number of IFN-γ-producing cells (Figure 38). In addition, the so far presented evidence 
cannot rule out indirect stabilization of Ifng mRNA in SLECs from san/san mice. Such 
stabilization of the mRNA of IFN-γ and other cytokines has been reported in the context of 
Ox40 stimulation 164. We therefore assume that elevated co-stimulation by receptors such as 
Ox40 or Icos aberrantly enhances IFN-γ production. 
We also assessed the role of IFN-γ in the accumulation of effector and Tfh cells in 
Rc3h1/2fl/fl; CD4-Cre mice. IFN-γ signaling was not only shown to influence CD8+ effector 
like properties 157, but was also demonstrated to be involved in the pathogenic accumulation 
of Tfh cells and spontaneous generation of germinal centers 159. Surprisingly however, loss of 
IFN-γ signaling in Rc3h1/2fl/fl; CD4-Cre, IFN-γ-/- mice did neither reverse the accumulation of 
effector CD4+ and CD8+ T cells nor the spontaneous formation of Tfh cells observed in 
Rc3h1/2-deficient mice (Figure 46 and Figure 47). However, several sanroque phenotypes 
were only partially reversed by the genetic removal of different co-stimulatory receptors or 
cytokines such as IFN-γ. This points at a cooperation of several factors in the development of 
the lupus-like autoimmune disease. 
Importantly, IFN-γ influences the splenic organization and continuous administration of large 
amounts of IFN-γ to rats causes severe alterations of the splenic architecture 180. Indeed, 
ablation of IFN-γ restored the follicular structure in spleens of IFN-γ TKO mice to a great 
extent (Figure 47) and consequently all of these animals developed ANAs with the age of 
only 11 weeks. Furthermore, loss of Icos co-stimulation was also sufficient to normalize the 
splenic architecture in Icos TKO mice. Therefore, we postulate the model that de-repressed 
co-stimulation in Rc3h1/2fl/fl; CD4-Cre mice causes a highly activated T cell phenotype with 
spontaneous formation of Tfh and GC B cells. However, ANAs do not occur due to the 
disrupted splenic architecture presumably caused by effector cytokines such as IFN-γ, which 
are overly produced due to enhanced co-stimulation. 
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9.4 Conclusion	  
This work revealed direct protein–RNA interaction via the amino-terminal ROQ domain as 
the first step of the molecular mechanism of mRNA target repression by Roquin family 
proteins. In addition, functional redundancy was demonstrated for the paralogs Roquin-1 and 
Roquin-2 in the repression of the known and novel mRNA targets Icos and Ox40. In vivo 
analyses further revealed the crucial functions of Roquin-1 and Roquin-2 in T cell activation 
and differentiation and consequently in the prevention of autoimmunity. 
Most importantly, this work solved a current paradox: The san mutation in Roquin-1 caused a 
severe autoimmune phenotype, but the complete loss of Roquin-1 did not. Our findings 
demonstrated compensation of Roquin-1 by Roquin-2, involving a previously unappreciated 
dominant-negative effect of Roquin-1 on Roquin-2 protein function. Such redundancy is a 
fundamental concept in evolution, establishing a safety mechanism to prevent fatal diseases 
such as autoimmunity. 
	   	   133 
10 References	  
 
1. Murphy, K., Travers, P. & Walport, M. Janeway's immunobiology. (Garland Science, 
2008). 
2. Hoffmann, J. A. Phylogenetic Perspectives in Innate Immunity. Science 284, 1313–
1318 (1999). 
3. Oettinger, M. A., Schatz, D. G., Gorka, C. & Baltimore, D. RAG-1 and RAG-2, 
adjacent genes that synergistically activate V(D)J recombination. Science 248, 1517–
1523 (1990). 
4. Schatz, D. G., Oettinger, M. A. & Baltimore, D. The V(D)J recombination activating 
gene, RAG-1. Cell 59, 1035–1048 (1989). 
5. Tonegawa, S. Somatic generation of antibody diversity. Nature 302, 575–581 (1983). 
6. Goodnow, C. C., Sprent, J., de St Groth, B. F. & Vinuesa, C. G. Cellular and genetic 
mechanisms of self tolerance and autoimmunity. Nat Cell Biol 435, 590–597 (2005). 
7. Starr, T. K., Jameson, S. C. & Hogquist, K. A. Positive and Negative Selection of T 
Cells. Annual Review of Immunology 21, 139–176 (2003). 
8. Kranz, D. M. Two mechanisms that account for major histocompatibility complex 
restriction of T cells. F1000 Biol Rep 1, 55 (2009). 
9. Hsieh, C.-S., Lee, H.-M. & Lio, C.-W. J. Selection of regulatory T cells in the 
thymus. Nature Reviews Immunology 12, 157–167 (2012). 
10. Bretscher, P. A. A two-step, two-signal model for the primary activation of precursor 
helper T cells. Proc. Natl. Acad. Sci. U.S.A. 96, 185–190 (1999). 
11. Heissmeyer, V., Ansel, K. M. & Rao, A. A plague of autoantibodies. Nature 
Publishing Group 6, 642–643 (2005). 
12. Schwartz, R. H. T Cell Anergy. Annual Review of Immunology 21, 305–334 (2003). 
13. Becker, J. C. et al. Negative transcriptional regulation in anergic T cells. Proc. Natl. 
Acad. Sci. U.S.A. 92, 2375–2378 (1995). 
14. Wells, A. D., Walsh, M. C., Bluestone, J. A. & Turka, L. A. Signaling through CD28 
and CTLA-4 controls two distinct forms of T cell anergy. J. Clin. Invest. 108, 895–
904 (2001). 
15. Nurieva, R. I., Liu, X. & Dong, C. Yin-Yang of costimulation: crucial controls of 
immune tolerance and function. Immunological reviews 229, 88–100 (2009). 
16. Walker, L. S. et al. Compromised OX40 function in CD28-deficient mice is linked 
with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal 
centers. J Exp Med 190, 1115–1122 (1999). 
17. McAdam, A. J. et al. Mouse inducible costimulatory molecule (ICOS) expression is 
enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J 
Immunol 165, 5035–5040 (2000). 
18. Sharpe, A. H. & Freeman, G. J. The B7–CD28 Superfamily. Nature Reviews 
Immunology 2, 116–126 (2002). 
19. Monks, C. R., Freiberg, B. A., Kupfer, H., Sciaky, N. & Kupfer, A. Three-
dimensional segregation of supramolecular activation clusters in T cells. Nature 395, 
82–86 (1998). 
20. Schwartz, R. H. T cell clonal anergy. Curr Opin Immunol 9, 351–357 (1997). 
21. Bachmann, M. F. et al. Distinct roles for LFA-1 and CD28 during activation of naive 
T cells: adhesion versus costimulation. Immunity 7, 549–557 (1997). 
22. Shahinian, A. et al. Differential T cell costimulatory requirements in CD28-deficient 
mice. Science 261, 609–612 (1993). 
134 
23. Borriello, F. et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin 
class switching and germinal center formation. Immunity 6, 303–313 (1997). 
24. Yoshinaga, S. K. et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 402, 
827–832 (1999). 
25. Rudd, C. E. & Schneider, H. Unifying concepts in CD28, ICOS and CTLA4 co-
receptor signalling. Nature Reviews Immunology 3, 544–556 (2003). 
26. Qureshi, O. S. et al. Trans-Endocytosis of CD80 and CD86: A Molecular Basis for 
the Cell-Extrinsic Function of CTLA-4. Science 332, 600–603 (2011). 
27. Khattri, R., Auger, J. A., Griffin, M. D., Sharpe, A. H. & Bluestone, J. A. 
Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-
regulated activation of Th2 responses. J Immunol 162, 5784–5791 (1999). 
28. Hutloff, A. et al. ICOS is an inducible T-cell co-stimulator structurally and 
functionally related to CD28. Nature 397, 263–266 (1999). 
29. Coyle, A. J. et al. The CD28-related molecule ICOS is required for effective T cell-
dependent immune responses. Immunity 13, 95–105 (2000). 
30. Bauquet, A. T. et al. The costimulatory molecule ICOS regulates the expression of c-
Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. 
Nature Publishing Group 10, 167–175 (2009). 
31. Kim, J. I., Ho, I. C., Grusby, M. J. & Glimcher, L. H. The transcription factor c-Maf 
controls the production of interleukin-4 but not other Th2 cytokines. Immunity 10, 
745–751 (1999). 
32. Ho, I. C., Lo, D. & Glimcher, L. H. c-maf promotes T helper cell type 2 (Th2) and 
attenuates Th1 differentiation by both interleukin 4-dependent and -independent 
mechanisms. J Exp Med 188, 1859–1866 (1998). 
33. Grimbacher, B. et al. Homozygous loss of ICOS is associated with adult-onset 
common variable immunodeficiency. Nature Immunology 4, 261–268 (2003). 
34. Dong, C., Temann, U. A. & Flavell, R. A. Cutting edge: critical role of inducible 
costimulator in germinal center reactions. J Immunol 166, 3659–3662 (2001). 
35. McAdam, A. J. et al. ICOS is critical for CD40-mediated antibody class switching. 
Nature 409, 102–105 (2001). 
36. Akiba, H. et al. The role of ICOS in the CXCR5+ follicular B helper T cell 
maintenance in vivo. J Immunol 175, 2340–2348 (2005). 
37. Bossaller, L. et al. ICOS deficiency is associated with a severe reduction of 
CXCR5+CD4 germinal center Th cells. J Immunol 177, 4927–4932 (2006). 
38. Dong, C. et al. ICOS co-stimulatory receptor is essential for T-cell activation and 
function. Nature 409, 97–101 (2001). 
39. Vinuesa, C. G. et al. A RING-type ubiquitin ligase family member required to repress 
follicular helper T cells and autoimmunity. Nature 435, 452–458 (2005). 
40. Pollok, K. et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. 
The Journal of Immunology 150, 771 (1993). 
41. Wang, C., Lin, G. H. Y., McPherson, A. J. & Watts, T. H. Immune regulation by 4-
1BB and 4-1BBL: complexities and challenges. Immunological reviews 229, 192–
215 (2009). 
42. Croft, M. Control of immunity by the TNFR-related molecule OX40 (CD134). 
Annual Review of Immunology 28, 57–78 (2010). 
43. Weinberg, A. D. The role of OX40 (CD134) in T-cell memory generation. Adv Exp 
Med Biol 684, 57–68 (2010). 
44. Murata, K. et al. Constitutive OX40/OX40 ligand interaction induces autoimmune-
like diseases. J Immunol 169, 4628–4636 (2002). 
45. Bansal-Pakala, P., Jember, A. G. & Croft, M. Signaling through OX40 (CD134) 
breaks peripheral T-cell tolerance. Nat Med 7, 907–912 (2001). 
References  135 
46. Vanhaesebroeck, B. & Alessi, D. R. The PI3K-PDK1 connection: more than just a 
road to PKB. Biochem. J. 346 Pt 3, 561–576 (2000). 
47. Sun, S.-C. Non-canonical NF-κB signaling pathway. Cell Res. 21, 71–85 (2010). 
48. Seminario, M.-C. et al. PTEN permits acute increases in D3-phosphoinositide levels 
following TCR stimulation but inhibits distal signaling events by reducing the basal 
activity of Akt. Eur. J. Immunol. 34, 3165–3175 (2004). 
49. Buckler, J. L., Walsh, P. T., Porrett, P. M., Choi, Y. & Turka, L. A. Cutting edge: T 
cell requirement for CD28 costimulation is due to negative regulation of TCR signals 
by PTEN. J Immunol 177, 4262–4266 (2006). 
50. Hagenbeek, T. J. The Loss of PTEN Allows TCR Lineage Thymocytes to Bypass IL-
7 and Pre-TCR-mediated Signaling. Journal of Experimental Medicine 200, 883–894 
(2004). 
51. Suzuki, A. et al. T cell-specific loss of Pten leads to defects in central and peripheral 
tolerance. Immunity 14, 523–534 (2001). 
52. Verweij, C. L., Geerts, M. & Aarden, L. A. Activation of interleukin-2 gene 
transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-
like response element. J. Biol. Chem. 266, 14179–14182 (1991). 
53. Lai, J. H. et al. RelA is a potent transcriptional activator of the CD28 response 
element within the interleukin 2 promoter. Molecular and Cellular Biology 15, 4260–
4271 (1995). 
54. Shapiro, V. S., Truitt, K. E., Imboden, J. B. & Weiss, A. CD28 mediates 
transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite 
element containing the CD28RE and NF-IL-2B AP-1 sites. Molecular and Cellular 
Biology 17, 4051–4058 (1997). 
55. Grumont, R. J. & Gerondakis, S. Rel induces interferon regulatory factor 4 (IRF-4) 
expression in lymphocytes: modulation of interferon-regulated gene expression by 
rel/nuclear factor kappaB. J Exp Med 191, 1281–1292 (2000). 
56. Vallabhapurapu, S. & Karin, M. Regulation and Function of NF-κB Transcription 
Factors in the Immune System. Annual Review of Immunology 27, 693–733 (2009). 
57. Liou, H. C., Nolan, G. P., Ghosh, S., Fujita, T. & Baltimore, D. The NF-kappa B p50 
precursor, p105, contains an internal I kappa B-like inhibitor that preferentially 
inhibits p50. The EMBO Journal 11, 3003–3009 (1992). 
58. Dobrzanski, P., Ryseck, R. P. & Bravo, R. Specific inhibition of RelB/p52 
transcriptional activity by the C-terminal domain of p100. Oncogene 10, 1003–1007 
(1995). 
59. Sun, S.-C. & Harhaj, E.in NF-κB/Rel Transcription Factor Family (Liou, H.-C.) 26–
40 (Springer US, 2006). 
60. Chen, Z. J. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 7, 758–765 
(2005). 
61. Perkins, N. D. Integrating cell-signalling pathways with NF-κB and IKK function. 
Nat Rev Mol Cell Biol 8, 49–62 (2007). 
62. Tuosto, L. et al. Mitogen-activated kinase kinase kinase 1 regulates T cell receptor- 
and CD28-mediated signaling events which lead to NF-kappaB activation. Eur. J. 
Immunol. 30, 2445–2454 (2000). 
63. Lai, J. H. & Tan, T. H. CD28 signaling causes a sustained down-regulation of I kappa 
B alpha which can be prevented by the immunosuppressant rapamycin. J. Biol. Chem. 
269, 30077–30080 (1994). 
64. Bryan, R. G. et al. Effect of CD28 signal transduction on c-Rel in human peripheral 
blood T cells. Molecular and Cellular Biology 14, 7933–7942 (1994). 
  
136 
65. Gerondakis, S. & Siebenlist, U. Roles of the NF- B Pathway in Lymphocyte 
Development and Function. Cold Spring Harbor Perspectives in Biology 2, 1–29 
(2010). 
66. Zhou, L., Chong, M. M. W. & Littman, D. R. Plasticity of CD4+ T Cell Lineage 
Differentiation. Immunity 30, 646–655 (2009). 
67. Nakayamada, S., Takahashi, H., Kanno, Y. & O'shea, J. J. Helper T cell diversity and 
plasticity. Curr Opin Immunol 24, 297–302 (2012). 
68. Murphy, K. M. & Stockinger, B. Effector T cell plasticity: flexibility in the face of 
changing circumstances. Nature Publishing Group 11, 674–680 (2010). 
69. Johnston, R. J. et al. Bcl6 and Blimp-1 Are Reciprocal and Antagonistic Regulators 
of T Follicular Helper Cell Differentiation. Science 325, 1006–1010 (2009). 
70. Nurieva, R. I. et al. Bcl6 Mediates the Development of T Follicular Helper Cells. 
Science 325, 1001–1005 (2009). 
71. Yu, D. et al. The Transcriptional Repressor Bcl-6 Directs T Follicular Helper Cell 
Lineage Commitment. Immunity 31, 457–468 (2009). 
72. Jabeen, R. & Kaplan, M. H. The symphony of the ninth: the development and 
function of Th9 cells. Curr Opin Immunol 24, 303–307 (2012). 
73. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. & Coffman, R. L. 
Two Types of Murine Helper T Cell Clone. I. Definition According to Profiles of 
Lymphokine Activities and Secreted Proteins. J. Immunol. 175, 5–14 (2005). 
74. Lighvani, A. A. et al. T-bet is rapidly induced by interferon-gamma in lymphoid and 
myeloid cells. Proc. Natl. Acad. Sci. U.S.A. 98, 15137–15142 (2001). 
75. Afkarian, M. et al. T-bet is a STAT1-induced regulator of IL-12R expression in naïve 
CD4+ T cells. Nature Immunology 3, 549–557 (2002). 
76. Shimoda, K. et al. Lack of IL-4-induced Th2 response and IgE class switching in 
mice with disrupted Stat6 gene. Nature 380, 630–633 (1996). 
77. Takeda, K. et al. Essential role of Stat6 in IL-4 signalling. Nature 380, 627–630 
(1996). 
78. Kaplan, M. H., Schindler, U., Smiley, S. T. & Grusby, M. J. Stat6 is required for 
mediating responses to IL-4 and for development of Th2 cells. Immunity 4, 313–319 
(1996). 
79. Ouyang, W. et al. Inhibition of Th1 development mediated by GATA-3 through an 
IL-4-independent mechanism. Immunity 9, 745–755 (1998). 
80. Hegazy, A. N. et al. Interferons Direct Th2 Cell Reprogramming to Generate a Stable 
GATA-3+T-bet+ Cell Subset with Combined Th2 and Th1 Cell Functions. Immunity 
32, 116–128 (2010). 
81. Krawczyk, C. M., Shen, H. & Pearce, E. J. Functional plasticity in memory T helper 
cell responses. J Immunol 178, 4080–4088 (2007). 
82. Chen, Z., Laurence, A. & O'shea, J. J. Signal transduction pathways and 
transcriptional regulation in the control of Th17 differentiation. Seminars in 
immunology 19, 400–408 (2007). 
83. Kanangat, S. et al. Disease in the scurfy (sf) mouse is associated with overexpression 
of cytokine genes. Eur. J. Immunol. 26, 161–165 (1996). 
84. Kim, J. M., Rasmussen, J. P. & Rudensky, A. Y. Regulatory T cells prevent 
catastrophic autoimmunity throughout the lifespan of mice. Nature Publishing Group 
8, 191–197 (2006). 
85. Khattri, R., Cox, T., Yasayko, S.-A. & Ramsdell, F. An essential role for Scurfin in 
CD4+CD25+ T regulatory cells. Nature Immunology 4, 337–342 (2003). 
86. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic 
effector TH17 and regulatory T cells. Nature 441, 235–238 (2006). 
  
References  137 
87. Mucida, D. et al. Reciprocal TH17 and Regulatory T Cell Differentiation Mediated 
by Retinoic Acid. Science 317, 256–260 (2007). 
88. Zhou, L. et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by 
antagonizing RORgammat function. Nature 453, 236–240 (2008). 
89. Osorio, F. et al. DC activated via dectin-1 convert Treg into IL-17 producers. Eur. J. 
Immunol. 38, 3274–3281 (2008). 
90. Brüstle, A. et al. The development of inflammatory TH-17 cells requires interferon-
regulatory factor 4. Nature Publishing Group 8, 958–966 (2007). 
91. Zheng, Y. et al. Regulatory T-cell suppressor program co-opts transcription factor 
IRF4 to control TH2 responses. Nature 458, 351–356 (2009). 
92. Linterman, M. A. et al. Foxp3+ follicular regulatory T cells control the germinal 
center response. Nat Med 17, 975–982 (2011). 
93. Chung, Y. et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress 
germinal center reactions. Nat Med 17, 983–988 (2011). 
94. Crotty, S. Follicular Helper CD4 T Cells (T FH). Annual Review of Immunology 29, 
621–663 (2011). 
95. Fazilleau, N., McHeyzer-Williams, L. J., Rosen, H. & McHeyzer-Williams, M. G. 
The function of follicular helper T cells is regulated by the strength of T cell antigen 
receptor binding. Nature Publishing Group 10, 375–384 (2009). 
96. Choi, Y. S. et al. ICOS receptor instructs T follicular helper cell versus effector cell 
differentiation via induction of the transcriptional repressor Bcl6. Immunity 34, 932–
946 (2011). 
97. Ansel, K. M., McHeyzer-Williams, L. J., Ngo, V. N., McHeyzer-Williams, M. G. & 
Cyster, J. G. In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 
and reprogram their response to lymphoid chemokines. J Exp Med 190, 1123–1134 
(1999). 
98. Kim, C. H. et al. Subspecialization of CXCR5+ T cells: B helper activity is focused 
in a germinal center-localized subset of CXCR5+ T cells. J Exp Med 193, 1373–1381 
(2001). 
99. Breitfeld, D. et al. Follicular B helper T cells express CXC chemokine receptor 5, 
localize to B cell follicles, and support immunoglobulin production. J Exp Med 192, 
1545–1552 (2000). 
100. Baumjohann, D., Okada, T. & Ansel, K. M. Cutting Edge: Distinct Waves of BCL6 
Expression during T Follicular Helper Cell Development. The Journal of 
Immunology 187, 2089–2092 (2011). 
101. Betz, B. C. et al. Batf coordinates multiple aspects of B and T cell function required 
for normal antibody responses. Journal of Experimental Medicine 207, 933–942 
(2010). 
102. Ise, W. et al. The transcription factor BATF controls the global regulators of class-
switch recombination in both B cells and T cells. Nature Publishing Group 12, 536–
543 (2011). 
103. Kroenke, M. A. et al. Bcl6 and Maf Cooperate To Instruct Human Follicular Helper 
CD4 T Cell Differentiation. The Journal of Immunology 188, 3734–3744 (2012). 
104. Kwon, H. et al. Analysis of Interleukin-21-Induced Prdm1 Gene Regulation Reveals 
Functional Cooperation of STAT3 and IRF4 Transcription Factors. Immunity 31, 
941–952 (2009). 
105. Bollig, N. et al. Transcription factor IRF4 determines germinal center formation 
through follicular T-helper cell differentiation. Proceedings of the National Academy 
of Sciences 109, 8664–8669 (2012). 
  
138 
106. Johnston, R. J., Choi, Y. S., Diamond, J. A., Yang, J. A. & Crotty, S. STAT5 is a 
potent negative regulator of TFH cell differentiation. Journal of Experimental 
Medicine 209, 243–250 (2012). 
107. Glasmacher, E. et al. A genomic regulatory element that directs assembly and 
function of immune-specific AP-1-IRF complexes. Science 338, 975–980 (2012). 
108. Nakayamada, S. et al. Early Th1 Cell Differentiation Is Marked by a Tfh Cell-like 
Transition. Immunity 35, 919–931 (2011). 
109. Lüthje, K. et al. The development and fate of follicular helper T cells defined by an 
IL-21 reporter mouse. Nature Publishing Group 13, 491–498 (2012). 
110. Hu, Y.-L., Metz, D. P., Chung, J., Siu, G. & Zhang, M. B7RP-1 blockade ameliorates 
autoimmunity through regulation of follicular helper T cells. The Journal of 
Immunology 182, 1421–1428 (2009). 
111. Linterman, M. A. et al. Follicular helper T cells are required for systemic 
autoimmunity. Journal of Experimental Medicine 206, 561–576 (2009). 
112. Simpson, N. et al. Expansion of circulating T cells resembling follicular helper T 
cells is a fixed phenotype that identifies a subset of severe systemic lupus 
erythematosus. Arthritis Rheum 62, 234–244 (2010). 
113. Cappione, A., III et al. Germinal center exclusion of autoreactive B cells is defective 
in human systemic lupus erythematosus. J. Clin. Invest. 115, 3205–3216 (2005). 
114. Vinuesa, C. G., Sanz, I. & Cook, M. C. Dysregulation of germinal centres in 
autoimmune disease. Nature Reviews Immunology 9, 845–857 (2009). 
115. Radic, M. Z. & Weigert, M. Genetic and structural evidence for antigen selection of 
anti-DNA antibodies. Annual Review of Immunology 12, 487–520 (1994). 
116. Rosen, A. & Casciola-Rosen, L. Clearing the way to mechanisms of autoimmunity. 
Nat Med 7, 664–665 (2001). 
117. Lohr, J., Knoechel, B., Nagabhushanam, V. & Abbas, A. K. T-cell tolerance and 
autoimmunity to systemic and tissue-restricted self-antigens. Immunological reviews 
204, 116–127 (2005). 
118. Linterman, M. A. et al. Roquin Differentiates the Specialized Functions of 
Duplicated T Cell Costimulatory Receptor Genes Cd28 and Icos. Immunity 30, 228–
241 (2009). 
119. Yu, D. et al. Roquin represses autoimmunity by limiting inducible T-cell co-
stimulator messenger RNA. Nature 450, 299–303 (2007). 
120. Bertossi, A. et al. Loss of Roquin induces early death and immune deregulation but 
not autoimmunity. Journal of Experimental Medicine 208, 1749–1756 (2011). 
121. Anderson, P. Post-transcriptional regulons coordinate the initiation and resolution of 
inflammation. Nature Reviews Immunology 10, 24–35 (2010). 
122. Hoefig, K. P. & Heissmeyer, V. MicroRNAs grow up in the immune system. Curr 
Opin Immunol 20, 281–287 (2008). 
123. Hao, S. & Baltimore, D. The stability of mRNA influences the temporal order of the 
induction of genes encoding inflammatory molecules. Nature Publishing Group 10, 
281–288 (2009). 
124. Stoecklin, G. & Anderson, P. Posttranscriptional mechanisms regulating the 
inflammatory response. Adv Immunol 89, 1–37 (2006). 
125. Hollams, E. M., Giles, K. M., Thomson, A. M. & Leedman, P. J. MRNA stability and 
the control of gene expression: implications for human disease. Neurochem. Res. 27, 
957–980 (2002). 
126. Ross, H. J., Sato, N., Ueyama, Y. & Koeffler, H. P. Cytokine messenger RNA 
stability is enhanced in tumor cells. Blood 77, 1787–1795 (1991). 
  
References  139 
127. Hollis, G. F., Gazdar, A. F., Bertness, V. & Kirsch, I. R. Complex translocation 
disrupts c-myc regulation in a human plasma cell myeloma. Molecular and Cellular 
Biology 8, 124–129 (1988). 
128. Aghib, D. F. et al. A 3' truncation of MYC caused by chromosomal translocation in a 
human T-cell leukemia increases mRNA stability. Oncogene 5, 707–711 (1990). 
129. Sandberg, R., Neilson, J. R., Sarma, A., Sharp, P. A. & Burge, C. B. Proliferating 
Cells Express mRNAs with Shortened 3' Untranslated Regions and Fewer MicroRNA 
Target Sites. Science 320, 1643–1647 (2008). 
130. Bernstein, P. & Ross, J. Poly(A), poly(A) binding protein and the regulation of 
mRNA stability. Trends in Biochemical Sciences 14, 373–377 (1989). 
131. Bernstein, P., Peltz, S. W. & Ross, J. The poly(A)-poly(A)-binding protein complex 
is a major determinant of mRNA stability in vitro. Molecular and Cellular Biology 9, 
659–670 (1989). 
132. Parker, R. & Song, H. The enzymes and control of eukaryotic mRNA turnover. Nat 
Struct Mol Biol 11, 121–127 (2004). 
133. Tharun, S. et al. Yeast Sm-like proteins function in mRNA decapping and decay. 
Nature 404, 515–518 (2000). 
134. Fenger-Grøn, M., Fillman, C., Norrild, B. & Lykke-Andersen, J. Multiple Processing 
Body Factors and the ARE Binding Protein TTP Activate mRNA Decapping. 
Molecular Cell 20, 905–915 (2005). 
135. Weston, A. Xp54 and related (DDX6-like) RNA helicases: roles in messenger RNP 
assembly, translation regulation and RNA degradation. Nucleic Acids Research 34, 
3082–3094 (2006). 
136. Anderson, P. Post-transcriptional control of cytokine production. Nature Publishing 
Group 9, 353–359 (2008). 
137. Taylor, G. A. et al. A pathogenetic role for TNF alpha in the syndrome of cachexia, 
arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 
4, 445–454 (1996). 
138. Brennan, C. M. & Steitz, J. A. HuR and mRNA stability. Cell. Mol. Life Sci. 58, 266–
277 (2001). 
139. Kim, H. H. et al. HuR recruits let-7/RISC to repress c-Myc expression. Genes & 
Development 23, 1743–1748 (2009). 
140. Jones, M. R. et al. Zcchc11-dependent uridylation of microRNA directs cytokine 
expression. Nat Cell Biol 11, 1157–1163 (2009). 
141. Thai, T. H. et al. Regulation of the Germinal Center Response by MicroRNA-155. 
Science 316, 604–608 (2007). 
142. Zhang, B., Pan, X., Cobb, G. P. & Anderson, T. A. microRNAs as oncogenes and 
tumor suppressors. Developmental Biology 302, 1–12 (2007). 
143. Xiao, C. et al. Lymphoproliferative disease and autoimmunity in mice with increased 
miR-17-92 expression in lymphocytes. Nature Publishing Group 9, 405–414 (2008). 
144. Watts, J. M. et al. Architecture and secondary structure of an entire HIV-1 RNA 
genome. Nature 460, 711–716 (2009). 
145. Parker, R. & Sheth, U. P Bodies and the Control of mRNA Translation and 
Degradation. Molecular Cell 25, 635–646 (2007). 
146. Chu, C.-Y. & Rana, T. M. Translation repression in human cells by microRNA-
induced gene silencing requires RCK/p54. Plos Biol 4, 1122–1136 (2006). 
147. Anderson, P. & Kedersha, N. Visibly stressed: the role of eIF2, TIA-1, and stress 
granules in protein translation. Cell Stress Chaperones 7, 213–221 (2002). 
148. Kedersha, N. et al. Stress granules and processing bodies are dynamically linked sites 
of mRNP remodeling. The Journal of Cell Biology 169, 871–884 (2005). 
  
140 
149. Glasmacher, E. et al. Roquin binds inducible costimulator mRNA and effectors of 
mRNA decay to induce microRNA-independent post-transcriptional repression. 
Nature Publishing Group 11, 725–733 (2010). 
150. Glasmacher, E. Roquin binds to ICOS mRNA for P body-dependent and miRNA-
independent posttranscriptional gene silencing. Ludwig-Maximilians-Universität 
München –Dissertation an der Fakultät für Biologie (2010). 
151. Siess, D. C. A Human Gene Coding for a Membrane-associated Nucleic Acid-
binding Protein. Journal of Biological Chemistry 275, 33655–33662 (2000). 
152. Lee, P. P. et al. A critical role for Dnmt1 and DNA methylation in T cell 
development, function, and survival. Immunity 15, 763–774 (2001). 
153. Wilkinson, K. A., Merino, E. J. & Weeks, K. M. Selective 2′-hydroxyl acylation 
analyzed by primer extension (SHAPE): quantitative RNA structure analysis at single 
nucleotide resolution. Nat Protoc 1, 1610–1616 (2006). 
154. Su, H., Trombly, M. I., Chen, J. & Wang, X. Essential and overlapping functions for 
mammalian Argonautes in microRNA silencing. Genes & Development 23, 304–317 
(2009). 
155. Athanasopoulos, V. et al. The ROQUIN family of proteins localizes to stress granules 
via the ROQ domain and binds target mRNAs. FEBS Journal 277, 2109–2127 
(2010). 
156. MacNicol, M. C. & MacNicol, A. M. Developmental timing of mRNA translation-
integration of distinct regulatory elements. Mol. Reprod. Dev. 77, 662–669 (2010). 
157. Chang, P. P. et al. Breakdown in Repression of IFN-  mRNA Leads to Accumulation 
of Self-Reactive Effector CD8+ T Cells. The Journal of Immunology 189, 701–710 
(2012). 
158. Chen, L. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell 
immunity. Nature Reviews Immunology 4, 336–347 (2004). 
159. Lee, S. K. et al. Interferon-&gamma; Excess Leads to Pathogenic Accumulation of 
Follicular Helper T Cells and Germinal Centers. Immunity 37, 880–892 (2012). 
160. Sawada, S., Scarborough, J. D., Killeen, N. & Littman, D. R. A lineage-specific 
transcriptional silencer regulates CD4 gene expression during T lymphocyte 
development. Cell 77, 917–929 (1994). 
161. Schneider, K., Potter, K. G. & Ware, C. F. Lymphotoxin and LIGHT signaling 
pathways and target genes. Immunological reviews 202, 49–66 (2004). 
162. Spolski, R. & Leonard, W. J. IL-21 and T follicular helper cells. International 
Immunology 22, 7–12 (2009). 
163. Lu, K. T. et al. Functional and Epigenetic Studies Reveal Multistep Differentiation 
and Plasticity of In&nbsp;Vitro-Generated and In&nbsp;Vivo-Derived Follicular T 
Helper Cells. Immunity 35, 622–632 (2011). 
164. Mestas, J. Endothelial cell co-stimulation through OX40 augments and prolongs T 
cell cytokine synthesis by stabilization of cytokine mRNA. International Immunology 
17, 737–747 (2005). 
165. Huber, M. et al. IRF4 is essential for IL-21-mediated induction, amplification, and 
stabilization of the Th17 phenotype. Proceedings of the National Academy of 
Sciences 105, 20846–20851 (2008). 
166. Murray, S. E. et al. NF-κB–inducing kinase plays an essential T cell–intrinsic role in 
graft-versus-host disease and lethal autoimmunity in mice. J. Clin. Invest. 121, 4775–
4786 (2011). 
167. Rolf, J. et al. Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude 
of the Germinal Center Reaction. The Journal of Immunology 185, 4042–4052 
(2010). 
  
References  141 
168. Lunde, B. M., Moore, C. & Varani, G. RNA-binding proteins: modular design for 
efficient function. Nat Rev Mol Cell Biol 8, 479–490 (2007). 
169. Laroia, G., Sarkar, B. & Schneider, R. J. Ubiquitin-dependent mechanism regulates 
rapid turnover of AU-rich cytokine mRNAs. Proc. Natl. Acad. Sci. U.S.A. 99, 1842–
1846 (2002). 
170. Cano, F. et al. The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination 
with MHC-I mRNA degradation. The EMBO Journal 31, 3596–3606 (2012). 
171. Nowak, M. A., Boerlijst, M. C., Cooke, J. & Smith, J. M. Evolution of genetic 
redundancy. Nature 388, 167–171 (1997). 
172. Chen, Q. et al. IRF-4-Binding Protein Inhibits Interleukin-17 and Interleukin-21 
Production by Controlling the Activity of IRF-4 Transcription Factor. Immunity 29, 
899–911 (2008). 
173. Fanzo, J. C. et al. Loss of IRF-4–binding protein leads to the spontaneous 
development of systemic autoimmunity. J. Clin. Invest. 116, 703–714 (2006). 
174. Gaspal, F. M. et al. Abrogation of CD30 and OX40 signals prevents autoimmune 
disease in FoxP3-deficient mice. Journal of Experimental Medicine 208, 1579–1584 
(2011). 
175. Brocker, T. et al. CD4 T cell traffic control: in vivo evidence that ligation of OX40 
on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the 
accumulation of CD4 T cells in B follicles. Eur. J. Immunol. 29, 1610–1616 (1999). 
176. Gigoux, M. et al. Inducible costimulator promotes helper T-cell differentiation 
through phosphoinositide 3-kinase. Proceedings of the National Academy of Sciences 
106, 20371–20376 (2009). 
177. So, T., Choi, H. & Croft, M. OX40 Complexes with Phosphoinositide 3-Kinase and 
Protein Kinase B (PKB) To Augment TCR-Dependent PKB Signaling. The Journal 
of Immunology 186, 3547–3555 (2011). 
178. Mueller, S. N. & Germain, R. N. Stromal cell contributions to the homeostasis and 
functionality of the immune system. Nature Publishing Group 9, 618–629 (2009). 
179. Simpson, T. R., Quezada, S. A. & Allison, J. P. Regulation of CD4 T cell activation 
and effector function by inducible costimulator (ICOS). Curr Opin Immunol 22, 326–
332 (2010). 
180. Steiniger, B. & van der Meide, P. H. High-dose interferon-gamma alters the 
distribution of B lymphocytes and macrophages in rat spleen and lymph nodes. 
Immunology 78, 461–467 (1993). 	  

	   	   143 
11 Publications	  
 
Articles based on this thesis 
 
Vigo Heissmeyer and Katharina U. Vogel. Molecular control of follicular helper T cell 
differentiation by Roquin family proteins. Immunological Reviews, 253(1):273–89 (2013) 	  
Vogel K.U.*, Edelmann S.L.*, Jeltsch K.M., Bertossi A., Heger K., Heinz G.A., Zöller J., 
Warth S.C., Hoefig K.P., Lohs C., Neff F., Kremmer E., Schick J., Schmidt-Supprian M. and 
Heissmeyer V. Combined loss of Roquin paralogs -1 and -2 derepresses Icos and Ox40 target 
mRNAs and imposes Tfh differentiation on CD4 (+) T cells. Immunity, 38(4):655–68 (2013)  
*equal contribution 	  
Glasmacher E., Hoefig K.P.*, Vogel K.U.*, Rath N., Du L., Wolf C., Kremmer E., Wang X. 
and Heissmeyer V. Roquin binds inducible costimulator mRNA and effectors of mRNA 
decay to induce microRNA-independent post-transcriptional repression. Nature Immunology, 
11(8):725–33 (2010) 
*equal contribution 
 
 
Posters presented based on this thesis 
 
Gene Expression and Signaling in the Immune System, 2012, CSHL, N.Y., USA 	  
Spring School on Immunology, 2012, Ettal, Germany 	  
Signaling in the immune system, 2011, Siena, Italy 	  
Autumn School – Current Concepts in Immunology, 2010, Bad Schandau, Germany 	  
40th Annual meeting of the DGfI, 2010, Leipzig, Germany 	  
Bayreuther Strukturtage, 2010, Thurnau, Germany 
 
  
144 
Oral presentations based on this thesis 
 
Combined loss of Roquin paralogs -1 and -2 derepresses their mRNA targets Ox40 and Icos 
and imposes Tfh differentiation on CD4 T cells. 
Munich Minisymposia in Immunology 2012, Munich, Germany 	  
Combined loss of Rc3h1 and Rc3h2 derepresses their mRNA targets Ox-40 and Icos and 
imposes Tfh differentiation on CD4 T cells. 
T cell Meeting 2012, Marburg, Germany 	  
Redundant and unique functions of Roquin and Mnab proteins. 
T cell Meeting 2011, Marburg, Germany 	  
Roquin and Mnab proteins: What role do they play in the prevention of autoimmunity. 
SFB571 Meeting 2009, Herrsching, Germany 
 
	   	   145 
12 Contributions	  and	  acknowledgements	  
 
I would like to thank all people who were involved in the development and support of this 
research project. 
 
First of all I would like to thank Prof. Dr. Vigo Heissmeyer for the committed supervision of 
this research project. I am deeply thankful for the unlimited support, the enormous motivation 
and ingenious input into this project, leading to a high quality publications. 
 
Furthermore I would like to thank Prof. Dr. Dirk Eick and PD Dr. Bettina Bölter for the 
evaluation of this thesis work. Also many thanks to Prof. Dr. Dirk Eick for the support in my 
Thesis Advisory Committee. 
 
Special thanks to Dr. Marc Schmidt-Supprian for the great support of this project as member 
of my Thesis Advisory Committee. In addition I cordially thank Dr. Marc Schmidt-Supprian 
and Dr. Arianna Bertossi for the Roquin-1 knockout mouse and Klaus Heger for the 
generation of the CAR-transgenic mouse. 
 
I would like to especially thank Dr. Elke Glasmacher for introducing me into the lab work and 
the perfect cooperation on the Roquin project, which I deeply enjoyed. 
 
I deeply thank Dr. Stephanie L. Edelmann for her help in the project. She provided 
outstanding help in the characterization of Rc3h1/2-deficient mice (Figure 29, Figure 30 and 
Figure 32) and accomplished almost all adoptive transfers of Th1-cultured T cells (Figure 35 
and Figure 36). 
 
Moreover, I am very grateful for the help of Gitta A. Heinz, Sebastian Warth, Dr. Kai P. 
Höfig, Christine Wolf and Claudia Lohs at the development and final completion of this 
thesis. Gitta A. Heinz performed the EMSA experiments on Ctla4 and Ox40 binding (Figure 
19 and Figure 42 A). Sebastian Warth conducted the in vitro differentiation experiments in 
Figure 38, after the cells had been isolated and sorted. Dr. Kai P. Höfig evaluated potential 
targets of Roquin-1/2 by qPCR (Figure 18). Christine Wolf technically supported this work 
and demonstrated interaction of Roquin-1 and Roquin-2 with Edc4 (Figure 31). Claudia Lohs 
146 
greatly helped in the development of Western blots in Figure 20 C and Figure 40 A–C and 
performed the qPCR analysis in Figure 41. Nina Martin conducted the Western blot and 
Coomassie gel (Figure 20 A–B) under my supervision. 
 
In addition, I would like to thank all staff of the animal facility, especially Michael 
Hagemann, Franziska Liebel and Martina Möschter for their excellent cooperativeness and 
Albert Geishauser for injecting mice on short notice. 
 
Many thanks also to Prof. Dr. Mathias Heikenwälder and Jessica Zöller for the generation and 
staining of splenic cryo-sections in Figure 33, Figure 34, Figure 45 and Figure 47. 
 
Moreover I appreciate the valuable cooperation with Prof. Dr. Wolfgang Wurst who provided 
the Roquin-2 knockout mouse and Dr. Joel Schick who validated the knockout by Southern 
blotting (Figure 22). 
 
Special thanks also to Prof. Dr. Birgitta Wöhrl and Dr. Maximilian Hartl for the help with the 
SHAPE assay and the accomplishment of the primer extension and sequencing reactions as 
well as the analysis of the SHAPE data (Figure 13 and Figure 14). 
 
I would like to thank Dr. Elisabeth Kremmer for the generation of valuable antibodies and Dr. 
Arie Geerlof for the purification of Roquin-2 (aa 1–438) protein. 
 
Furthermore I thank Dr. Helmut Blum for the conduction of the Affymetrix microarrays and 
Dr. Dirk Repsilber for the statistical evaluation. 
 
Many thanks to Christoph Vahl for always providing help and a running sorter device when 
needed. 
 
Finally I would like to thank Prof. Dr. Vigo Heissmeyer, Dr. Kai Höfig, Katharina M. Jeltsch, 
Dr. Stephanie Edelmann, Sebastian Warth, Gitta A. Heinz, Felix Deschler, Nina Martin and 
Alexander Vogel for critical proof-reading of my thesis. 
